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Chapter 1




Colorectal carcinoma has a high and growing incidence in the Western world. It 
is the second most commonly diagnosed cancer in the Netherlands, with an inci-
dence of over 57 per 100 000 per year (European Standardized Rate)1.
Over the years an expanding arsenal of treatment options has improved survival. 
The EUROCARE Working Group has reported five-year relative survival of elderly 
(70–84 years) and middle-aged cancer patients (55–69 years)2. They observed a 
significant survival improvement from 1988 to 1999 for all cancers combined and 
for almost every cancer site, including colon cancer. 
Surgery remains the mainstay of colorectal cancer treatment. Although colorectal 
cancer surgery is common, it is hazardous and can be considered high risk surgery. 
Colorectal surgery accounts for a disproportionate share of the morbidity, mortality 
and excess length of stay (LOS) in general surgery 3. Therefore, with its increasing 
frequency, colorectal cancer surgery is an important focus for quality enhance-
ment programs.  
To improve outcomes we can focus on improvement of the quality of care, and also 
on better patient selection with subsequent tailored treatment. 
Currently on a national level different quality enhancement strategies are being 
used. Firstly, the adherence to evidence based checklists and guidelines is stimu-
lated to induce a high standard of organised care. 
Secondly, selective referral is promoted. This concerns centralisation of medical 
care to dedicated centres of excellence. However, for colorectal surgery the litera-
ture on centralisation is not univocal. Some studies underline the importance of 
caseload and specialisation4-7, while others find no significant differences in out-
come between different categories of care providers8-10. Thirdly, outcome registra-
tion is used to measure and subsequently enhance the quality of care. Outcome 
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Chapter 1
registration with feedback has been shown to improve results of surgery. Rigorous 
and timely feedback about surgeon and hospital outcomes relative to peers can 
enhance quality as it helps to identify opportunities for improvement and stimu-
lates according action. There is strong evidence this can reduce both overall mor-
tality and variation between health care providers11-13. In 2006, in the Midwestern 
part of the Netherlands a regional audit for colorectal cancer care (KIC) was started 
in the nine affiliated hospitals of the Leiden Cancer Registry. The data collection 
of the cancer registry was extended to data that reflected quality of care and case 
mix factors. The prospectively collected data were used for benchmarking and 
feedback, ultimately to improve the quality of colorectal cancer care in the entire 
region. The definite results concerning a measurable improvement of colorectal 
cancer care have to be awaited. However, a similar program for breast cancer has 
shown a clear improvement of care 14. In 2009 a nationwide audit has started with 
the ultimate goal to improve the care for colorectal cancer patients in the Nether-
lands. The audit started as a surgical audit, but will be multidisciplinary in the near 
future. It intends both to increase the transparency of colorectal cancer care and 
to collect valuable data for quality enhancement through the same principles as 
outlined before.  
Quality of care    
Quality of care can be viewed from different perspectives. Policy makers often con-
sider it to have five dimensions. Good quality care must be safe, effective, patient 
centred, accessible and efficient. From a clinical perspective, a sound preoperative 
workup, meticulous operative technique, early detection of postoperative compli-
cations and adequate action when indicated are elementary to good surgical care 
and the mainstay of surgical quality. A more used analytic approach of describing 
the quality of care is in terms of structure of care, process of care and outcomes 15. 
The structure of care concerns surgeon and hospital factors, such as case load, 
specialisation, the level of intensive care unit and other dedicated facilities. 
The process of care concerns patient selection and evaluation, the intra-operative 
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General Introduction
care and last but not least prevention, recognition and management of complica-
tions. Three recent studies of Ghaferi et al. showed that the difference in deaths 
following major complications was the primary determinant of variation in mortal-
ity between hospitals 16-18. This failure to rescue phenomena indicates that effective 
management of postoperative complications can reduce postoperative mortality and 
improve patient outcomes. 
Finally, to describe quality of care, outcomes have to be defined such as complica-
tions and mortality. There is a growing recognition that the variations in surgical 
outcome are not completely contributable to variation in surgical quality of care. 
Variations in surgical outcome can also be attributed to chance and case mix 19. 
Surgical outcomes can vary simply due to chance, resulting in statistically impre-
cise estimates of performance. Furthermore, differences in patient factors (case 
mix) also contribute to variation in outcomes. 
Risk stratification
Surgery always concerns the balance of risk and benefit. Both risk and benefit can 
vary immensely among patients. For instance a right hemicolectomy in a sixty year 
old otherwise healthy woman does not compare to a low anterior resection in an 
eighty five year old man with serious cardiopulmonary co morbidity. Likewise a 
patient with stage IV disease and an asymptomatic colon tumour will not benefit 
from surgery as a symptomatic patient with stage II disease does. Outcome and 
prognosis are determined by several patient, tumour and treatment characteris-
tics. In order to achieve the best outcomes for colorectal cancer patients, detailed 
and objective information on risk profiles is indispensible. For the individual pa-
tient this should guide clinical judgment and the administration of tailored care. 
On a hospital or population level knowledge of risk factors can lead to adjusted 
(better tailored) treatment protocols and better information on case mix influences 
adding to an improved care for colorectal cancer patients.
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Outline of this thesis
In this thesis different risk factors and outcome measures for colorectal cancer pa-
tients are studied. More objective information on risk could improve patient selec-
tion and with subsequent better tailored treatment this has the potential to im-
prove the quality of care for colorectal cancer patients. Outcome and prognosis are 
determined by patient, tumour and treatment characteristics. 
Accurate staging is indispensable for a balanced decision on further treatment 
and an accurate estimation of prognosis. Currently, the UICC/AJCC TNM staging 
system20-21 is considered the most robust tool for prediction of prognosis and for 
decisions on the delivery of adjuvant treatment. However, some criticism is raised 
towards the validity of this system22 and the usefulness of other tools such as no-
mograms is being explored 23. In addition to the UICC / AJCC TNM stage20, the 
metastatic lymph node ratio (i.e. the ratio of metastatic to retrieved lymph nodes) 
was found to be an important independent prognostic factor in various malignan-
cies 24-27. In chapter 2 the prognostic capacity of the metastatic lymph node ratio 
is assessed for rectal cancer. 
If it has a predictive value in addition to the UICC / AJCC TNM stage 21, it could 
improve identification of high risk patients and may also have the advantage to be 
less dependent on the number of retrieved lymph nodes than N stage. Especially in 
rectal cancer adequate retrieval of lymph nodes may be troublesome.
Patient and treatment characteristics are main determining factors for risk and out-
come in colorectal cancer surgery. Often these factors interact. 
Anastomotic leakage is a major problem in colorectal surgery. It often results in 
serious morbidity, increased healthcare costs and even death. Anastomotic leaks 
are also associated with local recurrences and reduced survival28-30. It has been 
reported that clinical risk assessment for anastomotic leakage by the operating 
surgeon has a low predictive value and underestimates leakage risk 31. Chapter 3 
describes the development and testing of a risk score for anastomotic leakage, to 
help identify high risk patients. Such a risk score could facilitate the intra-operative 
Chapter 1
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decision regarding whether or not to construct a (non functional) stoma. 
As cancer treatment improves and cancer screening programs develop, the num-
ber of patients with multiple metachronous malignancies is increasing 32-35. 
Chapter 4 investigates the prognostic importance of a previous non-colorectal pri-
mary malignancy for colorectal cancer patients.
The presence of comorbidity effects treatment decisions36-39 and the prognosis of 
patients receiving colorectal cancer treatment 40-44. In colorectal cancer research, 
several validated comorbidity measures are used to predict mortality after treat-
ment 45-48. However, the comparability of these different comorbidity measures in 
predicting postoperative mortality remains unclear. Chapter 5 compares frequent-
ly used comorbidity measures and their additional value in models predicting the 
outcome of colorectal cancer. 
Colorectal cancer has a large incidence peak around 74-80 years and approximately 
half of colorectal patients are over seventy years of age 1. Chapters 6 and 7 address 
old age as a risk factor for impaired survival and elaborate on what constitutes age 
related survival differences. 
An important outcome measure for surgery is postoperative mortality. This is usu-
ally described as mortality within thirty days after surgery. However, earlier studies 
have shown that 30-day mortality after surgery is not an appropriate measure of 
surgical risk, as a significant proportion of patients die in the months that follow 
49-51. This suggests that there may be a prolonged impact of the insult of surgery. 
Chapter 8 and chapter 9 look into the aetiology of the excess mortality in the first 
postoperative year. Chapter 8 identifies risk factors and chapter 9 looks into causes 
of death.
Finally, in chapter 10 the thesis is summarised. This chapter also contains a general 
discussion with future directives. 
General Introduction
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Chapter 2
Abstract
Aims: Optimal staging in rectal cancer is indispensable for the decision on further 
treatment and estimation of prognosis. This study assesses the prognostic capacity 
of the metastatic lymph node ratio (LNR) in addition to the new TNM classifica-
tion.  
Methods: LNR was determined, in stage III patients from the Dutch TME trial. Six 
year median follow up data from the trial database were used to analyse the rela-
tion of LNR to overall survival (OS) and local recurrence (LR). The relation of LNR to 
lymph node yield was assessed and appropriate cut off values of LNR for clinical 
use were determined.  
Results: 605 patients were analyzed. 278 underwent preoperative radiotherapy. 
82 patients developed a local recurrence and 289 distant metastases. LNR was an 
independent risk factor for OS, hazard ratio 2.10 (95%CI 1.35-3.27) (in addition to 
age >= 65 years, involved circumferential resection margin (CRM) and new TNM 
stage) and LR, hazard ratio 2.25 (95%CI 1.02-4.56) (in addition to pre operative ra-
diotherapy and involved CRM). LNR is predictive of OS and LR from a lymph node 
yield of more than one and more than five respectively. A LNR value of 0.60 offers 
the best cut off to identify high risk patients. 
Conclusions: LNR is an independent risk factor for OS and LR in addition to the 7th 
edition of the TNM classification. It can aid in predicting prognosis and identifying 
patients that should be considered for adjuvant treatment.
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Introduction
Rectal cancer still poses many challenges to oncologists. Major advantages in sur-
gical technique with complete removal of the mesorectum under vision have led 
to a significant drop in local failure and improvement of overall survival1-2. Also 
the use of (neo-) adjuvant therapy has contributed to improved prognosis with a 
tendency towards pre- in stead of postoperative radiation3-5. 
Using TME surgery and pre-operative radiotherapy the problem of local recurrence 
seems to be contained (5.6% at five years6). However, as in colon cancer, distant 
recurrences are still a matter of concern and occur in 25-30% of patients at five years 
6. Adjuvant chemotherapy can possibly aid, but there is still no strong evidence 
that its benefits in rectal cancer are comparable to those in colon cancer patients 
7-10. Although there are some studies that show a minor benefit of adjuvant che-
motherapy in rectal cancer patients11-13 a recent European consensus conference 
failed to reach consensus on its use14. 
Optimal patient stratification is important to identify patients who will most likely 
benefit from adjuvant therapy. In this manner, overall morbidity from cytotoxic 
regimens will be reduced and health care costs are cut down by targeted delivery 
of expensive chemotherapeutic drugs. 
Currently, the UICC/AJCC TNM staging system15-16 is considered the most robust 
tool for prediction of prognosis and for decisions on the delivery of adjuvant treat-
ment. However, some criticism is raised towards the validity of this system17 and 
the usefulness of other tools such as nomograms is being explored18.
In addition to the UICC / AJCC TNM stage15, the metastatic lymph node ratio (i.e. 
the ratio of metastatic to retrieved lymph nodes) was found to be an important 
independent prognostic factor in various malignancies 19-22. Also in colon cancer 
some studies show a strong association of metastatic lymph node ratio (LNR) with 
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disease recurrence and survival 23-26. In rectal cancer the evidence is still limited.
If the LNR can be considered as a prognostic factor it may also have the advantage 
to be less dependent on the number of retrieved lymph nodes than N stage. Es-
pecially in rectal cancer adequate retrieval of lymph nodes may be troublesome 
as it is dependent on many factors such as age over 60, obesity, female sex, small 
tumour size and localisation, poor differentiation grade, the absence of a lymphoid 
reaction and neo-adjuvant therapy 27-29. 
Some questions remain unanswered. To what extend can the LNR be considered 
a reliable prognostic indicator? What is the effect of lymph node yield is on the 
predictive capacity of LNR? Which LNR cut off values have the best discriminative 
power? Most importantly, very recently the UICC / AJCC TNM system was updated 16 
and T stage and N stage were further specified to improve its prognostic capacity. 
More emphasis is made to the number of retrieved malignant lymph nodes. Con-
sidering the inherent correlation between LNR and the number of positive lymph 
nodes it is not clear whether LNR remains an independent predictor prognosis in 
addition to this 7th edition of the TNM classification.
The aim of this study is to assess the prognostic capacity of the metastatic lymph 
node ratio in stage III rectal cancer in addition to the 7th edition of the TNM clas-
sification and to identify high risk patients.
Chapter 2
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Methods
From the database of the Dutch TME-trial, a prospective multicentre randomized 
trial investigating the value of neo-adjuvant short term radiotherapy applying 5x5 
Gy, all UICC / AJCC stage III patients were selected for this study. Inclusion and ex-
clusion criteria for the TME-trial have been published previously by Kapiteijn et al. 
30-31. Tumours had to be below the level of S1/S2 with the inferior tumour margin 
being 15 centimetres or less from the anal verge as measured during withdrawal 
of a flexible coloscope. 
Surgery was performed between 1996 and 1999. Patients that died in the postop-
erative phase and patients that did not have adenocarcinoma on definitive patho-
logical examination were excluded. The total number of retrieved lymph nodes 
and the number of metastatic lymph nodes were recorded and the metastatic 
lymph node ratio (LNR) was calculated. This was defined as the number of meta-
static lymph nodes divided by that of retrieved lymph nodes. 
Classic prognostic data were available from the Dutch TME-trial records. 
Follow up was registered within the Dutch TME-trial. For the purpose of this study 
outcome data with a median follow up of 6 years were used (earlier reported by 
Peeters et al.6 ). 
Statistics
Overall survival (OS) was calculated from surgery to all cause mortality or end of 
follow up (censoring). Local recurrence time (LR) was defined from surgery to the 
time of evidence of tumour within the pelvic or perineal area, or death (censoring) 
or end of follow up (censoring). 
Univariate and multivariate analyses (of all univariate relations with p <= 0.1) were 
performed using a Cox regression analysis. Since the objective of the multivariate 
Metastatic lymph node ratio in stage III rectal cancer; 
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analysis was to assess the independent prognostic value of LNR, first a multivariate 
model was constructed using forward selection with the selected (p < 0.1 at uni-
variate analysis) covariates. To this model, LNR was then added.
For all Cox regression analyses, hazard ratios were calculated including 95 % confi-
dence intervals (95% CI). 
Furthermore LNR was stratified on quartiles and again survival analyses were con-
ducted using Cox regression analyses. Overall survival probabilities were estimated 
using the Kaplan-Meier method, while for LR the cumulative incidence was esti-
mated accounting for death as competing risk 32. 
To determine the best cut off values for LNR, the p-value from a log-rank test com-
paring LNR < cut off with LNR >= cut off were calculated for every possible cut off 
value. The smallest p-value was identified indicating the most significant cut off. It 
is known that such a minimum p-value approach yields biased p-values33. 
Adjusted p-values suggested in that paper, were calculated (based on leaving out 
the smallest and largest cut off points.
Finally the minimal number of retrieved lymph nodes needed for a reliable LNR was 
evaluated using a Cox model with number of retrieved lymph nodes (log-trans-
formed), LNR and their interaction. From the estimated coefficients and covariance 
matrix of this model, for each number of retrieved lymph nodes, the implied hazard 
ratios and 95% confidence intervals were determined.
For all tests statistical significance was stated as two tailed p< 0.05.
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Results
Six hundred five patients were included in the present analysis. There was a com-
plete registration of lymph node harvest and survival data for all patients. For two 
patients information on local recurrence was unknown. 
Patients had an average age of 63 years (range 26-92). Preoperative radiotherapy 
was given to 278 patients (46.0%). Baseline characteristics are shown in table 1.
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Table 1. 
Baseline characteristics of patients from dataset  
(605 stage III rectal cancer patients)
variable characteristics number
Age, years < 65  312 
>= 65 293
 
sex Male  370 
Female 235
Preoperative Radio Therapy PRT+ 278
PRT- 327
Largest tumour diameter < 5 cm 370
>= 5 cm 221
missing 14








Tumour stage III A  (T1-2/N1, T1/N2a) 85
III B (T3-4a/N1, T2-3/N2a, T1-2/N2b) 405
III C (T4a/N2a, T3-4/N2b, T4b/N1-2) 115
Involved CRM No 427
Yes 175
missing 3
Retrieved lymph nodes < 12 378
>=12 227
Adjuvant treatment Chemotherapy 99
Radiotherapy* 53
Chemo radiation* 14
The pT stage, pN stage and tumour stage were defined according to the 7th edition of the UICC / AJCC TNM staging. 
CRM, circumferential resection margin
 * Patients receiving adjuvant radiotherapy/ chemo radiation had an involved CRM according to the 
    pathology report (Marijnen et al. reported on this group (43)).   
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The median number of retrieved lymph nodes was 9 (range 1-47). The median 
number of malignant lymph nodes was 2 (range 1-40).
During the follow up period 306 patients (50.7%) had a recurrence, 82 (13.6%) had 
a local recurrence and 289 (47.8%) developed distant metastases. Sixty three pa-
tients (10.4%) developed both local and distant recurrences. Three hundred twenty 
eight patients (54.2%) died during follow up. Two hundred sixty (43.6%) patients 
died of disease recurrence. Median follow up time for patients still alive at the end 
of study (n=277) was 6 years (range 1-9 years).
Univariate Cox regression analyses incorporating baseline characteristics showed 
that LNR, pN-stage, tumour-stage, number of malignant lymph nodes and involved 
circumferential resection margin (CRM) were significantly correlated to overall sur-
vival (OS) and local recurrence (LR).  Age of 65 or more years, pT-stage and retrieved 
lymph nodes < 12 were significantly related to OS, but not to LR. Pre operative 
radiotherapy significantly decreased LR, but not OS.
Multivariate analysis is shown in table 2. When LNR was added, it was found to be 
an independent risk factor for OS and LR (hazard ratio 2.10 (95% CI 1.35-3.35 and 
2.25 (95% CI 1.02-4.96) respectively).
Chapter 2
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Table 2 
Multivariate Cox regression analysis for OS and LR 
Overall Survival        Local Recurrence
variable characteristics HR (95%CI) P- value HR (95%CI) P-valueI
Age, years >= 65  1.77  (1.41-2.22) <0.01 n.a.
Preoperative PRT+ n.a. 0.43  (0.27-0.70) <0.01
Radio Therapy








Tumour stage III A <0.01 0.55
III B 1.78  (1.18-2.67)
III C 2.88  (1.73-4.78)
Involved CRM Yes 1.52   (1.20-1.93) <0.01 2.30  (1.46-3.62) <0.01
Retrieved lymph nodes < 12 0.86 n.a.
Malignant lymph nodes 1.02 0.08 0.71
LNR  2.10  (1.35-3.27) <0.01 2.25  (1.02-4.96) 0.04
Covariates with trend-significance (p<0.10) in univariate analysis were entered in multivariate analysis. 
HR, hazard ratio; CI, confidence interval; CRM, circumferential resection margin; n.a., variables not selected for 
multivariate analyses because they were not trend significant in univariate analysis.
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Influence of lymph node yield
The Cox model used to determine the influence of the number of retrieved lymph 
nodes on the predictive capacity of LNR showed that LNR is predictive of OS from a 
lymph node yield of two nodes or more (figure 2A). For a significant prediction on 
LR at least six lymph nodes had to be retrieved (figure 2B)
Cut off values
To determine cut off values for LNR further analyses were performed. First LNR was 
stratified on quartiles (LNR 0-0.17, 0.17- 0.33, 0.33-0.60, 0.60-1). 
Univariate and multivariate analyses were repeated for LNR quartiles. LNR-quartile 
groups were independent risk factors for OS (p<0.04), but not for LR (p=0.62). 
Kaplan-Meier curves for OS according to quartiles are shown in figure 1. Kaplan-
Meier curves for stage I and stage II patients (from TME trial records) are added. 
Stage II patients did not have different outcomes from the lowest LNR quartile 
group (HR 1.15 (95% CI 0.85-1.55)
Figure 1
Kaplan-Meier estimates of overall survival according to stage I, II and III 
divided by LNR-quartiles; q1, q2, q3, q4. 
Chapter 2
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Figures 2C and D show the p-values of the log-rank test comparing low (LNR < cut 
off) and high (LNR >= cut off) LNR according to all cut off values in the data. 
Only patients with a sufficient lymph node yield (>1 and >5 respectively) were en-
tered into this model. For OS the lowest p-value indicating the best cut off was 
found for LNR=0.60. The adjusted minimum p-value found was 2.3*10-13. For LR 
p-values were not so small. Here no distinct cut off value could be identified (figure 
2d); the adjusted minimum p-value found was 0.34.
When patients were  stratified on LNR < 0.60 and >=0.60, 5-years OS was 61 vs. 32%, 
HR 2.45 (95% CI 1.96-3.08) and 5-years LR rate 12.6 versus 16.3%, HR 1.65 (95% CI 
1.03-2.64). Kaplan-Meier and cumulative incidence curves are shown in figure 3.
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Figure 2
a/b Influence of number of retrieved lymph nodes on predictive capacity of    
 LNR for OS (a) and LR (b)
c/d Inverse unadjusted p-values for LNR cut offs for OS (c) and LR (d), 
 indicating discriminative value of all possible cut off values. 
 Lowest p-value indicating best discriminative power 
 (= highest point on curve) 




Kaplan-Meier curves of OS (a) and cumulative incidence curve of LR (b) for Stage III patients subdivi-
ded by LNR cut off value 0.60 and Kaplan-Meier curves of OS for Stage III patients subdivided by TNM 
stage IIIA, IIIB, IIIC and within sub-stage by LNR cut off value 0.60 (c) 
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Discussion
The present study investigated the predictive capacity of metastatic lymph node 
ratio (LNR) in stage III rectal cancer. LNR was, in addition to the updated (7th) edi-
tion of the UICC/ AJCC TNM staging, an independent prognostic factor for LR and 
OS. Furthermore we determined the minimum number of retrieved lymph nodes 
required to ensure that LNR is a prognostic factor (two for prediction of OS and six 
for prediction of LR rate). Finally a cut off value of 0.60 was calculated for which LNR 
is most discriminating. 
For rectal cancer the prognostic significance of the metastatic LNR was earlier ad-
dressed in four studies 34-37. All these studies determined the predictive capacity 
of LNR in addition to the previous (6th edition) TNM classification. In comparison to 
the present (7th edition) TNM classification the earlier classification contained less 
detailed information on the number of malignant nodes and thus less prognostic 
information. This could mean these studies found a larger effect of LNR than they 
would have in addition to the updated TNM classification. The present study shows 
that even with the 7th edition of the TNM classification, LNR can still improve pa-
tient stratification.
Influence of lymph node yield
The use of preoperative radiotherapy may alter the prognostic impact of clinical 
parameters among which the LNR. Only in the study by Moug et al. 37 neo-adjuvant 
radiotherapy was used and then only in 21 patients. 
Neo-adjuvant therapy diminishes the number of retrieved lymph nodes 27-29-38. 
The influence of lymph node yield on the predictive capacity of LNR has been a 
matter of debate. It is argued that the poor prognosis in patients with a high LNR 
might be attributed to an inadequate LN dissection 39. 
After all, if the denominator (the number of retrieved lymph nodes) is smaller the 
LNR will be higher and an inadequate LN dissection itself is associated with poor 
survival 40. However Derwinger et al. 41 found that in colorectal cancer at least part 
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of this association is due to stage migration. Interestingly this is exactly where LNR 
can be useful. Reports on gastric cancer 19-42 show, that LNR-based staging can 
halve the incidence of stage migration. 
In this study inadequate lymphadenectomy as defined by the UICC and AJCC as the 
retrieval of less than 12 lymph nodes was not independently related to OS and LR. 
Furthermore there was no interaction between LNR and the retrieval of less than 
12 or 12 and more lymph nodes in relation to OS and LR (p=0.41 and p=0.84). 
For a more specific answer to the question whether lymph node yield affects the 
predictive capacity of LNR, the present study tried to quantify this effect for every 
lymph node harvested.
LNR showed to be predictive for OS for a lymph node yield of more than one (fig-
ure 2A). This means it is a reliable predictor for OS in the vast majority of patients 
(594 out of 605 patients (98%) in this study).  For a significant prediction on LR 
more than five lymph nodes need to be retrieved (figure 2B), which was the case in 
474/605 patients (78%).
As expected the number of retrieved lymph nodes was lower in patients that re-
ceived preoperative radiotherapy compared to the other patients (median 8 and 
11 respectively, p<0.01). As a consequence the LNR was higher (median 0.39 and 
0.29, p<0.01). However, this had no effect on the predictive capacity of the LNR. A 
test for interaction showed no interaction between LNR and radiotherapy in rela-
tion to OS and LR (p=0.94, p=0.50 respectively).
Cut off values
Previous studies have stratified patients according to LNR in different ways. Meth-
ods to determine the cut off varied and different cut off values are used. Stocchi 
et al. 34 stratified by the percentage of positive nodes (0-25%, 25-50%, 50-75%, 
75-100%).
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Most studies, including the other studies in rectal cancer 35-37, stratified on quartiles. 
After stratifying in quartiles, overall the LNR lost its value for predicting LR. Only the 
highest quartile remained strongly associated with LR. All quartiles were prognos-
tic for OS. 
Interestingly stage II patients did not have a different prognosis from patients in 
the lowest quartile group (0-0.16). This is probably due to inadequate staging for 
stage II patients. When stage II patients were subdivided to adequacy of lymph 
node yield (<12 versus >=12), adequately sampled stage II patients (>=12 lymph 
nodes retrieved) had a better prognosis than stage III patients (p=0.04; data not 
shown). However, inadequately sampled patients (<12 lymph nodes retrieved) had 
no different survival than stage III patients in the lower two quartile groups (p=0.82 
and p=0.13 respectively; data not shown). 
The actuarial overall survival data in the lowest 3 quartiles (0-0.60) are comparable, 
while there is an apparent difference with the highest quartile (0.60-1) (figure 1). 
These findings do not match the results of Peng et al.35, Kim et al.36 and Moug 
et al.37 They all found that only OS in the middle quartiles was comparable and 
Peng suggested combining them for stratification. These different findings could 
be based on differences in distribution of quartiles. In this study cut off values be-
tween quartiles seem to be somewhat higher than in the previous studies. This 
could be the effect of preoperative radiotherapy (46% of patients) resulting in a 
higher LNR as outlined above. In patients that did not receive preoperative radio-
therapy quartile distribution was 0-0.14; 0.14-0.29; 0.29-0.50; 0.50-1, in accordance 
with Peng’s data. Kaplan Meier curves for these patients also match the previous 
studies (not shown). However it should be stressed again that neo-adjuvant radio-
therapy has proven its value and it is the standard of care in the Netherlands and 
many Northern European countries. Therefore the distribution of quartiles in the 
present study is probably more applicable to patients treated in these countries. 
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Figures 2C and D show the p-values of the log-rank test comparing low (LNR < cut 
off) and high (LNR >= cut off) LNR according to all cut off values in the data. In 
search of the cut off value with the best discriminative power for OS we found the 
LNR value of 0.60 (figure 2c). For LR rate no discriminating cut off value was found 
(figure 2d). The cut off value of 0.60 produces absolute differences for 5-years OS 
and LR (figures 3A and B). Using one cut off is very practical for modifying existing 
staging practices. Applying it in addition to the 2009 TNM stage it can modify pa-
tient stratification to more accurately reflect the impact on prognosis (figure 3C). 
A possible limitation of this study could be the fact we used data from a trial that 
was designed to study the effect of preoperative short course radiotherapy and did 
not have LNR as a covariate or outcome measure. However, this multicentre study 
with contributions of more than 80 hospitals reflects common practice among 
radiation oncologists, surgeons and pathologists throughout the Netherlands. 
Furthermore the data were gathered under extensive quality control within the 
framework of the TME trial 30. Therefore, we believe that this study provides useful 
information that may improve rectal cancer treatment.
Conclusions
Accurate staging in rectal cancer is indispensable for a balanced clinical decision on 
further treatment and an accurate estimation of prognosis. This study shows that 
in addition to the 7th edition of the UICCC / AJCC TNM classification the metastatic 
lymph node ratio (LNR) is an independent prognostic factor for overall survival and 
local recurrence in stage III rectal cancer. LNR is a reliable measure for OS from a 
lymph node yield of two or more. For adequate prediction of LR at least six lymph 
nodes need to be retrieved. Stratification of patients is possible by dividing them in 
quartiles, but the LNR value with the best discriminating power is 0.60. This cut off 
value can improve TNM staging per stage and identify high risk patients. This could 
add to the discussion on further (adjuvant) treatment in the multidisciplinary team 
meeting.
Acknowledgements 
Merlijn Hutteman is thanked for his help with the lay out of the figures.
DEF-zw-Proefschrift-JW#PROEF-13-april-2012.indd   36 13-4-2012   18:20:25
37
Metastatic lymph node ratio in stage III rectal cancer; 
prognostic significance in addition to the 7th edition of the TNM classification 
Reference List
(1)  Kapiteijn E, Putter H, van de Velde CJ. Impact of the introduction and training of total 
 mesorectal excision on recurrence and survival in rectal cancer in The Netherlands. 
 Br J Surg 2002; 89(9):1142-1149.
(2)  den DM, Krijnen P, Marijnen CA, Rutten HJ, van de Poll-Franse LV, Putter H et al. 
 Improved overall survival for patients with rectal cancer since 1990: the effects of TME 
 surgery and pre-operative radiotherapy. Eur J Cancer 2008; 44(12):1710-1716.
(3)  Pahlman L, Glimelius B. Pre- or postoperative radiotherapy in rectal and rectosigmoid 
 carcinoma. Report from a randomized multicenter trial. Ann Surg 1990; 211(2):187-195.
(4)  Adjuvant radiotherapy for rectal cancer: a systematic overview of 8,507 patients from 22 
 randomised trials. Lancet 2001; 358(9290):1291-1304.
(5)  Sauer R, Becker H, Hohenberger W, Rodel C, Wittekind C, Fietkau R et al. Preoperative versus   
 postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351(17):1731-1740.
(6)  Peeters KC, Marijnen CA, Nagtegaal ID, Kranenbarg EK, Putter H, Wiggers T et al. 
 The TME trial after a median follow-up of 6 years: increased local control but no survival 
 benefit in irradiated patients with resectable rectal carcinoma. 
 Ann Surg 2007; 246(5):693-701.
(7)  Taal BG, van TH, Zoetmulder FA. Adjuvant 5FU plus levamisole in colonic or rectal cancer:   
 improved survival in stage II and III. Br J Cancer 2001; 85(10):1437-1443.
(8)  Glimelius B, Dahl O, Cedermark B, Jakobsen A, Bentzen SM, Starkhammar H et al. 
 Adjuvant chemotherapy in colorectal cancer: a joint analysis of randomised trials by the 
 Nordic Gastrointestinal Tumour Adjuvant Therapy Group. Acta Oncol 2005; 44(8):904-912.
(9)  Dahl O, Fluge O, Carlsen E, Wiig J, Myrvold H, Vonen B et al. Final results of a randomised   
  III study on adjuvant chemotherapy with 5 FU and levamisol in colon and rectum 
 cancer stage II and III by the Norwegian Gastrointestinal Cancer Group. 
 Acta Oncologica 2009; 48(3):368-376.
(10)  Bosset JF, Collette L, Calais G, Mineur L, Maingon P, Radosevic-Jelic L et al. 
 Chemotherapy with preoperative radiotherapy in rectal cancer. 
 N Engl J Med 2006; 355(11):1114-1123.
(11)  Quasar Collaborative Group, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS et al. 
 Adjuvant chemotherapy versus observation in patients with colorectal cancer: 
 a randomised study. Lancet 2007; 370(9604):2020-2029.
(12)  Akasu T, Moriya Y, Ohashi Y, Yoshida S, Shirao K, Kodaira S. Adjuvant chemotherapy with 
 uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with 
 selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial. 
 Jpn J Clin Oncol 2006; 36(4):237-244.
(13)  Collette L, Bosset JF, den DM, Nguyen F, Mineur L, Maingon P et al. Patients with curative   
 resection of cT3-4 rectal cancer after preoperative radiotherapy or radiochemotherapy:   
 does anybody benefit from adjuvant fluorouracil-based chemotherapy? A trial of the Euro  
 pean Organisation for Research and Treatment of Cancer Radiation Oncology Group. 
 J Clin Oncol 2007; 25(28):4379-4386.
(14)  Valentini V, Aristei C, Glimelius B, Minsky BD, Beets-Tan R, Borras JM et al.
 Multidisciplinary Rectal Cancer : 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). 
 Radiother Oncol 2009; 92(2):148-163.
(15)  Sobin LH, Wittekind CH. UICC (2002) TNM Classification of malignant tumours, 6th edition.  2002.  
 Wiley & Sons, New York. 
 Ref Type: Generic
(16)  Sobin LH, Gospodarowicz M.K., Wittekind CH. UICC (2009) TNM Classification of malignant tumours, 
  edition.  2009.  Wiley & Sons, New York. 
 Ref Type: Generic
(17)  Quirke P, Williams GT, Ectors N, Ensari A, Piard F, Nagtegaal I. The future of the TNM staging system in 
 colorectal cancer: time for a debate? Lancet Oncol 2007; 8(7):651-657.
(18)  Shariat SF, Capitanio U, Jeldres C, Karakiewicz PI. Can nomograms be superior to other prediction tools?  
 BJU Int 2009; 103(4):492-495.
DEF-zw-Proefschrift-JW#PROEF-13-april-2012.indd   37 13-4-2012   18:20:25
38
Chapter 2
(19)  Bando E, Yonemura Y, Taniguchi K, Fushida S, Fujimura T, Miwa K. Outcome of ratio of lymph node 
 metastasis in gastric carcinoma. Ann Surg Oncol 2002; 9(8):775-784.
(20)  Voordeckers M, Vinh-Hung V, Van De Steene J, Lamote J, Storme G. The lymph node ratio as prognostic  
 factor in node-positive breast cancer. Radiother Oncol 2004; 70(3):225-230.
(21)  Herr HW. Superiority of ratio based lymph node staging for bladder cancer. J Urol 2003; 169(3):943-945.
(22)  Berger AC, Watson JC, Ross EA, Hoffman JP. The metastatic/examined lymph node ratio is an 
 important prognostic factor after pancreaticoduodenectomy for pancreatic adenocarcinoma. 
 Am Surg 2004; 70(3):235-240.
(23)  Berger AC, Sigurdson ER, LeVoyer T, Hanlon A, Mayer RJ, Macdonald JS et al. Colon cancer survival is 
 associated with decreasing ratio of metastatic to examined lymph nodes. 
 J Clin Oncol 2005; 23(34):8706-8712.
(24)  Derwinger K, Carlsson G, Gustavsson B. A study of lymph node ratio as a prognostic marker in colon 
 cancer. Eur J Surg Oncol 2008; 34(7):771-775.
(25)  Lee HY, Choi HJ, Park KJ, Shin JS, Kwon HC, Roh MS et al. Prognostic significance of metastatic lymph 
 node ratio in node-positive colon carcinoma. Ann Surg Oncol 2007; 14(5):1712-1717.
(26)  Schumacher P, Dineen S, Barnett C, Jr., Fleming J, Anthony T. The metastatic lymph node ratio predicts  
 survival in colon cancer. Am J Surg 2007; 194(6):827-831.
(27)  Thorn CC, Woodcock NP, Scott N, Verbeke C, Scott SB, Ambrose NS. What factors affect lymph node yield 
 in surgery for rectal cancer? Colorectal Dis 2004; 6(5):356-361.
(28)  Mekenkamp LJ, van Krieken JH, Marijnen CA, van de Velde CJ, Nagtegaal ID. Lymph node retrieval in 
 rectal cancer is dependent on many factors--the role of the tumor, the patient, the surgeon, 
 the radiotherapist, and the pathologist. Am J Surg Pathol 2009; 33(10):1547-1553.
(29)  Morcos B, Baker B, Al MM, Haddad H, Hashem S. Lymph node yield in rectal cancer surgery: 
 effect of preoperative chemoradiotherapy. Eur J Surg Oncol 2010; 36(4):345-349.
(30)  Kapiteijn E, Kranenbarg EK, Steup WH, Taat CW, Rutten HJ, Wiggers T et al. Total mesorectal excision 
 (TME) with or without preoperative radiotherapy in the treatment of primary rectal cancer. 
 Prospective randomised trial with standard operative and histopathological techniques. 
 Dutch ColoRectal Cancer Group. Eur J Surg 1999; 165(5):410-420.
(31)  Kapiteijn E, Marijnen CA, Nagtegaal ID, Putter H, Steup WH, Wiggers T et al. Preoperative radiotherapy  
 combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001; 345(9):638-646.
(32)  Putter H, Fiocco M, Geskus RB. Tutorial in biostatistics: competing risks and multi-state models. 
 Stat Med 2007; 26(11):2389-2430.
(33)  Altman DG, Lausen B, Sauerbrei W, Schumacher M. Dangers of using “optimal” cutpoints in the 
 evaluation of prognostic factors. J Natl Cancer Inst 1994; 86(11):829-835.
(34)  Stocchi L, Nelson H, Sargent DJ, O’Connell MJ, Tepper JE, Krook JE et al. Impact of surgical and pathologic  
 variables in rectal cancer: a United States community and cooperative group report. J Clin Oncol 2001;  
 19(18):3895-3902.
(35)  Peng J, Xu Y, Guan Z, Zhu J, Wang M, Cai G et al. Prognostic significance of the metastatic lymph 
 node ratio in node-positive rectal cancer. Ann Surg Oncol 2008; 15(11):3118-3123.
(36)  Kim YS, Kim JH, Yoon SM, Choi EK, Ahn SD, Lee SW et al. lymph node ratio as a prognostic factor in 
 patients with stage III rectal cancer treated with total mesorectal excision followed by 
 chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009; 74(3):796-802.
(37)  Moug SJ, Saldanha JD, McGregor JR, Balsitis M, Diament RH. Positive lymph node retrieval ratio 
 optimises patient staging in colorectal cancer. Br J Cancer 2009; 100(10):1530-1533.
(38)  Marijnen CA, Nagtegaal ID, Klein KE, Hermans J, van de Velde CJ, Leer JW et al. No downstaging after 
 short-term preoperative radiotherapy in rectal cancer patients. J Clin Oncol 2001; 19(7):1976-1984.
(39)  Dane F, Ozturk MA, Turhal S. Adequacy of Lymph node dissection should be taken into consideration 
 while determining the prognostic significance of the lymph node ratio: in regard to Kim et al. 
 (Int J Radiat Oncol Biol Phys 2009;74:796-802). Int J Radiat Oncol Biol Phys 2009; 75(5):1625.
(40)  Tepper JE, O’Connell MJ, Niedzwiecki D, Hollis D, Compton C, Benson AB, III et al. Impact of number 
 of nodes retrieved on outcome in patients with rectal cancer. J Clin Oncol 2001; 19(1):157-163.
(41)  Derwinger K, Carlsson G, Gustavsson B. Stage migration in colorectal cancer related to improved 
 lymph node assessment. Eur J Surg Oncol 2007; 33(7):849-853.
(42)  Inoue K, Nakane Y, Iiyama H, Sato M, Kanbara T, Nakai K et al. The superiority of ratio-based lymph node  
 staging in gastric carcinoma. Ann Surg Oncol 2002; 9(1):27-34.
DEF-zw-Proefschrift-JW#PROEF-13-april-2012.indd   38 13-4-2012   18:20:25
39
Chapter 3 
Predicting the risk of anastomotic leakage in left-sided 
colorectal surgery using a colon leakage score
JWT Dekker
GJ Liefers 
JCA de Mol van Otterloo 
H Putter 
RAEM Tollenaar 
Journal of Surgical Research 2011 Mar; 166(1): e27-34. Epub 2010 Dec 1.
DEF-zw-Proefschrift-JW#PROEF-13-april-2012.indd   39 13-4-2012   18:20:26
40
Predicting the risk of anastomotic leakage in left-sided colorectal surgery 
using a colon leakage score
Abstract
Aims: Anastomotic leakage following colorectal surgery still occurs all too fre-
quently, and this complication is difficult to predict. A nonfunctional stoma may 
reduce the risk of clinically relevant leaks but is overtreatment for most patients. 
More accurate assessments of the risk of anastomotic leakage would be very help-
ful in tailoring treatment in colorectal surgery. Therefore, a Colon Leakage Score 
(CLS) was developed and tested.
Methods: The CLS was developed based on information from the literature and 
expert opinions. It was tested in a retrospective cohort of consecutive patients 
undergoing left-sided colorectal surgery with primary anastomosis in a teaching 
hospital in the Netherlands.
Results: the test cohort, 10 of 121 patients that were not treated with a nonfunc-
tional stoma experienced anastomotic leakage. The mean CLS in the leakage group 
was 16 versus 8 in the group that did not have a leak (p<0.01). Using  receiver-
operating characteristics, the area under the curve (AUC) showed that the CLS was 
a good predictor (AUC=0.95, CI 0.89 - 1.00) of anastomotic leakage. Furthermore, 
logistic regression analysis with CLS as a predictor for anastomotic leakage showed 
an odds ratio of 1.74 (95% CI 1.32 – 2.28, P < 0.01).
Conclusions: The CLS can predict the risk of anastomotic leakage following left-
sided colorectal surgery. After further validation, this score may help the surgeon 
make a more individualized, safer decision regarding whether to perform an anas-
tomosis or a make a (nonfunctional) stoma. 
Chapter 3
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Introduction
Anastomotic leakage after colorectal surgery is a major and potentially life-threat-
ening complication. Unfortunately, it still occurs all too frequently. The incidence 
rate, especially after low anterior resections, has been reported to be as high as 15 
to 20% in some series 1-2. 
Over the years, many studies have identified risk factors for anastomotic leakage 1-48. 
However, to date, it is not possible to predict the likelihood of leakage in an indi-
vidual patient. Few of the risk factors are conditionally independent, so combin-
ing these factors is methodologically unsound. In addition, multiple regression 
analysis does not seem to offer the solution. In studies with less than ten cases of 
anastomotic leakage per variable entered into the model, this technique lacks the 
required sample size and regression coefficients, such that the results are likely to 
be imprecise 49. Judging by the plethora of risk factors identified in the literature, 
anastomotic leakage has multiple overlapping etiologies. Therefore, studies that 
use multiple regression analysis are not useful if they only identify a small number 
of independent risk factors. Combining the odds ratios for these risk factors with 
odds ratios for risk factors identified in other studies is methodologically hazard-
ous. Therefore, the clinical decision about whether to perform a colonic anastomo-
sis or a stoma remains difficult. 
Clinical risk assessment for anastomotic leakage by the operating surgeon has a 
low predictive value and underestimates leakage risk 50. There has been a recent 
trend to create more (nonfunctional) stomas to counteract the problem of anasto-
motic leakage. However, unnecessary stoma’s can also induce morbidity and dis-
comfort and increase healthcare costs 51. In addition, continuity is never restored 
in many patients. 
There is a need for patient stratification. However, in absence of large and detailed 
datasets that can overcome the methodological problems described above, ap-
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propriate stratification criteria cannot be identified through logistic regression 
analysis of risk factors. Therefore, this study used an alternative approach. The aim 
was to develop a risk score for anastomotic leakage based on information from the 
literature and expert opinion, after which we planned to test the predictive value 
of the scoring system. 
Methods
Construction of the Colon Leakage Score (CLS)
A systematic search for English language literature published between January 
1990 and September 2010 was undertaken on the biomedical bibliographical da-
tabases Pubmed and the Cochrane Library to identify risk factors for anastomotic 
leakage.
The search headings “anastomotic leakage and colorectal surgery” in combination 
with the keywords “risk factor” were used. The “related articles” function was used 
to broaden the search. Reference lists from each study were used to obtain more 
studies that were eligible. Letters, reviews without original data, non-English lan-
guage papers, overlapping patient populations and animal studies were excluded. 
Initial searches focused on studies that analyzed risk factors associated with the 
occurrence of leaks in colorectal anastomosis. These clinical studies were required 
to have primary or secondary goals of identifying risk factors for anastomotic leak-
age.
The definitions used in the reviewed literature were not always well defined. The 
clinical signs and symptoms most frequently described were localized or general-
ized peritonitis, but fecal or purulent discharge from the wound and pelvic or anal 
drainage were also considered signs of anastomotic leakage. Some studies also 
included patients in whom anastomotic leak was discovered only on routine radio-
logical examination; these were excluded from our study.
For practical reasons, a set of easily accessible clinical items was chosen. The lit-
erature does not offer practical combinations of clinical factors with quantified 
Chapter 3
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impacts. Therefore, the contribution of various risk factors was weighted by the 
collective expertise of three dedicated colorectal surgeons, analogous to the Del-
phi-method52, with multiple iterations. Points were attributed to each factor, re-
sulting in a “Colon Leakage Score” (CLS).
Patients in the test set
The CLS was tested in a retrospective cohort of all consecutive patients that un-
derwent left-sided colorectal surgery with primary anastomosis at Medical Center 
Haaglanden (a teaching hospital in the Netherlands) in 2005 and 2006. Left-sided 
colorectal surgery was defined as left colectomy, sigmoid resection or rectal resec-
tion. The CLS was calculated from information on patient charts and hospital com-
puter records. Patients that received a nonfunctional stoma were analyzed both 
separately and in combination with the other patients. Patients with colonic and 
rectal anastomoses were analyzed as one group and as separate groups. Some pa-
tients had laparoscopic surgery. To rule out any possible influences of laparoscopic 
surgery, these patients were compared to patients that had open surgery. 
Patients that underwent an elective rectal resection had an enema prior to surgery. 
During the study period, the hospital protocol was not to use further mechanical 
bowel preparation. 
The type of anastomosis - i.e., stapled or hand sewn and single- or double-layered 
- was not recorded in our series.  
Anastomotic leakage was defined by clinically relevant operative and / or radio-
logical findings. Postoperative pyrexia or septicemia with localized or generalized 
peritonitis and fecal or purulent discharge from the wound or pelvic drains were 
considered signs of anastomotic leakage. Patients whose leak was only detected 
on radiological examination and was not clinically relevant were not considered 
to have an anastomotic leak. Routine contrast enema was not performed after the 
operation.
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Statistics
The mean total-scores for patients with and without anastomotic leakage were 
compared using a student’s t-test for equality of means. Fisher’s exact test was used 
to identify differences in occurrence of anastomotic leakage between groups. The 
strength of the CLS in predicting anastomotic leakage was assessed by the receiv-
er-operating characteristics (ROC). Furthermore logistic regression analysis was 
used to determine the correlation between the CLS and the presence or absence 
of anastomotic leakage. In addition, the predicted probability of anastomotic leak-
age per CLS value was determined. For all tests, statistical significance was stated 
as two-tailed p< 0.05. 
Results
Our search of the literature resulted in a total of 221 studies, of which 64 were eli-
gible for inclusion [1-48] 53-68. Consensus was reached on inclusion of risk factors 
and their relative weight after four iterations. 
The constructed Colon leakage Score (CLS) system is shown in Table 1. The mini-
mum possible total-score for left-sided colorectal surgery = 0, and the maximum 
total-score = 43 points.
In 2005 and 2006 at Medical Center Haaglanden, a total of 139 consecutive patients 
underwent left-sided colorectal surgery with primary anastomosis (101 colons and 
38 rectums). Eighteen patients had a nonfunctional stoma. Operations were per-
formed by nine different surgeons and residents. Data collection resulted in a com-
plete list of items for all but two patients. In these two patients, the only missing 
data were perioperative blood loss. Here, the mean blood loss for all patients was 
used as a value to compute the CLS. These two patients had average operative 
times. Furthermore, the difference between their pre- and postoperative hemoglo-
bin levels did not exceed 1.0 mmol/l. Neither patient received a blood transfusion.
Chapter 3
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Table 1
Colon Leakage Score (CLS) points per variable
Between brackets references are shown for each variable
score
Age (years) [2;29;57]
   < 60 0
   60-69 1
   70-79 2
   >= 80 4
Gender [3;17;19;29;30;37;41;43;44;67;68]
   Female 0
   Male 1
ASA  [10;28;42;45;67]
   I 0
   II 1
   III 3
   IV 6
BMI [10;13;16;30;34]
   19-< 25 0
   25-30 1
   > 30/< 19 or weight loss (> 5 kg/6 months) 3
Intoxication
   No 0
   smoking (any) [2;23;32;37;56] 1
   alcohol (> 3U/day) [2;13;56;59] 1
   steroids (present use, excluding inhalers) [3;21;46] 4
Neoadjuvant therapy 
   No 0
   Radiotherapy [15;17;28;35 ] 1
   Chemoradiation [39;43;58;66] 2
Emergency surgery [2;11;13;21;34;45-47]  
   No 0
   Bleeding 2
   Obstruction 3
   Perforation 4
Distance of anastomosis to anal verge (cm) 
[9;15;17;19;20;22;24;26;28;29;31;32;37;39;41;47;48;54;57;64 ]
   > 10 0
   5-10  3
   < 5 6
Additional procedures
   no 0
   yes 1
Blood loss (cc) [28;37;41;57;68] blood transfusion 
[11;13;22;36;46;47] 0
   < 500 1
   500-1000  3
   1001-2000 6
   > 2000
Duration of operation (hours:minutes) [3;13;21;40;42;65]
   < 2:00 0
   2:00 - 2:59 1
   3:00 - 3:59 2
   >= 4:00  4
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The patient, treatment and outcome-characteristics of the validation set are shown 
in Table 2. CLS values and anastomotic leak data for all 139 consecutive patients are 
shown in Figure 1. In one patient, primarily undetected stapler failure occurred. On 
the first postoperative day, urgent relaparotomy revealed dehiscence of the com-
plete stapled anastomosis. This patient is the one outlier in Figure 1 with a CLS of 
six. Anastomotic leakage occurred in 10 of 121 cases (8.3%) that did not receive a 
nonfunctional stoma and in two of 18 cases with a nonfunctional stoma (p=0.66).
After colon resections, the incidence of anastomotic leakage was 4/101, and after 




Age (years) Median 66












Alcohol (> 3 U/day) 6
Steroids 3
Table 2 
Patients, Treatment and Outcome Characteristics of Validation-set. (n=121) 
The number of patients is given for binary and ordinal variables. 
Median and range are given for continuous variables.
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characteristics number continuous
Treatment
preop. Radiotherapy 7 






                       conversions 11
Additional intervention 29 
Colonic anastomosis 95
Rectal anastomosis 26
Distance to anal verge (cm) median 5
      (for rectal anastomoses) Range 3 - 12
Blood loss (cc) Median 300
Range 20 – 14 000
Duration of operation (hours:minutes) Median 2:45







bleeding gastric ulcer 1
CLS Median 8
range 0 - 20
Figure 1
Scatter-plot of CLS for all 139 consecutive patients that had left sided colorectal surgery
with and without anastomotic leakage. 
DEF-zw-Proefschrift-JW#PROEF-13-april-2012.indd   47 13-4-2012   18:20:26
48
Predicting the risk of anastomotic leakage in left-sided colorectal surgery 
using a colon leakage score
Patients without a nonfunctional stoma
For all patients without a nonfunctional stoma, the mean computed CLS for pa-
tients with anastomotic leakage was 15.7 versus 7.6 for those without this compli-
cation (p<0.01, mean difference 8.1 (CI 5.7 - 10.5)). When colon and rectum cases 
were analyzed separately, the equivalent mean computed CLS values were 7.0 ver-
sus 16.0 for colonic (p<0.01, mean difference 9.0 (CI 5.6 - 12.3)) and 10.2 versus 
15.5 for rectal anastomoses (p<0.01, mean difference 5.3 (CI 1.5 - 9.0)), respectively. 
The mean difference for colonic anastomoses was not significantly higher than that 
for rectal anastomoses (p=0.12), so there is no evidence suggesting a difference in 
the association between CLS and anastomotic leakage based on site of anastomo-
sis. No differences were found in CLS values between colon and rectum patients 
(p=0.26).
Using the receiver-operating characteristics curve, the area under the curve (AUC) 
showed the CLS to be an excellent predictor (AUC=0.95, CI 0.89 - 1.00) for the oc-
currence of anastomotic leakage (Figure 2). When they were analyzed separately, 
different ROC-curves were found for colon (AUC=0.99, CI 0.96 - 1.00) and rectum 
patients (AUC=0.83 (CI 0.64 - 1.00) (Figure 2). 
Chapter 3
Figure 2
ROC curve for CLS versus Anastomotic Leakage for all patients with primary anastomosis without a 
defunctioning stoma (n=121) and patients that had colonic or rectal surgery separately. 
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Logistic regression analysis using CLS as predictor of anastomotic leakage revealed 
an odds ratio of 1.74 (CI 1.32 - 2.28, P < 0.01). For patients who underwent colonic 
anastomosis, the CLS was 2.92 (CI 1.16 - 7.39, p=0.02), and for patients who under-
went a rectal anastomosis, it was 1.39 (CI 1.04 -1.86, p=0.02). The predicted prob-
ability of anastomotic leakage versus CLS for all unprotected anastomosis, and for 
colon and rectum separately, is shown in Figure 3. 
Patients with a nonfunctional stoma
When patients with a nonfunctional stoma (n=18) were included in the analyses, 
the mean CLS in the leakage group was 15.1 versus 8.0 in patients without a leak 
(mean difference 7.1, CI 4.80 - 9.32, p<0.01). The ROC revealed an AUC= 0.89 (CI 0.77 
- 1.00, p<0.01). Logistic regression analysis including patients with a nonfunctional 
stoma showed an odds ratio of 1.55 (CI 1.27 - 1.88, p<0.01). The mean CLS value for 
patients with a nonfunctional stoma was different from the mean CLS for patients 
that only underwent primary anastomosis (10.9 vs. 8.3; difference 2.66 (CI 0.56 - 
Predicting the risk of anastomotic leakage in left-sided colorectal surgery 
using a colon leakage score
Figure 3
CLS versus predicted probability of anastomotic leakage for all patients with primary anastomosis 
without a defunctioning stoma (n=121) and patients that had colonic or rectal surgery separately. 
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4.75; p=0.01)). However, there was no difference in the incidence of anastomotic 
leakage between the nonfunctional group and the other patients (2/18 vs. 10/121; 
difference 2.8% (CI -12.5 - 18.2; p=0.79)).
Laparoscopic surgery
Laparoscopic surgery was not a risk factor for anastomotic leakage (5/56 in lap-
aroscopy versus 7/83 in open surgery (p=0.919) for all patients and 4/46 versus 
6/75 (p=0.893) for nonfunctional stoma patients). There was no difference in the 
mean total CLS values for the open versus the laparoscopic groups (respectively 9.0 
versus 8.1; difference 0.9 (CI -0.64 - 2.28; p=0.27) for all patients and 8.7 versus 7.6; 
difference 1.1 (CI -0.44 – 2.70) for patients with a stoma).
Discussion
Anastomotic leakage is a major problem in colorectal surgery. It often results in 
serious morbidity, increased healthcare costs and even death. Though there have 
been numerous studies on the subject, no evidence-based tools exist to predict 
anastomotic leakage. Judging by the plethora of risk factors identified in the litera-
ture, anastomotic leakage is thought to have many causes. Therefore, creation of a 
predictive model that takes all these factors into account requires a very large and 
detailed database. For example, if there are less than ten cases of anastomotic leak-
age available per variable in a multivariate model, the regression coefficients will 
likely be imprecise 49. To test a predictive model that would take into account the 
16 items we address in this study (on the basis of our overall leakage percentage of 
8.6%), a cohort of 1860 patients would be needed to overcome this problem. 
Therefore, we pursued an alternative approach for this study. Instead of using a 
statistically-derived predictive model, we created a risk score system by a heuristic 
combination of risk factors identified from the literature. This risk score, the CLS, 
was then tested in a retrospective cohort of patients from a teaching hospital in 
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the Netherlands. Although the CLS was generated by a well-structured process, it 
is subjective. Ultimately, however, the essence of a risk score is that it can predict 
risk. As long as it can be objectively applied, any subjectivity in the design is incon-
sequential.
In this study, the CLS accurately predicted the risk of anastomotic leakage follow-
ing left-sided colorectal surgery. Application of this score correctly predicted which 
patients should undergo primary anastomosis and which should receive a proxi-
mal nonfunctional stoma or a definitive stoma. 
To our knowledge, this is the first attempt to construct a scoring system that could 
predict a patient’s risk of anastomotic leakage. The various surgical risk scores that 
have been developed focus on mortality or overall postoperative morbidity and 
do not offer straightforward guidance for the intra-operative decision on whether 
or not to perform an anastomosis. An enormous and detailed database such as 
the one from the American College of Surgeons National Surgical Quality Improve-
ment Program could possibly help, but we were unable to determine if this data-
base contained all of the necessary information from the publication of Cohen et 
al. on the ACS NSQIP colorectal risk calculator 69. 
Ideally, the CLS would be calculated pre-operatively. However, intra-operative 
blood loss and duration of the operation are important predictive factors 3-13-21-28-
37-40-42-57-65-68. They can be considered surrogate markers of technical difficulties 
during the operation. Since an anastomosis is made at the end of a procedure, this 
information will be available and can be incorporated in the CLS to facilitate clini-
cal decision making in the operating room. All of the other necessary information 
will be available pre-operatively. This can provide information for patients and their 
family. In anticipation of the final score, their personal preferences concerning risk 
of morbidity and mortality versus (temporary) stomata can be taken into account.
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Cohort
To test the CLS, we selected a cohort of consecutive patients that underwent left-
sided colorectal surgery. Using any cohort of patients to test a predictive score for 
anastomotic leakage presents a methodological problem when some patients re-
ceive a nonfunctional stoma. 
Inclusion of these stoma patients could confound the analysis. In patients that re-
ceive a nonfunctional stoma (even though they are likely high risk patients), the 
risk of anastomotic leakage is reduced by a temporary stoma. There is accumulat-
ing evidence for similar risk reduction by a nonfunctional stoma in low rectal resec-
tions 70-71. Therefore, the association between the CLS and anastomotic leakage 
becomes confounded. This methodological problem is not solved if the nonfunc-
tional stoma patients are left out of the analysis, because then the residual group 
of patients would not be representative of the population for which the CLS would 
be used in clinical practice. This issue would arise even in a prospective trial unless 
stomas were only performed when indicated by the risk score under investigation. 
This policy is unethical in the absence of evidence that the risk score is a reliable 
predictor of outcome. Therefore, we accepted this problem and decided to per-
form analyses both with and without the nonfunctional stoma patients. 
In our cohort, the decision about whether or not to construct a nonfunctional sto-
ma was made by the surgeon. As expected, the stoma patients had a higher mean 
CLS. However, the surgeons did not identify patients according to CLS. There were 
no differences in the incidence of anastomotic leakage between the nonfunction-
al stoma group and the other patients. This could be because patients that were 
regarded as high-risk were treated with a nonfunctional stoma, thereby reducing 
the risk of anastomotic leak. Ultimately the CLS could accurately predict the risk of 
anastomotic leakage in all patients irrespective of inclusion or exclusion of patients 
with a nonfunctional stoma.
Patients with colon resections and rectal resections were analyzed as one group 
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and as separate groups because of potential differences in surgical complexity and 
risk. These analyses should be interpreted with caution. Although it seems that CLS 
has a better predictive capacity for colon than rectum patients, there were no sta-
tistical differences between colon and rectum patients for the association between 
CLS values and anastomotic leakage. This could be due to small sample size, so a 
difference may still exist. It is possible that certain risk factors are not equally dis-
tributed between colon and rectum patients. For instance, acute surgery occurred 
more often in colon cases. It is also possible that within the rectum group, the cho-
sen cut off values for height of the anastomosis did not differentiate enough be-
tween high or low risk. Unfortunately these subgroups are too small for reliable 
analyses of possible differences.
A possible limitation of this study is that the operations in our series were per-
formed by nine different surgeons and residents. Although they all had training in 
colorectal surgery, it is possible that this introduced some bias. Unfortunately, the 
numbers are too small for further analysis. However, because this series consists of 
consecutive patients it represents routine practice.
Cut off values for routine practice
The purpose of the CLS is patient stratification. It could help to define subgroups 
with high, intermediate and low risks of anastomotic leakage. But which cut off val-
ues are useful? On the ROC-curve, the cut off point that best discriminates between 
groups is the point closest to the left upper corner of the graph. In our study, this 
is a CLS of 11. One of the interesting features of the ROC, however, is the ability to 
choose a suitable cut off point, depending on the emphasis on sensitivity or speci-
ficity. Therefore, if you want to minimize the risk of anastomotic leakage, you can 
choose a lower CLS cut off. If, on the other hand, you want to avoid unnecessary 
stomata you can use a higher CLS cut off.  
With logistic regression analysis (Figure 3) it is possible to determine the risk of 
anastomotic leakage per CLS value and thus for the individual patient. This forces 
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us to determine what risk we consider acceptable. For instance, in our opinion, a 
risk of anastomotic leakage of lower then 3% does not justify a nonfunctional sto-
ma. A stoma can also cause problems (morbidity, discomfort and higher cost). If a 
3% risk of anastomotic leakage is accepted as a cut off, a CLS value of more than 
11 indicates that a stoma should be made. It should be noted here that in our se-
ries, less than 20% of patients had a CLS value of more than 11, so 80% of patients 
would not be considered high-risk for leakage.
In the end, it is up to the surgeon and patient to determine their own cut off CLS 
value considering their preferences concerning the risk of anastomotic leakage 
versus (temporary) stomata. The receiver-operating characteristics curve and the 
logistic regression curves offer a perfect tool to guide this clinical decision. 
Since it is a simple formula and all of the necessary information is easily available in 
standard clinical practice, the CLS could be very useful for the intra-operative deci-
sion regarding whether or not to construct a nonfunctional stoma. Confirmation of 
the value of this scoring system in a larger multi-center series offers the potential 
to solve a difficult clinical problem.
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Abstract
Aims: Patients with colorectal cancer followed by an extracolonic primary tumour, 
have a shorter survival. However, the influence of colorectal cancer as a second 
primary tumour on survival is not clear. We assessed the mortality of colorectal 
cancer patients with a colorectal cancer as a second primary versus a first primary 
malignancy. 
Methods: Sixty-two patients with a second primary colorectal cancer were com-
pared to a control series of 220 patients with colorectal cancer from the regional 
Comprehensive Cancer Center matched for age, sex, year of diagnosis and tumour 
size, and as well to 409 patients from the Leiden Colorectal Database with a first 
primary colorectal cancer. Cox proportional hazard analysis was used to assess the 
association of second primary colorectal cancer versus primary colorectal cancer 
and all cause mortality. 
Results: All cause mortality after a second primary colorectal cancer was signifi-
cantly increased when compared to both the matched controls (HR 1.6, 95% CI 
1.2-2.3, p<0.01) and to the controls from the remaining patients of the Leiden Col-
orectal Database with colorectal cancer as a first malignancy (HR 1.7, 95% CI 1.2-
2.3, p<0.01). The difference in mortality was not explained by differences in stage 
or treatment. 
Conclusions: Patients with a second primary colorectal cancer have a higher mor-
tality compared to patients with a primary colorectal cancer. 
Chapter 4 Mortality of patients diagnosed with colorectal cancer as second primary malignancy
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Introduction
Life expectancy in western societies is still increasing. Therefore, the number of 
people with colorectal cancer, as for other age-related tumours, is rising 1-3. The 
incidence of invasive colorectal tumours in the Netherlands has increased from 
376/100.000 patients in 1989 to 437/100.000 in 2007 according to the Dutch Can-
cer Registration1. Cancer survivors may increasingly develop a second primary tu-
mour because cancer treatment improves and cancer screening programs develop 
4-7. The proportion of second- or higher order invasive cancers reported to the US 
International Cancer Institutes Surveillance, Epidemiology and End Results Pro-
gram (SEER) has increased to over 10% in 2008 4.
Patients with colorectal cancer followed by an extracolonic primary tumour, have 
a shorter survival 2, 8-10. Several studies have shown that subjects with ovarian, 
endometrial, breast, renal and urethral cancer have a higher incidence of colorec-
tal cancer as a second primary tumour 11-17. However, the influence of colorectal 
cancer as a second primary tumour on survival is not clear. To our knowledge two 
studies have assessed the survival of patients with colorectal cancer as a second 
primary malignancy compared to patients with non-colon cancer as primary tu-
mour 18-19. One study showed better survival for patients with colorectal cancer as 
a second primary malignancy 18 while the other study found a similar survival 19. 
These results seem contradictory to studies that show that co-morbidity is a strong 
prognostic factor for survival in colorectal cancer 20-21. Therefore, the objective of 
our study was to assess the mortality of colorectal cancer patients with a colorectal 
tumour as a second primary versus first primary malignancy.
 
Mortality of patients diagnosed with colorectal cancer as second primary malignancy




All 531 consecutive patients undergoing surgical treatment for colorectal cancer 
between 1991 and 2002 at the Leiden University Medical Center, the Netherlands 
were included in our study. According to hospital protocol, pre- and postoperative 
staging was performed using the TNM classification 22. For this research all clinico-
pathological records were examined for patients’ medical history and prognostic 
factors of colorectal cancer such as sex, location, TNM classification, and year of 
diagnosis. To compare severity of co-morbidity, the Adult Co-morbidity Evaluation-
27 (ACE-27) was derived from the medical history 23. Patients who had a carcinoma 
in situ in a polyp or adenoma and patients who had previous treatment for col-
orectal cancer were excluded, leading to 471 patients for the current analysis. From 
this database, the Leiden Colorectal Database (LCD), we identified all patients with 
extracolonic metachronous or synchronous primary malignancies. Synchronous 
tumours were defined as those diagnosed simultaneous or within an interval of 
3 months. Cancers were considered metachronous when the second malignancy 
was diagnosed more than three months after the first. All skin cancers except mel-
anomas, neuro-endocrine tumours and benign brain tumours were excluded as 
previous primary malignancies. A total of 62 patients with a previous cancer were 
identified.
Control series 
Patients with a second primary colorectal cancer were matched with patients with 
a first primary colorectal cancer as identified in our regional Comprehensive Can-
cer Center. For each case a maximum of 5 controls were selected, ranging from 0 
control (n=1) to 5 controls (n=20). A total number of 220 controls were found. The 
mean number of controls was 3.6. All control patients were surgically treated for 
their colorectal cancer and were matched for age within a decade (+/- 5 years), 
sex, tumour location, year of diagnosis (+/- 1 year or with less than 3 matches +/- 2 
years). 
Chapter 4 Mortality of patients diagnosed with colorectal cancer as second primary malignancy
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In addition to the control group from the regional Comprehensive Cancer Center, 
we used the remaining 409 patients with colorectal cancer as a first primary malig-
nancy from our Leiden Colorectal Database as a second control group. This control 
group was used to prevent possible selection bias because the matched controls 
were also diagnosed in general hospitals within our region. 
Mortality
Mortality data on all subjects were obtained form our regional Comprehensive 
Cancer Center. The Comprehensive Cancer Center does not record cause of death. 
The censor date for all cases and controls was 31 December 2008. 
Statistical analysis
Statistical analysis was performed using SPSS 16.0 statistical software. Differences 
in characteristics of patients from our study group and the control groups were as-
sessed using chi-square tests. Cox proportional hazard analysis was used to assess 
the association between individual factors and all cause mortality. Moreover, cause 
specific mortality was also assessed between cases and controls from the Leiden 
Colorectal Database. This information was obtained from ONCDOC, a patient fol-
low up system within our hospital maintained by professional data-managers.
Results
Patient characteristics
Of the 471 patients included in this study, 62 patients had a history of a previous 
extracolonic malignancy. These 62 patients had 76 previous tumours (12 patients 
had 2 previous tumours and 1 patient had 3 previous tumours). The most preva-
lent initial tumours were breast cancer, head and neck cancer, urothelial cancer 
and melanoma (table 1). No patients were known to have a familial colon cancer 
syndrome. Eleven patients had first or second grade family members with a gastro-
intestinal tumour. Of the 62 patients with colorectal cancer as a second primary tu-
mour, 32 patients had the most recent primary tumour less than five years ago and 
30 patients more than five years ago. Eleven tumours were found synchronous to 
Mortality of patients diagnosed with colorectal cancer as second primary malignancy
DEF-zw-Proefschrift-JW#PROEF-13-april-2012.indd   63 13-4-2012   18:20:28
64
Chapter 4 Mortality of patients diagnosed with colorectal cancer as second primary malignancy
colorectal cancer, five of which were renal cell cancers. Within the group of patients 
with a second primary colorectal cancer, no significant differences in survival times 
were found between type of first cancer and type of treatment.
The distribution of age, sex, tumour location, tumour stage, and year of diagno-
sis in our study population as well as the matched control group and the Leiden 
Colorectal Database (LCD) control group is shown in table 2. Patients were similar 
in all baseline characteristics in all three groups except for the mean age (p=0.01) 
and ACE-27 score (p<0.0001) of patients in the LCD control group. Of the 409 LCD 
controls 11 patients had a familial cancer syndrome and a further 66 patients had 
first or second grade family members with a gastro-intestinal tumour. 
Table 1
Previous malignancies in study group 
Type of cancer Total group %
(n=76)*
Breast 20 26.3
Head and neck 9 11.8
Urothelial 7 9.2
Melanoma 7 9.2
Cervical and endometrial 6 7.9
Lymphoma/leukemia 6 7.9







* there were 76 malignancies in 62 patients
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Study group versus matched control group
Five-year mortality in patients with a second primary colorectal cancer was 60% 
compared with 39% in the matched control patients with a first primary colorectal 
cancer. This resulted in an increased overall mortality of the patients with a second 
primary cancer (HR 1.6, 95% CI 1.2-2.3, p<0.01) (figure 1). Adjustment for tumour 
Table 2












study group vs 
LCD controls
Age (mean, SD) 69.7 (10.1) 69.5 (9.4) 65.1 (13.1) 0.94 0.01
Gender
   Males 31 (50) 108 (49) 207 (51) 0.90 0.98
   Females 31 (50) 112 (51) 202 (49)
Location 
   Colon 44 (71) 168 (76) 271 (66) 0.39 0.57
   Rectum 18 (29) 52 (24) 138 (34)
Classification 
   Stage 1 13 (21) 76 (35) 86 (21) 0.10 0.44
   Stage 2 16 (26) 62 (28) 155 (38)
   Stage 3 15 (24) 66 (30) 109 (27)
   Stage 4 17 (27) 16 (7) 59 (14)
   unknown 1 (2) - -
Year of diagnosis 
  1991-1995 20 (32) 72 (33) 186 (46) 0.87 0.07
  1996-2001 42 (68) 148 (67) 223 (54)
ACE-27
  0 - NA 189 (46) NA <0.0001
  1 25 (40) 130 (32)
  2 21 (34) 63 (15)
  3 16 (26) 16 (6)
  unknown - 1
Mortality of patients diagnosed with colorectal cancer as second primary malignancy
Study group are patients from Leiden Colorectal Database (LCD) with a previous malignancy, matched controls 
from the regional Comprehensive Cancer Center and a control group consisting of remaining patients from Leiden 
Colorectal Database (LCD).
All data are presented in n(%) unless otherwise stated
NA= not applicable. SD= standard deviation
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classification stage or removal of patients from the database with tumour classifi-
cation stage 4 did not affect the hazard ratio. Mortality of patients who had their 
first primary tumour more than five years ago was similar to the mortality of pa-
tients who had their first primary tumour less than five years ago (HR 1.1, 95% CI 
0.6-2.0, p=0.75). 
Study group versus LCD control group
Overall mortality of patients with a second primary colon cancer compared to 
patients with colorectal cancer as a primary tumour from the Leiden Colorectal 
Database was also significantly increased (HR 1.7, 95% CI 1.3-2.3, p<0.01) (figure 
2). After adjustment for age, tumour classification stage, and year of diagnosis the 
increased mortality risk remained (HR 1.7, 95% CI 1.2-2.3, p<0.01). 
Mortality was not affected by possible differences in treatment: adjuvant chemo-
therapy (9.7% versus 14.9%, p=0.27), adjuvant radiotherapy (1.6% versus 4.2%, 
Figure 1
Overall survival of 62 patients with colorectal cancer as second primary cancer compared to 220 
matched patients with colorectal cancer as a first primary tumour from the regional Comprehensive 
Cancer Center with colorectal cancer. 
Chapter 4 Mortality of patients diagnosed with colorectal cancer as second primary malignancy
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p=0.33) or surgical radicality (82.2% versus 80.6%, p=0.72), since further adjust-
ment for these factors did not affect the observed hazard ratio. The increased mor-
tality risk in patients with a second primary colorectal cancer could also not be 
explained by a survival benefit in patients with familial cancer syndromes as the 
overall mortality of the second primary group was similar after removal of patients 
with familial cancer syndromes from the LCD control group (HR 1.6, 95% CI 1.2-2.2, 
p<0.01). 
Figure 2
Overall survival of 62 patients with colorectal cancer as second primary cancer compared to 409 pa-
tients from the Leiden Colorectal Database with colorectal cancer as a first primary tumour. 
Mortality of patients diagnosed with colorectal cancer as second primary malignancy
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Discussion
This study shows that mortality in patients with a secondary primary colorectal 
tumour is increased compared to patients with colorectal cancer as a primary tu-
mour. Differences in mortality were not explained by differences in age, tumour 
classification stage, year of diagnosis, and treatment.
 
The five-year mortality in patients with a second primary colorectal cancer was 
60% compared with 39% in the control patients with a first primary colorectal can-
cer, matched for stage, age, sex, tumour location and year of diagnosis. The interval 
between first and second cancer had also no influence on mortality. The reduction 
in survival may be attributable to an increased co-morbidity caused by the first pri-
mary tumour or its treatment 24. Furthermore, life style and genetic factors could 
also be involved 25-28.
Our results are not in line with two previously published studies assessing the sur-
vival of patients with colorectal cancer as a second primary malignancy compared 
to patients with non-colon cancer as primary tumour 18,19. One study showed bet-
ter survival for patients with colorectal cancer as a second primary malignancy18-
while the other study found a similar survival 19. Results from both studies were 
unexpected because co-morbidity is a strong prognostic factor for mortality of 
colorectal cancer 20-21, although some studies have reported better survival for 
patients with multiple primary malignancies 29. Furthermore, a better survival has 
also been shown in studies with familial cancer syndromes 30. However, after ex-
cluding patients with known familial cancer syndromes from our study, results re-
mained unchanged. 
There are some differences between the two previously reported studies and our 
study. The mean age of the patients in the study by Varty et al. 18 was 73 years com-
pared to 70.5 years in our study. Additionally, that study seems similar in material 
and methods to our study but their control group was formed only by the remain-
Chapter 4 Mortality of patients diagnosed with colorectal cancer as second primary malignancy
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ing patients from the database. Furthermore, 5.3% of the patients of their database 
had colorectal cancer second to a previous extracolonic malignancy compared to 
13% in our study. The difference in frequency could be explained by improved case 
finding and treatment or by the fact that our database had its origin in a tertiary 
hospital. The study by Sankila et al. 19 was based on data from the population-
based Finnish Cancer Registry and only included women with a previous diagnosis 
of breast cancer. The overall uncorrected ratio of relative risk was 1.0 for patients 
with colon carcinoma and prior breast cancer compared with patients with colon 
carcinoma and no prior breast cancer. The corresponding overall corrected ratio 
of relative risk (corrected for the excess mortality related to the first breast cancer) 
was .87. They concluded that, the combined risk of death from breast cancer and 
colorectal carcinoma is similar to that from colorectal carcinoma only.
The number of patients with multiple malignancies is increasing. It is a challenge 
to seek a differentiated individual treatment in these cases because of differences 
in co-morbidity and prognosis. This study showed that patients with a previous 
extracolonic cancer have a higher mortality compared to patients with colorectal 
cancer as a first primary tumour. 
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Abstract
Aims: Comorbidity affects outcomes after colorectal cancer surgery. However, its 
importance in risk adjustment is unclear and different measures are being used. 
This study aims to assess its impact on postoperative outcomes.
Methods: All 2204 patients who were operated on for stage I-III colorectal cancer 
in the Midwestern region of the Netherlands between January 1, 2006 and De-
cember 31, 2008 were analyzed. A multivariate two-step enter-model was used to 
evaluate the effect of the American Society of Anesthesiologists Physical Status 
classification (ASA) score, the sum of diseased organ systems (SDOS), the Charlson 
Comorbidity Index (CCI) and a combination of specific comorbidities on 30-day 
mortality, surgical complications and a prolonged length of stay (LOS). For each 
retrieved model, and for a model without comorbidity, a ROC curve was made.
Results: High ASA score, SDOS, CCI, pulmonary disease and previous malignancy 
were all strongly associated with 30-day mortality and a prolonged LOS. High ASA 
score and gastro-intestinal comorbidity were risk factors for surgical complications. 
Predictive values for all comorbidity measures were similar with regard to all ad-
verse postoperative outcomes. Omitting comorbidity only had a marginal effect on 
the predictive value of the model.
Conclusions: Irrespective of the measure used, comorbidity is an independent risk 
factor for adverse outcome after colorectal surgery. However, the importance of co-
morbidity in risk-adjustment models is limited. Probably the work and costs of data 
collection for auditing can be reduced, without compromising risk-adjustment.
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Introduction
Almost 60% of newly diagnosed colorectal cancer patients aged 65 years and older 
suffer from at least one comorbid condition. 1-2 The presence of comorbidity af-
fects treatment decisions 3-6 and the prognosis of patients receiving colorectal 
cancer treatment. 7-12 Consequently, comorbidity is believed to be an important 
confounder in the analysis of postoperative adverse events and omitting riskad-
justment for comorbidity is argued to introduce bias in studies that do not take it 
into account. The growing emphasis on comparative effectiveness research and 
hospital quality rankings has revived the discussion on the importance of comor-
bidity as a confounding factor.13 
Surgical audits are introduced to measure variations in care process and outcomes 
between hospitals, and to feed back detailed information related to a benchmark 
to care givers, to improve the quality of care. The drawback of these programs is 
that the amount of variables needed for analysis, make them time consuming and 
costly. A reduction in the number of variables needed for risk-adjustment could 
significantly relieve this burden.   
However, despite the growing number of studies addressing comorbidity, the role 
of different comorbidity-scores in models predicting mortality after colorectal can-
cer is not clarified. It is also unknown if different comorbidity scores are similar in 
predicting other postoperative adverse events, such as postoperative complica-
tions. 
In colorectal cancer research, the Charlson Comorbidity Index (CCI) and the sum of 
diseased organ systems (SDOS) (i.e., NIA/NCI or Elixhauser lists) are randomly used 
in prediction models for postoperative adverse outcomes after colorectal surgery. 
14-17 Also, the American Society of Anaesthesiologists Physical Status classification 
(ASA) score, is used for this purpose.  The ASA- score, SDOS and CCI have the ad-
vantage that the required data are readily available. More detailed indices may cor-
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relate better with outcome, but have the disadvantage that not all required items 
can be easily obtained for clinical registration and auditing. 
The aim of this study is to assess the impact of comorbidity, estimated by three 
different scores, on postoperative mortality, surgical complications and length of 
stay (LOS) after colorectal cancer surgery. The second aim is to compare the predic-
tive value of these scores with a set of specific comorbidities, and a model with no 
riskadjustment for comorbidity at all.  
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Methods
Data source
In the Netherlands, all newly diagnosed malignancies are registered in the nation-
wide population based Netherlands Cancer Registry (NCR). Independent trained 
data managers collect data from the original patient files after receiving an auto-
matic report from the Dutch pathology reporting system “PALGA.” Completeness 
of the cancer registry is crosschecked with the Dutch National Registry of Hospital 
Discharge Diagnosis, which is a near complete registry of hospital discharge data. 
Information on patient characteristics, tumour characteristics, hospital of diagnosis 
and/or treatment and follow-up are routinely recorded. Tumour site and morphol-
ogy are coded according to the International Classification of Diseases for Oncol-
ogy (ICD-0).18 All cancers are staged by the NCR according to the TNM classification 
of Malignant Tumours, 6th edition.19 The quality of the data is high, and complete-
ness is estimated to be at least 95%.20-21
The Leiden Cancer Registry, which is part of the NCR, collects data on all cancer 
patients diagnosed in one of the nine affiliated hospitals of the comprehensive 
cancer centre west (CCCW) in the Midwestern part of the Netherlands. This region 
comprises of one university hospital, six teaching hospitals and two non-teaching 
hospitals and serves a population of 3.5 million. 
In 2006, a regional audit for colorectal cancer surgery (KIC) was started. The data 
collection was extended to data that reflected quality of care, such as postop-
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erative surgical complications. These prospectively collected data were used for 
benchmarking and reflection, ultimately to improve the quality of care in the entire 
region. 
Patients
All patients who were diagnosed with a neoplasm of the colon (C18), the rectosig-
moid (C19) or the rectum (C20) from January 1, 2006 to December 31, 2008 in one 
of the affiliated hospitals of the CCCW were identified from the cancer registry. Pa-
tients with a stage IV tumour, those with a tumour of the appendix, and those who 
did not undergo a surgical resection of the tumour were excluded. 
Data were collected on patient demographics (age, sex, comorbidities, ASA score), 
tumour characteristics (localization, TNM staging) and type of treatment (neo-ad-
juvant treatment, type of surgery, urgency of the operation, and hospital of treat-
ment). 
All comorbidities present at time of diagnosis were registered and categorized ac-
cording to the NCR guideline (appendix I). 
For each patient, the CCI was calculated. Patients were categorized as CCI 0, 1, or 
CCI >1. In addition, the SDOS was calculated for each patient. Patients were cat-
egorized as no comorbidity, 1 or 2 diseased organ systems, and > 2 diseased organ 
systems. For the ASA score, patients were categorized as ASA 1 or 2 and ASA 3 or 
higher. Missing data from the ASA score were included as a separate category in 
multivariate analysis.22
Outcomes
Postoperative mortality was defined as 30-day mortality: death from any cause 
between date of surgery and 30 days thereafter. Vital status of all patients was ob-
tained actively on a regular basis through linking with the integrated database of 
the municipal registry and the central bureau for genealogy. Surgical complications 
were classified as wound infections (both superficial and deep), wound dehiscence 
(including all abdominal wall problems) and abdominal problems, including all 
intra-abdominal complications such as bleeding, ileus, infections, abscess or anas-
tomotic leaks. There were no data available on non-surgical complications. Instead, 
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a prolonged LOS was used as a proxy for postoperative complications in general. In 
this study, a prolonged LOS was defined as a stay of more than 14 days. A LOS more 
than 14 days is associated with the occurrence of complications and an uneventful 
postoperative period is unlikely to result in a longer hospital stay. Therefore a LOS 
of longer than 14 days can function as a proxy for complications in general.    
Statistics
Descriptive statistics were calculated for all variables. The possible influences of pa-
tient-, tumour-, and treatment characteristics were analyzed by means of univari-
ate logistic regression analysis. A multivariate two-step enter-model was used to 
evaluate the effect of comorbidity on postoperative mortality, surgical complica-
tions and a prolonged LOS for colorectal cancer patients and for colon and rectal 
cancer patients separately. 
For each outcome, four different models were made and compared. In each model 
a fixed set of parameters were included in the first step irrespective of statistical 
significance: age, gender, urgency, T stage, neo-adjuvant therapy and hospital of 
surgery. In the second step of each model, one of the scores was added: the ASA 
score, the SDOS, the CCI or a combination of specific comorbidities, selected with 
univariate analysis (comorbidities with P < 0.05 were selected). 
For each retrieved model, an ROC curve was made, and the area under the curve 
(AUC) was calculated.23 The retrieved AUC curves were compared to each other 
and with the AUC curve of the model without comorbidity. The overlap of 95%-
confidence intervals of the AUC’s was compared to calculate statistical significance. 
For all analyses, PASW statistics® version 18 software (SPSS inc, Chicago, Illinois, 
USA) was used.




Between January 1, 2006 and December 31, 2008, 2204 patients were diagnosed 
and surgically treated for stage I-III colorectal cancer in one of nine affiliated hospi-
tals of the CCCW, of which 1435 patients had colon cancer and 769 had rectal can-
cer. The mean age was 70 years. All patient characteristics are shown in table 1.
Table 1
Baseline characteristics of 2204 stage I - III colorectal cancer patients from the Comprehensive Cancer 








Variable Characteristic Number % Number % Number %
Gender Male 689 48.0 435 56.6 1124 51.0
Female 746 52.0 334 43.4 1080 49.0
Age < 65 378 26.3 279 36.3 657 29.8
65-74 397 27.7 257 33.4 654 29.7
75-84 504 35.1 192 25.0 696 31.6
> 85 156 10.9 41 5.3 197 8.9
Mean (range) 71 (24-96) 68 (22-94) 70.3 (22-96)
pT 0 8 0.6 30 3.9 38 1.7
1 78 5.4 46 6.0 124 5.6
2 203 14.1 242 31.5 445 20.2
3 951 66.3 423 55.0 1374 62.3
4 195 13.6 28 3.6 223 10.1
Stage 1 237 16.5 220 28.6 457 20.7
2 672 46.8 237 30.8 909 41.2
3 518 36.1 282 36.7 800 36.3
Neo-adjuvant Yes 6 0.4 473 61.5 479 21.7
treatment
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The majority of patients had at least one comorbid disease (54%): 145 patients 
(6.6%) had three or more affected organ systems, and 426 patients (19.3%) had a 








Variable Characteristic Number % Number % Number %
Urgency Elective 1247 86.9 752 97.8 1999 90.7
Urgent/ acute 188 13.1 17 2.2 205 9.3
ASA 1 154 10.7 124 16.1 278 12.6
2 488 34.0 301 39.1 789 35.8
3 267 18.6 120 15.6 387 17.6
4 31 2.2 9 1.2 40 1.8
missing 495 34.5 215 28 710 32.2
SDOS None 615 42.9 400 52.0 1015 46.1
1 or 2 710 49.5 334 43.4 1044 47.4
> 2 110 7.7 35 4.6 145 6.6
CCI 0 769 53.6 474 61.6 1243 56.4
1 365 25.4 170 22.1 535 24.3
>1 301 21.0 125 16.3 426 19.3
Particular Cardiac 367 25.6 150 19.5 517 23.5
comorbidities Hypertension 424 29.5 204 26.5 628 28.5
Pulmonary 179 12.5 74 9.6 253 11.5
Malignancy 204 14.2 90 11.7 294 13.3
Gastro-intestinal 85 5.9 25 3.3 110 5.0
Uro-renal 34 2.4 13 1.7 47 2.1
Reumatologic 22 1.5 8 1.0 30 1.4
Neurologic 38 2.6 19 2.5 57 2.6
Diabetes 211 14.7 79 10.3 290 13.2
Infectious 18 1.3 9 1.2 27 1.2
CVA 61 4.3 19 2.5 80 3.6
Thrombosis 47 3.3 18 2.3 65 2.9
Vascular disease 82 5.7 46 6.0 128 5.8
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cardiac disease (23.5%), pulmonary disease (11.5%), a previous malignancy (13.3%) 
and diabetes (13.2%). The presence of comorbidity increased with age, although 
patients older than 85 years had a lower percentage of comorbidities.
The prevalence of comorbidity was higher in patients with colon cancer compared 
to patients with rectal cancer (57% versus 48%, p <0.001).
Outcomes
In total, 106 patients (4.8%) died within 30 days after surgery (table 2). The 30-day 
mortality was 6.2% in the patients with colon cancer and 2.2% in the patients with 
rectal cancer (p<0.001). In approximately 20% of all patients, postoperative surgical 
complications occurred, 14 which the majority were abdominal events (14%). The 
median LOS was 10 days, and 671 patients (30.4%) had a prolonged LOS. 
Table 2





patients % All patients %
30- day mortality 89 6.2 17 2.2 106 4.8
Surgical 
Complications None 1181 82.3 597 77.6 1778 80.7
1 232 16.2 159 20.7 391 17.7
2 22 1.5 13 1.7 35 1.6
Wound 
infection 62 4.3 48 6.2 110 5.0
Abdominal 
problem 183 12.8 123 16.0 306 14.1
Wound 
dehiscence 31 2.2 14 1.8 45 2.0
Length of Stay > 14 days 423 29.5 248 32.2 671 30.4
Median (days) 9 (1-230) 11 (2-374) 10 (1-374)
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Impact of comorbidity on postoperative mortality
In the model, a high ASA score, SDOS and CCI were all strongly associated with 
30-day mortality (table 3). Pulmonary disease and a previous malignancy were 
independent risk factors as well. A history of thrombosis was a significant inde-
pendent risk factor in rectal cancer patients. The ROC curves of all retrieved mod-
els are shown in figure 1. The AUC of the model with the ASA score was 0.843 
(0.806-0.880), with the SDOS 0.838 (0.800-0.876), with the CCI 0.846 (0.810-0.882), 
and with a combination of specific comorbidities 0.853 (0.817-0.890). There was no 
significant difference in AUC between the models. 
Table 3
Multivariable logistic regression analysis of the association of different comorbidity measures with 






Variable OR (95%CI) p-value OR (95%CI) p-value OR (95% CI) p-value
ASA 1 or 2 1 0.002 1 0.148 1 <0.001
3 or 4 3.18 (1.59-6.36) 3.73 (0.95-14.73) 3.25 (1.76-5.99)
missing 3.02 (1.49-6.11) 3.39 (0.64-17.88) 2.93 (1.55-5.53)
SDOS 0 1 0.141 1 0.046 1 0.014
1 or 2 1.32 (0.78-2.24) 14.04 (1.71-115.60) 1.75 (1.07-2.87)
> 2 2.15 (1.01-4.61) 17.23 (1.19-249.44) 2.71 (1.33-5.51)
CCI 0 1 0.014 1 0.025 1 < 0.001
1 1.30 (0.72-2.34) 5.24 (1.14-24.19) 1.63 (0.95-2.78)
>1 2.27 (1.30-3.98) 8.10 (1.73-38.01) 2.73 (1.63-4.57)
Specific 
comorbidities
Cardiac 0.59 (0.34-1.04) 0.066 1.64 (0.52-5.24) 0.401 0.70(0.43-1.14) 0.155
Hypertension 1.44 (0.87-2.40) 0.160 1.89 (0.55-6.49) 0.309 1.50 (0.94-2.37) 0.087
CVA 1.70 (0.70-4.09) 0.239 6.09 (0.85-43.43) 0.072 1.87 (0.86-4.09) 0.115
Pulmonary 2.39 (1.36-4.20) 0.002 2.77 (0.58-13.28) 0.202 2.23 (1.33-3.73) 0.002
Diabetes 1.44 (0.78-2.67) 0.248 0.68 (0.10-4.51) 0.688 1.37 (0.78-2.43) 0.276
Previous 
Malignancy 1.84 (1.03-3.29) 0.041 1.46 (0.34-6.30) 0.612 1.72 (1.02-2.90) 0.042
Uro-renal 1.26 (0.34-4.72) 0.731 2.81 (0.30-26.03) 0.363 1.68 (0.59-4.79) 0.336
Thrombosis 2.03 (0.75-5.50) 0.164 9.39 (1.28-69.04) 0.028 2.31 (0.99-5.40) 0.054
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Impact of comorbidity on surgical complications
In univariate analysis ASA score ≥ 3, SDOS >2, CVA and gastro-intestinal disease 
were identified as risk factors for surgical complications. In multivariate analysis, 
only ASA score and gastro-intestinal disease remained significant (table 4). 
The ROC curves of all retrieved multivariable models are shown in figure 1. The 
AUC of the model with the ASA score was 0.621 (0.592-0.650), with the SDOS 0.614 
(0.584-0.643), with the, CCI 0,615 (0.586-0.644) and with a combination of specific 
comorbidities 0.619 (0.589-0.648). There was no significant difference in AUC be-
tween the models. 
Figure 1
ROC-curves of prediction-models of 30-day mortality, surgical complications and prolonged LOS (>14 
days) with different comorbidity measures added to the model. Abreviations: ASA, American Society 
of Anaesthesiologists Score; SDOS, Sum of Diseased Organ Systems; CCI, Charlson Comorbidity Index; 





Variable OR (95%CI) p-value OR (95%CI) p-value OR (95% CI) p-value
ASA 1 or 2 1 0.002 1 0.148 1 <0.001
3 or 4 3.18 (1.59-6.36) 3.73 (0.95-14.73) 3.25 (1.76-5.99)
missing 3.02 (1.49-6.11) 3.39 (0.64-17.88) 2.93 (1.55-5.53)
SDOS 0 1 0.141 1 0.046 1 0.014
1 or 2 1.32 (0.78-2.24) 14.04 (1.71-115.60) 1.75 (1.07-2.87)
> 2 2.15 (1.01-4.61) 17.23 (1.19-249.44) 2.71 (1.33-5.51)
CCI 0 1 0.014 1 0.025 1 < 0.001
1 1.30 (0.72-2.34) 5.24 (1.14-24.19) 1.63 (0.95-2.78)
>1 2.27 (1.30-3.98) 8.10 (1.73-38.01) 2.73 (1.63-4.57)
Specific 
comorbidities
Cardiac 0.59 (0.34-1.04) 0.066 1.64 (0.52-5.24) 0.401 0.70(0.43-1.14) 0.155
Hypertension 1.44 (0.87-2.40) 0.160 1.89 (0.55-6.49) 0.309 1.50 (0.94-2.37) 0.087
CVA 1.70 (0.70-4.09) 0.239 6.09 (0.85-43.43) 0.072 1.87 (0.86-4.09) 0.115
Pulmonary 2.39 (1.36-4.20) 0.002 2.77 (0.58-13.28) 0.202 2.23 (1.33-3.73) 0.002
Diabetes 1.44 (0.78-2.67) 0.248 0.68 (0.10-4.51) 0.688 1.37 (0.78-2.43) 0.276
Previous 
Malignancy 1.84 (1.03-3.29) 0.041 1.46 (0.34-6.30) 0.612 1.72 (1.02-2.90) 0.042
Uro-renal 1.26 (0.34-4.72) 0.731 2.81 (0.30-26.03) 0.363 1.68 (0.59-4.79) 0.336
Thrombosis 2.03 (0.75-5.50) 0.164 9.39 (1.28-69.04) 0.028 2.31 (0.99-5.40) 0.054
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Impact of comorbidity on prolonged LOS
In multivariate analysis, high ASA score, SDOS and CCI were all strongly associated 
with a prolonged LOS (table 5). CVA, pulmonary disease and a previous malignan-
cy were also identified as independent risk factors
The ROC curves of all retrieved multivariable models are shown in figure 1. The 
AUC of the model with the ASA score was 0.695 (0.672-0.718), with the SDOS 0.696 
(0.672-0.719), with the CCI 0,690 (0.666-0.713), and with a combination of specific 
comorbidities 0.702 (0.678-0.725). There were no significant differences in AUC of 
the different models. 
Table 4
Multivariable logistic regression analysis of the association of different comorbidity measures with 
surgical complications (Factors included in each model were age, gender, urgency, T stage, neo-adjuvant therapy 





Variable OR (95%CI) p-value OR (95%CI) p-value OR (95% CI) p-value
ASA 1 or 2 1 0.124 1 0.099 1 0.019
3 or 4 1.34 (0.93-1.93) 1.72 (1.05-2.82) 1.49 (1.11-1.99)
missing 0.89 (0.62-1.28) 1.23 (0.76-2.00) 1.02 (0.77-1.36)
SDOS 0 1 0.708 1 0.508 1 0.696
1 or 2 1.13 (0.84-1.53) 1.11 (0.77-1.61) 1.09 (0.86-1.36)
2 1.06 (0.62-1.84) 0.63 (0.23-1.75) 0.94 (0.58-1.51)
CCI 0 1 0.349 1 0.637 1 0.422
1 0.99 (0.70-1.40) 1.23 (0.80-1.89) 1.05 (0.81-1.37)
>1 1.27 (0.90-1.81) 1.12 (0.67-1.88) 1.21 (0.91-1.62)
Specific 
comorbidities
CVA 1.49 (0.81-2.73) 0.201 1.45 (0.52-4.04) 0.481 1.51 (0.90-2.52) 0.119
Gastro-intestinal 1.87 (1.13-3.10) 0.015 1.20 (0.45-3.15) 0.718 1.63 (1.05-2.55) 0.030
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Additional value of comorbidity for the predictive value of the models
When comorbidity was removed from the multivariable models, the AUC of the 
different ROC curves did not change (figure 2). Indicating a marginal contribution 
of comorbidity to the predictive value of the models for 30-day mortality, surgical 
complications and prolonged LOS.    
Table 5
Multivariable logistic regression analysis of the association of different 
comorbidity measures with prolonged LOS (> 14 days) (Factors included in each model were age, 





Variable OR (95%CI) p-value OR (95%CI) p-value OR (95% CI) p-value
ASA 1 or 2 1 <0.001 1 0.009 1 <0.001
3 or 4 1.89 (1.37-2.60) 1.88 (1.19-2.98) 1.90 (1.47-2.46)
missing 1.14 (0.82-1.57) 1.77 (1.06-2.65) 1.30 (1.00-1.69)
SDOS 0 1 < 0.001 1 0.006 1 < 0.001
1 or 2 1.52 (1.17-1.98) 1.43 (1.01-2.03) 1.44 (1.17-1.78)
> 2 2.26 (1.43-3.56) 3.18 (1.47-6.90) 2.39 (1.62-3.52)
CCI 0 1 0.007 1 0.254 1 0.004
1 1.31 (0.98-1.76) 1.31 (0.88-1.96) 1.28 (1.01-1.62)
>1 1.63 (1.20-2.22) 1.36 (0.86-2.15) 1.51 (1.17-1.94)
Specific 
comorbidities
Cardiac 1.16 (0.87-1.54) 0.321 1.56 (1.03-2.37) 0.035 1.23 (0.98-1.55) 0.080
Hypertension 1.18 (0.91-1.54) 0.213 1.36 (0.59-3,14) 0.427 1.18 (0.95-1.46) 0.139
CVA 1.10 (0.61-1.96) 0.756 6.79 (2.08-22.19) 0.002 1.67 (1.02-2.72) 0.040
Pulmonary 1.62 (1.14-2.30) 0.007 1.60 (0.93-2.72) 0.087 1.57 (1.17-2.09) 0.002
Previous Malig-
nancy 1.46 (1.04-2.05) 0.027 1.60 (0.95-2.70) 0.076 1.46 (1.10-1.92) 0.008
Uro-renal 1.69 (0.80-3.54) 0.167 1.19 (0.33-4.23) 0.792 1.75 (0.94-3.28) 0.080
Thrombosis 1.79 (0.94-3.40) 0.077 1.17 (0.42-3.24) 0.770 1.59 (0.93-2.73) 0.094





Variable OR (95%CI) p-value OR (95%CI) p-value OR (95% CI) p-value
ASA 1 or 2 1 0.124 1 0.099 1 0.019
3 or 4 1.34 (0.93-1.93) 1.72 (1.05-2.82) 1.49 (1.11-1.99)
missing 0.89 (0.62-1.28) 1.23 (0.76-2.00) 1.02 (0.77-1.36)
SDOS 0 1 0.708 1 0.508 1 0.696
1 or 2 1.13 (0.84-1.53) 1.11 (0.77-1.61) 1.09 (0.86-1.36)
2 1.06 (0.62-1.84) 0.63 (0.23-1.75) 0.94 (0.58-1.51)
CCI 0 1 0.349 1 0.637 1 0.422
1 0.99 (0.70-1.40) 1.23 (0.80-1.89) 1.05 (0.81-1.37)
>1 1.27 (0.90-1.81) 1.12 (0.67-1.88) 1.21 (0.91-1.62)
Specific 
comorbidities
CVA 1.49 (0.81-2.73) 0.201 1.45 (0.52-4.04) 0.481 1.51 (0.90-2.52) 0.119
Gastro-intestinal 1.87 (1.13-3.10) 0.015 1.20 (0.45-3.15) 0.718 1.63 (1.05-2.55) 0.030
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Discussion
Comorbidity is an independent risk factor for 30-day mortality and a prolonged 
LOS after colorectal cancer surgery. All used comorbidity measures (ASA score, the 
SDOS, the CCI) had similar predictive values. For the occurrence of postoperative 
surgical complications, the only predictive comorbidity measure was ASA  score 
and the only specific risk factor was gastro-intestinal comorbidity. Apparently, any 
of these measures can be used in predicting adverse outcome in colorectal cancer 
surgery. 
However, the importance of comorbidity in models predicting the risk of postop-
erative adverse events is limited.  
Figure 2
ROC-curves of prediction-models of 30-day mortality, surgical complications and prolonged LOS (>14 
days) without comorbidity added to the model. 
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Different comorbidity measures
The results of the present study show that all used models are similar in predict-
ing postoperative adverse events after colorectal cancer surgery. This goes for all 
three examined outcomes. The predictive values of the ASA score, the SDOS and 
the CCI on postoperative mortality of colorectal cancer patients have been previ-
ously studied .10-24-26 These studies showed a strong correlation with postopera-
tive mortality and moderate correlation with postoperative morbidity, which com-
pares to our findings. 
However, few studies compared the predictive value of different comorbidity scores. 
Hines and colleagues evaluated the impact of the choice of comorbidity measure 
on long-term survival after colorectal cancer surgery.27 They found similar results 
for the Adult Comorbidity Evaluation-27 score (ACE-27), the NIA/NCI comorbidity 
index and the CCI. Dimick et al evaluated if reduction in the number of variables 
for risk-adjustment would alter the predictive value of the models predicting post-
operative outcome in data of the National Surgical Quality Improvement Program 
(NSQIP).28-29 Their results demonstrated that a reduced set of case mix variables 
could be used without compromising risk-adjustment. The authors conclude that 
risk-adjustment could be simplified, thus lowering the registration burden. 
Comorbidity and risk adjustment
In the present study, adding comorbidity to the model only slightly increased the 
predictive value of the model. This contradicts the common believe that extensive 
risk-adjustment for comorbidity, is always important. Although comorbidity repre-
sents an important risk domain, it adds little to the predictive value of the model. 
This can be explained by the fact that the influence of comorbidity is already cap-
tured by other variables in the model, such as age and emergency surgery. 
Nevertheless, also in the present study, comorbidity remains a significant risk fac-
tor for postoperative mortality and prolonged LOS, independent of the choice of 
comorbidity measure. Although the association with postoperative surgical com-
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plications was limited, a strong association was seen with a prolonged LOS, imply-
ing that comorbidities do have an impact on postoperative non-surgical complica-
tions. This confirms previous evidence showing the impact of comorbidities on the 
occurrence of complications and LOS. 30-32
However, only patients with severe comorbidities seemed to be at higher risk of ad-
verse events. In this study, only patients with severe comorbidity (ASA III or higher, 
SDOS >2 and CCI > 1) were at greater risk. This could mean that limited comorbidity 
does not necessarily have to influence treatment decisions.
It should be noted that the registration of comorbidities and risk-adjustment for 
comorbidities has several advantages. First, it increases the face validity and pre-
vents gaming of quality measurement efforts. Omitting risk adjustment for comor-
bidities could lead to more defensive treatment regimes and even avoidance of 
high risk patients. 
Also, when individual hospitals receive feedback on their performance, insight in 
the characteristics of their patient population, including comorbidities, could guide 
quality improvement initiatives. Lastly, the registration of comorbidities allows for 
the identification of procedure specific and outcome specific comorbidities, that 
represent a greater post-operative risk in large population based databases. 
Strengths and weaknesses
The present study has several strengths. Clinical, accurate data of the Netherlands 
Cancer Registry are used, and variables included an extensive registration of co-
morbidities and other relevant case mix factors such as the urgency of the opera-
tion and tumour stage. 
Nevertheless, the results of this study should be interpreted with regard of several 
limitations to the dataset. The number of missing data regarding the ASA score 
is large. However, patients with missing ASA scores formed a distinct category in 
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multivariate analysis. In all analyses, the missing ASA category showed outcomes 
between the outcomes for ASA I-II and ASA III-IV; therefore, it could be assumed 
ASA data were randomly missing, and missing data did not interfere with the out-
come of this study. 
Also, only data on postoperative surgical complications were available. A prolonged 
LOS was used as a substitute of postoperative complications in general. In this 
study, a prolonged LOS was defined as a stay of more than 14 days. An uneventful 
postoperative period is unlikely to result in a longer hospital stay. Therefore, it can 
be used as a substitute measure for overall complications. This assumption is sup-
ported by a study of Cohen et al, who demonstrated a mean LOS after colorectal 
surgery of 16 days in the presence of complications versus 6 days when no com-
plications occurred.30 In the present study 30.4% of the patients had a prolonged 
LOS. This is also consistent with findings in literature.30-31
Acknowledging these limitations, the findings of this study can have important im-
plications for current and future audit initiatives, as the number of variables may be 
reduced.33-34  The results are especially important for the ‘European Registration of 
Cancer Care’ (EURECCA) framework, an initiative of the European CanCer Organisa-
tion (ECCO), to develop a European colorectal audit structure.33 In this dataset, the 
universal ASA score may be sufficient to assure both adequate risk adjustment and 
face validity. 
Conclusion
This study demonstrates that comorbidity is a significant risk factor for postopera-
tive adverse events after colorectal cancer surgery. However, the role of comorbid-
ity in risk adjustment for colorectal cancer surgery is  limited. Obviously risk adjust-
ment for case mix influences remains elementary, but the effect of comorbidity in 
predictive models seems only marginal. These findings suggest that the workload 
and costs of data collection could be reduced. Nevertheless, advantages of exten-
sive risk-adjustment for comorbidities should be considered in the decisions to re-
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duce the number of variables collected. Further efforts should be made to identify 
the most important clinical comorbid factors to minimize the amount of necessary 
data, without compromising risk-adjustment.   
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Abstract
Aims: For several types of cancer, including colon cancer, the survival gap between 
middle-aged patients and elderly patients widened between 1988 and 1999 in Eu-
rope. The aim of our study was to describe treatments and compare survival rates 
over time (1991-2005) between middle-aged (<65 years), aged (65-74 years) and 
elderly (≥75 years) colon cancer patients in the mid-western part of the Nether-
lands to assess whether this survival gap further increased.
Methods: All 8926 patients with invasive colon cancer diagnosed between 1991 
and 2005 were selected from the Comprehensive Cancer Centre West. Relative sur-
vival was calculated. Relative Excess Risks of death (RER) were estimated using a 
multivariable generalized linear model with a Poisson distribution. 
Results: There were no significant changes in the treatment for stage I and II colon. 
Patients with stage III and IV more often received chemotherapy over time (from 
9.6% to 54.3% and from 7.5% to 44.2% for all ages, respectively), while less stage IV 
patients were operated on (from 73.1% to 55.2%). Relative 5-year survival increased 
significantly for middle-aged patients (RER=0.97, 95%CI=0.95-0.98, p<0.001), bor-
derline significantly (RER=0.98, 95% CI=0.97-0.99, p=0.05) for elderly patients and 
not significantly for aged patients (RER=0.99, 95%CI=0.97-1.00, p=0.08) after ad-
justment for sex, age, grade, stage, and treatment. 
Conclusions: The survival gap earlier found by the EUROCARE is confirmed for the 
mid-western part of the Netherlands, even after adjustment for age, sex, grade, 
stage and treatment. However, present study does not show an increase in the sur-
vival gap between middle-aged and elderly patients.
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Introduction
Colorectal cancer is the second most commonly diagnosed cancer in the Nether-
lands.1 The incidence in the Netherlands is more than 57 per 100 000 persons per 
year (European Standardized Rate) and increases with age. There is an incidence 
peak around 74-80 years and approximately half of colorectal patients are over 70 
years of age. 
The EUROCARE Working Group has compared five-year relative survival between 
elderly (70–84 years) and middle-aged cancer patients (55–69 years).2 They ob-
served a significant survival improvement between 1988 and 1999 for all cancers 
combined and for almost every cancer site including colon cancer. Survival in-
creased at a slower rate in the elderly. As a result the gap in survival between mid-
dle-aged and elderly patients widened. In particular middle-aged women showed 
more marked improvements than elderly women for colon cancer.2 Differences in 
survival for colon cancer may be explained by variations in tumour factors, patient 
characteristics and therapy. Elderly patients receive adjuvant chemotherapy less 
frequently and more often discontinue treatment.3 Moreover, the administration 
of adjuvant treatment for elderly stage III colon cancer patients is influenced by 
socioeconomic status, gender, and co-morbidity.4 Besides, co-morbidity also influ-
ences surgical eligibility and other treatment options. 
In recent years the focus on elderly colon cancer patients has increased. Several 
studies have concluded that age per se is not a contraindication for more aggres-
sive or adjuvant treatment.5 Therefore, the past ten years more elderly patients are 
considered for extensive therapy in routine clinical practice.5 As a consequence 
an improved outcome for elderly patients might be expected. We hypothesized 
that the gap in survival between middle-aged and elderly patients as observed 
in the EUROCARE data between 1988 and 1999 might be decreasing.  Hence, the 
aim of our study was to describe treatments and compare survival rates over time 
between middle-aged (<65 years), aged (65-74 years) and elderly (≥75 years) colon 
cancer patients. 
The survival gap between middle-aged and elderly colorectal cancer patients. 
Time trends in treatment and survival.




Patients were selected from the regional cancer registry of the Comprehensive 
Cancer Centre West (CCCW) covering the mid-western part of the Netherlands. 
The nationwide Dutch network and registry of histo- and cytopathology (PALGA) 
regularly submits reports of all diagnosed malignancies to the cancer registries. 
The national hospital discharge databank, which receives discharge diagnoses 
of admitted patients from all Dutch hospitals, completes case ascertainment. Af-
ter notification, trained registry personnel collect data on diagnosis, staging, and 
treatment from the medical records, including pathology and surgery reports, us-
ing the registration and coding manual of the Dutch Association of Comprehensive 
Cancer Centres. Cancer registry data show actual variations in patterns of staging, 
treatment and survival by age. Therefore, these data offer a scope for improvement 
of care and for creating guidelines, in addition to randomized clinical trials.6
From the regional cancer registry, patients with their first primary invasive colon 
cancer were selected (International Classification of Diseases for Oncology (ICD-O) 
code C18.0), diagnosed between 1991 and 2005 (n = 8926). CCCW established vital 
status either directly from the patients’ medical record or through linkage of cancer 
registry data with the municipal population registries which record information on 
their inhabitants’ vital status (last linkage at December 31st 2009). Stage was based 
on pathological information; clinical information was used if pathology data were 
missing.  
Statistical analyses
Patients were divided into middle-aged (younger than 65 years), aged (65-74 years) 
and elderly (75 years and older). We chose to divide the patients into those three 
age groups, so differences between middle-aged and elderly patients would be 
more pronounced. Differences between age groups were tested with Chi-Square 
tests. Statistical significance was defined as p≤0.05. The study period was divided 
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into three 5-year strata for the analyses of the treatment data; 1991-1995, 1996-
2000, and 2001-2005. Treatment was divided into no treatment, surgery only, sur-
gery and chemotherapy, chemotherapy only, and other (radiotherapy, in combi-
nation with surgery and/or chemotherapy). Changes over time were assessed for 
stage at diagnosis and age. 
For survival analyses, relative survival is the preferred way to describe the progno-
sis of elderly cancer patients, as it takes into account the risk of dying from other 
causes than the cancer of interest.6 Relative survival was calculated by the Haku-
linen method as the ratio of the observed survival among the cancer patients and 
the survival that would have been expected based on the corresponding (age, sex 
and year) general population. National life tables were used to estimate expected 
survival. Patients diagnosed between 1991 and 2004 were selected for 5-years sur-
vival analyses (n=8197). Patients diagnosed in 2005 were excluded from survival 
analyses by year, because five year follow-up was not available. Relative Excess 
Risks of death (RER) were estimated using a multivariate generalized linear model 
with a Poisson distribution, based on collapsed relative survival data, using exact 
survival times. Relative Excess Risks of death over time were calculated according 
to age and according to year of incidence stratified for age groups, with their 95% 
confidence interval (95%CI). The RER was adjusted for sex, age, grade, and stage. 
Models with and without adjustment for treatment are shown to assess the effect 
of therapy on the RER. Model fit was assessed for each multivariable analysis. Based 
on the model fit, continuous or categorical data were selected for the analyses. 
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Between 1991 and 2005, 8926 patients with incident primary colon cancer were 
registered in the database of the Comprehensive Cancer Centre West (CCCW) in the 
Netherlands. The characteristics of the patients are shown in Table 1. 
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Table 1







Sex Male 1311 (51.0) 1328 (51.8) 1571 (41.4) p<0.001
Female 1259 (49.0) 1236 (48.2) 2221 (58.6)
Year 1991-1995 794 (30.9) 829 (32.3) 1162 (30.6) p=0.08
1996-2000 791 (30.8) 844 (32.9) 1240 (32.7)
2001-2005 985 (38.3) 891 (34.8) 1390 (36.7)
Grade I 151 (5.9) 158 (6.2) 219 (5.8) p<0.001
II 1466 (57.0) 1610 (62.8) 2212 (58.3)
III 428 (16.7) 396 (15.4) 649 (17.1)
Unknown 525 (20.4) 400 (15.6) 712 (18.8)
Stage I 320 (12.5) 386 (15.1) 480 (12.7) p<0.001
II 799 (31.1) 922 (36.0) 1502 (39.6)
III 644 (25.1) 634 (24.7) 819 (21.6)
IV 619 (24.1) 488 (19.0) 590 (15.6)
Unknown 188 (7.3) 134 (5.2) 401 (10.6)
Surgery No 271 (10.5) 242 (9.4) 630 (16.6) p<0.001
Yes 2299 (89.5) 2322 (90.6) 3162 (83.4)
Chemotherapy No 1760 (68.5) 2125 (82.9) 3661 (96.6) p<0.001
Yes 810 (31.5) 439 (17.1) 131 (3.4)
Age Groups
Number displayed are n (%)
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The male to female ratio changed over time from 0.8 to 1.0. The age distribution 
was stable from 1991 to 2005 (p=0.08). The distribution between men and women 
changed with age, with relatively more elderly women diagnosed than men. The 
median age at diagnosis was 72 years (range 7-101 years) and stable over time. 
Patients between 65 and 75 years at time of diagnosis were more often diagnosed 
with grade II, and less often with unknown grade (p<0.001). Stage distribution was 
associated with age, with more elderly patients having an unknown stage of dis-
ease. 
Elderly patients did not have more advanced disease at time of diagnosis. Elderly 
patients were less frequently operated on their colon cancer compared with mid-
dle-aged and aged patients, while use of chemotherapy gradually declined over 
the age strata. 
Treatment
Changes in treatment over time for the three age groups are shown in Figure 1. 
During the study period, almost all patients with stage I to III colon cancer under-
went resection of their primary tumour (98.5%). Over time, there were no signifi-
cant changes in treatment for stage I and II in all age groups. Patients with stage III 
colon cancer received significantly more often surgery with adjuvant chemother-
apy over time: from 31% to 85% among the middle-aged patients (p<0.001), from 
8% to 59% among the aged patients (p<0.001), and from 2% to 13% for the oldest 
patients (p<0.001). Resection rates of stage IV colon cancer patients (with or with-
out chemotherapy) decreased over time: from 73% to 60% among middle-aged 
patients (p=0.02), from 73% to 64% among aged patients (p=0.2), and from 67% to 
51% among elderly patients (p=0.004). The use of chemotherapy only for stage IV 
colon cancer increased: from 10% to 26% in the middle-aged patients (p<0.001), 
from 6% to 17% in the aged patients (p=0.002), and from 0% to 7% in the elderly 
patients (p<0.001). Elderly patients with stage IV colon cancer received more of-
ten no treatment compared to middle-aged patients, 17% in the middle-aged and 
aged group compared to 38% in the elderly group(p<0.001).
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Survival
Overall, there was a significant increase in the 5-year relative survival from 54.9% 
in 1991-1995, to 56.5% in 1996-2000, and to 57.9% in 2001-2004 (p=0.03). The 
5-year relative survival of men increased from 52.5% in 1991-1995 to 58.9% in 
2001-2004(p=0.02), the 5-year relative survival of women remained stable in the 
same period from 56.7% to 57.0% (p=0.5). After adjustment for age (as a continu-
ous variable in the model), grade, and stage, men showed a significant increase in 
5-year relative survival over time with a RER of 0.98 (95%CI=0.97-0.99, p<0.001). 
Women did not show a significant increase in their 5-year relative survival with a 
RER of 0.99 (95%CI=0.98-1.00, p=0.1). After additional adjustment for treatment, 
both men and women showed a small, but significant increase in 5-year relative 
survival over time with a RER of 0.99 (95%CI=0.97-1.00, p=0.02) for men and a RER 
of 0.99 (95%CI=0.98-1.00, p=0.03) for women.
Stratified for stage, relative survival did not increase for stage I colon cancer 
(Figure 2). In stage II colon cancer both aged and elderly showed a significant im-
provement in their unadjusted relative survival. After adjusting for sex, age, and 
grade, only aged patients still showed a significant improvement in their relative 
survival, while after additional adjustment for treatment, both aged and elderly 
patients showed an improved relative survival. In stage III colon cancer for all age 
groups unadjusted relative survival increased significantly. After adjustment for 
sex, age, and grade both middle-aged and elderly patients showed an increased 
relative survival, and after additional adjustment for treatment, only elderly pa-
tients showed an increased relative survival. Unadjusted relative survival in stage 
IV colon cancer did not increase in any of the age groups, after adjustment for sex, 
age and grade only middle-aged patients had an increased relative survival, which 
remained after additional adjustment for treatment.
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Figure 2
Unadjusted relative 5-year survival per stage and per age group in 3-year moving means, 
combined with tables with unadjusted and adjusted RER.
Unadjusted Adjusted (1) Adjusted (2)
< 65 years 0.96 0.95 0.94
65-74 years 0.93 0.88 0.99
≥ 75 years 0.97 0.97 0.97
Unadjusted Adjusted (1) Adjusted (2)
< 65 years 0.97 0.96 0.96
65-74 years 0.95 * 0.95 * 0.95 *
≥ 75 years 0.97 * 0.97 0.97 *
Unadjusted Adjusted (1) Adjusted (2)
< 65 years 0.94 * 0.94 * 0.98
65-74 years 0.97 * 0.97 1.02
≥ 75 years 0.97 * 0.96 * 0.97 *
Unadjusted Adjusted (1) Adjusted (2)
< 65 years 0.99 0.98 * 0.97 *
65-74 years 0.99 0.98 0.99





























































<65 years 65-74 years ≥75 years
* 0.05 
(1) adjusted r se ae and rade 
(2) adjusted r se ae rade and treatent
Chapter 6 The survival gap between middle-aged and elderly colorectal cancer patients. 
Time trends in treatment and survival.
DEF-zw-Proefschrift-JW#PROEF-13-april-2012.indd   102 13-4-2012   18:20:32
103
For comparison with the EUROCARE study, which showed a widening survival gap 
between 1988 and 1999, we calculated the adjusted RER over time, with 1991 as 
reference, stratified by age groups. (Figure 3(A)) None of the age groups showed a 
significant increase in their adjusted relative survival between 1991 and 2004 after 
adjustment for sex, age, grade, and stage. After additional adjustment for treat-
ment (Figure 3(B)) both middle-aged patients (< 65 years) and elderly patients (≥ 
75 years) showed a significant increase in their adjusted relative survival between 
1991 and 2004 (RER=0.97, 95%CI=0.95-0.98, p<0.001 and RER=0.98, 95% CI=0.97-
0.99, p=0.05, respectively). There was no significant increase in adjusted relative 
survival for patients aged between 65 and 75 years (RER=0.99, 95%CI=0.97-1.00, 
p=0.08).
We calculated the RERs over time per age group adjusted for sex, grade, and stage 
without treatment (Table 2A) and with treatment (Table 2B), with middle-aged 
patients (<65 years) as reference. Aged and elderly patients always showed a lower 
survival than middle-aged patients in all years. When there is a significant differ-
ence in the RERs, the survival of the aged or elderly patients is significant worse 
than the survival of the middle-aged patients. The higher the RER is, the larger the 
difference in survival between age groups. Looking at the study period of the EU-
ROCARE, until 1999, we see a gap between the survival of middle-aged patients 
and elderly patients, which is the largest in 1997 and 1998. In more recent years, 
the gap between middle-aged and elderly patients is still present, with 2001 and 
2002 comparable with 1997 and 1998, even when adjusted for treatment, but the 
gap has not further increased. 
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Figure 3
Adjusted RER and 95% CI per age group over time, with 1991 of each age group as a reference. (A) 
Adjusted for sex, age, grade, and stage, (B) Adjusted for sex, age, grade, stage, and treatment. 
3A
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Discussion
In this population-based study covering the mid-western region of the Nether-
lands over a period of 15 years, substantial changes in treatment of colon cancer 
were found. Adjuvant chemotherapy for patients with stage III disease increased 
over time, resection rates remained stable over time for patients with stage I, II, 
and III disease in all age groups, while resection rates among metastatic patients 
decreased, and administration of chemotherapy for stage IV colon cancer patients 
increased for all age groups. Moreover, survival increased significantly over time 
for middle-aged and elderly patients after adjusting for age, sex, grade, stage and 
treatment. The adjusted survival of aged patients did not increase significantly over 
the years. However, the present study did not show a further increase in the survival 
gap between middle-aged and elderly patients.
Treatment 
During the study period, some major changes in the adjuvant treatment of colon 
cancer have occurred. After Moertel et al.7 published the first clinically important 
survival benefit of one year adjuvant therapy with fluorouracil and levamisole for 
patients with stage II and III colon cancer, the United States quickly adopted this as 
standard therapy for stage III colon cancer patients. However, in the Netherlands 
adjuvant chemotherapy for stage III colon cancer was incorporated in the guide-
lines from the mid 1990’s and since 2005 the guideline also includes adjuvant che-
motherapy for high risk stage II patients.8 The changes in the guidelines for treating 
patients with colon cancer are visible in the data; in the period 1996-2000, for all 
age groups a large increase in the adjuvant treatment of stage III colon cancer pa-
tients was visible (from 31% to 68%, from 8% to 47%, and from 2 to 10% for middle-
aged, aged, and elderly patients respectively), although this showed much smaller 
survival benefit in the cohort than expected. During the study period stage IV colon 
cancer patients were increasingly treated with chemotherapy and less often with 
surgery. Over the past three decades, stage IV colon cancer has turned from a le-
thal, incurable disease, into a potentially curable disease for a selected group of 
patients.9 
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The surgical technique for colon cancer has not changed in the Netherlands dur-
ing the study period. However, in 2009 Hohenberger et al. presented their prom-
ising results about the complete mesocolic excision for patients with colon can-
cer.10  Possibly with use of this technique local recurrence rates might decrease 
and 5-year survival rates might increase further in the future. Also centralisation 
and auditing are relatively new for colon cancer in the Netherlands which might 
improve survival in the future.11 
Survival 
Overall we found a small increase in relative survival for colon cancer patients over 
the years. However, stage migration could have influenced this study. More ad-
vanced diagnostic tools have been used in the recent years,12-13 possibly leading to 
detecting a more advanced stage of disease. Furthermore, a more extensive search 
for affected lymph nodes could have had a similar effect. The harvesting of more 
lymph nodes could also have contributed directly to an improved survival.14-15 
Another factor that might have influenced the survival results, is the improvement 
of peri-operative care.16 With the hypothesis that survival would not increase over 
time when adjusted for sex, age, grade, stage, and treatment, the data in this paper 
show that there are residual influences related to outcome. Even after adjusting 
for sex, age, grade, stage, and treatment, a significant improvement was found in 
relative survival of elderly patients with stage III and of middle-aged patients with 
stage IV colon cancer. 
Changes in treatment and improvements in survival of colon cancer in the mid-
western region of the Netherland found in this study, are in line with the results of 
a previous study covering national data.17 Notable is that the improvement in sur-
vival and the increase in use of adjuvant treatment are more visible in middle-aged 
patients than in aged and elderly patients. One of the main problems found in the 
treatment of elderly patients is that current guidelines are based on randomized 
controlled trials, in which elderly patients or patients with severe co-morbidity are 
underrepresented or excluded. The improvement in survival of middle-aged colon 
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cancer patients over time has mostly been due to a decrease in operative mortal-
ity and an increase in the resection rate, possibly coupled with a more aggressive 
approach to the treatment of local and distant recurrences.18-21 Elderly patients 
on the other hand usually present with more advanced stage and tend to undergo 
more emergency surgery. Although, in the present study we could not confirm the 
higher stage at diagnosis, but more elderly patients were registered with an un-
known stage of disease which could include undiagnosed stage III and IV. Elderly 
patients are also less likely to receive adjuvant treatment and receive “suboptimal” 
management.22-27 Adjuvant chemotherapy has shown to be an effective treat-
ment for elderly patients with stage III colon cancer, but the benefit is lower with 
older age.18-28-29 However, elderly patients do not necessarily experience greater 
chemotherapy-related toxicity.19-29  
Gap in survival between younger and elderly
EUROCARE recently reported that for colon cancer, as well as other cancer types, 
the survival gap between elderly (70-84 years) and middle-aged (55-69 years) pa-
tients was widening in the period between 1988 and 1999.2 Due to the information 
available in the EUROCARE study, adjusting for several factors, like stage, was not 
possible. In the present study we were able to adjust for sex, age, grade, stage, and 
treatment. Besides, we were able to analyze more recent data. Patients were divid-
ed into three age groups instead of two; this would make the difference between 
middle-aged and elderly patients more visible. We found a significant difference in 
survival between patients middle-aged and elderly patients over all the years, even 
after adjusting for sex, age, grade, stage, and treatment. The largest difference in 
survival was between 1997 and 1998 and between 2001 and 2002. Besides the gap 
between 1997 and 1998, which is similar to the gap shown by the EUROCARE, we 
also show a more recent survival gap in 2001 and 2002, which is similar in size to 
the gap in 1997 and 1998. However, the survival differences between middle-aged 
and elderly patients are not consistent over time. The survival gap is mainly caused 
by an increase in survival of middle-aged patients and a stable survival of elderly 
patient. In the present study, this gap did not widen any further, but is stabilising. 
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Hopefully in the future aged and elderly patients will also benefit of the increased 
survival, possibly due to improved treatment. 
Stage distribution differs between several countries in Europe.13 As tumour stage 
is one of the most important prognostic factors in most cancer types, survival rates 
for several countries are difficult to compare. A new initiative is needed and found-
ed in EURECCA, which aims to collect prospective information about colorectal 
cancer patients in several countries in Europe.30
Conclusions
In the mid-western region of the Netherlands no changes in treatment have oc-
curred for stage I and II colon cancer during the study period. Patients with stage 
III and IV were treated with significantly more adjuvant chemotherapy over time, 
although less prominent for elderly patients, while the resection rate of patients 
with stage IV decreased for all age groups. The survival gap earlier found by the 
EUROCARE is confirmed for the mid-western part of the Netherlands, even after ad-
justing for several confounders. However, the present study did not show a further 
increase in the survival gap between middle-aged and elderly patients. The near 
future will have to show if a more extensive and hopefully better tailored treatment 
can help elderly to close this gap.
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Chapter 7 Importance of the first postoperative year in the prognosis of elderly colorectal cancer patients.
Abstract
Aims: Elderly colorectal cancer patients have a worse prognosis than younger pa-
tients. Age related survival differences may be cancer or treatment related, but also 
due to death of other causes. This study aims to compare population based survival 
data for young (<65 years), aged (65-75 years) and elderly (≥75 years) colorectal 
cancer patients
Methods: All patients operated for stage I-III colorectal cancer, between 1991 and 
2005 in the Western region of the Netherlands were included. Crude survival, rela-
tive survival and conditional relative survival curves, under the condition of surviv-
ing 1-year, were made for colon and rectal cancer patients separately. Furthermore, 
30-day, 1-year and 1-year excess mortality data were compared.
Results: A total of 9 397 stage I-III colorectal cancer patients were included in this 
study. Crude survival curves showed clear survival differences between the age 
groups. These age related differences were less prominent in relative survival and 
disappeared in conditional relative survival (CRS). Only in stage III disease, elderly 
patients had a worse CRS than young patients. Furthermore, significant age related 
differences in 30-day and 1-year excess mortality were found. Thirty-day mortality 
vastly underestimated 1-year mortality for all age groups. 
Conclusions: Elderly colorectal cancer patients that survive the first year, have the 
same cancer related survival as younger patients. Therefore, decreased survival in 
the elderly is mainly due to differences in early mortality. Treatment of elderly col-
orectal cancer patients should focus on peri-operative care and the first postopera-
tive year.
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Introduction
The number of elders in the population and the incidence of colorectal cancer are 
increasing. Therefore, it is to be expected that the number of elderly colorectal can-
cer patients will further increase. Various population-based studies show that sur-
vival of elderly colorectal cancer patients is worse compared to younger patients. 
Differences in survival by age groups in colorectal cancer may be explained by 
variations in tumour factors, patient characteristics and therapy. Elderly colorec-
tal cancer patients tend to have a more advanced stage of disease.1 Besides, they 
have more co-morbidity and are treated less aggressive than their younger coun-
terparts.2 Co-morbidity influences surgical eligibility and other treatment options.3 
Furthermore, it represents a greater risk of non cancer related mortality. Elderly pa-
tients less frequently receive adjuvant chemotherapy and more often discontinue 
treatment before completion. 4 
Notwithstanding all these differences, several studies found a similar disease spe-
cific survival for elderly and young colorectal cancer patients.5-7 This would indi-
cate the excess mortality in elderly colorectal cancer patients is due to competing 
causes of death. To gain a better insight in survival differences between age groups, 
the present study aims to compare population-based survival data of colorectal 
cancer patients for different age groups. It will not only regard overall and relative 
survival but also conditional relative survival under the condition of surviving one 
year. Furthermore, this study will focus on age related differences in 30-day and 
1-year mortality. 
Methods 
Patients were selected from the regional cancer registry of the Comprehensive 
Cancer Centre West (CCCW) covering the Western part of the Netherlands. The na-
tionwide Dutch network and registry of histo- and cytopathology (PALGA) regularly 
Importance of the first postoperative year in the prognosis of elderly colorectal cancer patients.
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submits reports of all diagnosed malignancies to the cancer registries. The national 
hospital discharge databank, which receives discharge diagnoses of admitted pa-
tients from all Dutch hospitals, completes case ascertainment. After notification, 
trained registry personnel collect data on diagnosis, staging, and treatment from 
the medical records, including pathology and surgery reports, using the registra-
tion and coding manual of the Dutch Association of Comprehensive Cancer Cen-
ters. Cancer registry data show actual variations in patterns of staging, treatment 
and survival by age and therefore offer a scope for improvement of care and for 
creating guidelines, in addition to randomized clinical trials.8 
From the regional cancer registry, patients diagnosed between 1991 and 2005 with 
their first primary colon or rectal cancer stage I, II or III and surgically treated were 
selected. Vital status was established either directly from the patient’s medical re-
cord or through linkage of cancer registry data with the municipal population reg-
istries which record information on their inhabitant’s vital status. Stage was based 
on pathological information; clinical information was used if pathology data were 
missing. 
Statistics
Patients were divided into younger than 65 years, 65-74 years and 75 years and 
older. Differences between characteristics were tested with Chi-Square tests. Over-
all Survival was calculated with death due to any cause as event. Relative survival 
is the preferred way to describe the prognosis of elderly cancer patients, as it takes 
into account the risk of dying from other causes than the disease of interest.8 Rela-
tive survival was calculated by the Hakulinen method as the ratio of the survival ob-
served among the cancer patients and the survival that would have been expected 
based on the corresponding (age, sex and year) general population. National life 
tables were used to estimate expected survival. Conditional relative survival was 
calculated for patients who survived the first year. Relative Excess Risks of death 
(RER) were estimated using a multivariate generalized linear model with a Poisson 
distribution, based on collapsed relative survival data, using exact survival times. 
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Finally, 30-day and 1 year overall mortality were calculated as well as the 1-year 
excess mortality (observed – expected deaths / number of patients). 
Results  
From January first 1991 trough December 31st 2005 in the CCCW region 9 611 
stage I -III colorectal cancer patients were diagnosed and 9 397 (97.8%) were op-
erated, 6 405 patients with colon cancer and 2 992 rectal cancer patients. These 
patients had a median age of 72 years (range 7-100) for colon cancer and 69 years 
(range 18-98) for rectal cancer patients. Patient characteristics according to age 
groups for colon and rectum separately are shown in Table 1. The percentage of 
female patients was significantly higher in the oldest age groups, especially for co-
lon cancer patients. The number of treated colon cancer patients increased over 
the years. Tumor grade is evenly divided for rectal cancer but not for colon cancer 
patients, with more grades III in the elderly. In this cohort younger patients had 
higher tumor stages than the elderly, although the percentage of patients with an 
unknown stage of disease was higher in the elderly (data not shown). The use of 
adjuvant chemotherapy decreased with advancing age groups. Radiotherapy for 
rectal cancer patients was comparable for the young and aged groups and was 
lower in the elderly group. 
Figure 1 shows survival curves for overall survival (a), relative survival (b) and con-
ditional relative survival (c) for colon and rectal cancer patients in the different age 
groups. Differences in survival between age groups for colorectal cancer patients 
disappear when a correction is made for death of other causes under the condition 
of surviving one year. As shown in Table 2 the elderly patients had a RER of 1.6 
(95%CI 1.4-1.9; p<0.001) as compared to the young patients for colon cancer and 
1.4 (95%CI 1.2-1.7; p<0.001) for rectal cancer. When relative survival was calculated 
for the patients who survived the first year relative excess risks were around 1.0 
(RER 1.1; p=0.2 for colon and RER 1.1; p=0.3 for rectal cancer). Going into more de-
Importance of the first postoperative year in the prognosis of elderly colorectal cancer patients.
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tail and considering different stages a significant difference in conditional relative 
survival remains for stage III patients for both colon and rectal cancer.
Figure 1a
Overall Survival according to age for stage I - III patients operated for colon and rectal cancer 
Figure 1b
Relative Survival according to age for stage I -III patients operated for colon and rectal cancer 
Figure 1c
Conditional Relative Survival (conditioning on patients who survived 1 year) according 
to age for stage I -III patients operated for colon and rectal cancer 
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Table 3 shows overall 30-day, 1-year and 1-year excess mortality according to type 
of tumor in reference to baseline factors. Gender was a significant factor for first 
year mortality in rectal cancer, with more male patients dying. Age was the most 
significant factor for all three mortality endpoints for both colon and rectal can-
cer patients. Tumor grade did not influence 30-day mortality but was a significant 
factor for 1 year mortality for both colon and rectal cancer patients. Tumor stage 
also influenced 30-day mortality for colon cancer patients, but not for rectal cancer 
patients. Thirty-day and 1-year mortality rates decreased over the years (data not 
shown). For colon cancer patients this was only significant (p<0.05) for 1-year mor-
tality rates for all age groups (lowest RER 0.94). For rectal cancer patients 30-day 
mortality was significantly reduced (p<0.01) for the elderly (RER 0.89). One-year 
mortality for the young and aged patients (lowest RER 0.93) was significantly im-
proved (p= 0.03), however not for the elderly patients (p=0.3; RER 0.98).
 
Table 3
Overall 30-day and 1-year mortality and 1-year excess mortality rates in percentages according to type 
of tumor 









N † ≤30 d † 1st year † 1st year N † ≤30 d †1st year † 1st year
Sex
  Male 2976 4.6 15.7 11.3 1639 2.1 13.2 9.4
  Female  3429 4.1 14.5 10.9 1353 1.3 9.9 6.9
Age (years) 
   <65 1740 1.4 6.8 6.1 1047 0.2 5.1 4.4
   65-75 1916 2.4 10.8 8.5 892 1.4 9.5 7.2
   ≥75 2749 7.5 23.2 16.0 1053 3.7 20.1 13.1
Grade 
   I 436 2.1 9.9 6.0 162 3.1 8.0 4.9
   II 4284 4.4 12.6 8.5 2140 1.8 10.2 6.6
   III 1065 4.7 25.2 21.3 440 1.6 22.3 19.5
   Unknown 620 4.8 18.2 14.8 250 1.2 8.4 5.2
Stage 
   I 1179 1.7 8.0 4.0 1023 1.5 7.6 3.8
   II 3143 5.0 13.5 9.2 966 2.4 12.7 9.1
   III 2083 4.8 21.4 18.0 1003 1.5 14.9 12.1
Importance of the first postoperative year in the prognosis of elderly colorectal cancer patients.
DEF-zw-Proefschrift-JW#PROEF-13-april-2012.indd   121 13-4-2012   18:20:34
122
Discussion
Crude survival is a solid outcome measure that shows evident age related differ-
ences. However, crude survival will overestimate the impact of cancer on survival, 
because it also includes mortality due to other causes. To adjust for this, relative 
survival is used, defined as the ratio of observed to expected survival. This reduces 
age related differences in colorectal cancer survival. However, the results of age 
related relative survival are still largely influenced by early mortality (defined as 
mortality in the first postoperative year). Postoperative complications are a more 
probable cause for early mortality than the colorectal cancer itself in stage I to III 
patients (who in general had curative surgery). Therefore, in order to get a clear 
image of the impact of colorectal cancer on survival for different age groups, we 
used conditional relative survival under the condition of surviving one year. As a 
result age related differences in survival disappeared, indicating that probably col-
orectal cancer itself is not the main cause of age related differences in survival. 
This is in line with earlier studies that found no age related differences in cancer 
specific survival.5-7 However, this remains intriguing since many papers indicate 
that differences in survival between the young and the elderly can be attributed to 
undertreatment in the elderly.1-9 Our study confirms these variations in treatment 
and conditioned survival in stage III patients is indeed significantly worse in the 
elderly. Nonetheless, the excess mortality in the first postoperative year was the 
main determining factor for age related survival differences. 
Postoperative mortality
The 30-day mortality rates for the different age groups in the present study are 
in accordance with earlier findings by other studies.10-11 However, the most strik-
ing finding of this analysis is the fact that 30-day mortality vastly underestimates 
1-year mortality for all age groups. Apparently, the impact and consequences of 
treatment have a prolonged effect on mortality. This effect is very strong even for 
patients in the youngest group. With increasing age, also the excess mortality in-
creases. It has been shown earlier that with age not only mortality, but also postop-
Chapter 7 Importance of the first postoperative year in the prognosis of elderly colorectal cancer patients.
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erative morbidity increases.12-14 Furthermore, Manku et al.15 showed that in hospi-
tal complications had a prognostic significance. In five hundred seventeen patients 
who underwent non-cardiac surgery, they found that postoperative complications 
caused mortality up to 3 months after surgery, with a sustaining effect on survival. 
Greenblatt et al.16 studied stage I to III colon cancer patients from the Surveillance, 
Epidemiology, and End Results-Medicare database and found that readmission 
was strongly associated with 1-year mortality. The same variables that predicted 
readmission in this study also predicted 1-year mortality (male gender, comorbid-
ity, emergent admission, prolonged hospital stay, blood transfusion, ostomy and 
discharge to a nursing home). Kunitake et al.17 showed that patients older than 
eighty years were readmitted almost twice as much as patients younger than sixty 
five years. Furthermore, in their study 75% of readmittances were not related to 
the surgery itself. With the present study, all these studies seem to imply that for a 
significant number of patients the assault of surgery has delayed effects that can 
cause mortality outside the scope of the surgeon. 
Stage III patients
Only in stage III patients we found age related differences in conditional relative 
survival. Here differences in (neo-) adjuvant therapy between the age groups were 
most apparent. This is in line with earlier studies, that show that elderly patients 
are undertreated.4 This undertreatment of elderly patients could explain the age 
related differences in conditional relative survival for stage III patients. However, 
also in stage III patients, first year mortality remains a crucial factor for survival. The 
difference in conditional relative survival between young and elderly stage III pa-
tients was 10.4% for colon and 5.6% for rectal cancer, while the differences in 1-year 
excess mortality rates were 17.2 and 12.0% respectively.  
Limitations
An obvious limitation of this study is the lack of information on emergency surgery, 
and comorbidity. Both are associated with increased postoperative complications 
and mortality. They will not only have had a prominent influence on early mortality 
Importance of the first postoperative year in the prognosis of elderly colorectal cancer patients.
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Chapter 7 Importance of the first postoperative year in the prognosis of elderly colorectal cancer patients.
for all age groups, but they probably account for the differences between the age 
groups as well. Elderly patients are more likely to undergo emergency surgery and 
also the incidence of comorbidity increases with age.10 Nevertheless, the strength 
of this study is that it shows the essence of age related survival and early mortality 
differences in a large population based cohort.
Clinical Implications 
The results of this study could provide a focus for future studies and have implica-
tions for the clinical setting. As age related differences in mortality are most appar-
ent the first postoperative year, this is where the focus must be in treating elderly 
colorectal cancer patients. Although some risk factors may not be modifiable, oth-
ers relate to the processes of care. More attention should be given to patient selec-
tion and careful preoperative evaluation, followed by medical optimization, proper 
timing of surgery and planning of peri-operative care. Furthermore, appropriate re-
ferral to high volume or dedicated centers should be considered if anticipated that 
patients will require higher level of resources and care following surgery. Quality 
enhancement programs could focus on particular complications. These should not 
only try to prevent the occurrence of peri-operative complications, but also focus 
on early identification and adequate treatment of complications to avoid related 
mortality.18
The excess mortality of the first postoperative year forms a clear indication of the 
prolonged impact of the peri-operative period, especially when complications oc-
cur. Therefore, we should anticipate preoperatively on the level of functioning after 
discharge.13 The targets of treatment for elderly patients should extend beyond 
the in-hospital period and continued attention should be given to comorbidity and 
complications in the post-hospital period. 
The prolonged impact of the peri-operative period could also have a profound ef-
fect on functional status and quality of life. For elderly patients these issues should 
be evaluated with care, especially when they have limited life expectancies. How-
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ever, for the majority of patients, age per se is not a contra indication for surgery. 
Not in the least because surgery for colorectal cancer is often the best way to en-
sure palliation.
Conclusions
This study can help to comprehend the challenge of treating elderly colorectal can-
cer patients. When survival data for colorectal cancer are corrected for expected 
death of other causes and first year mortality, age differences disappear. Therefore, 
decreased survival in the elderly is mainly due to differences in early mortality. Only 
for stage III disease elderly patients fare worse, probably as a result of less extensive 
adjuvant treatment. The overall difference between the younger and elderly age 
groups is that within the elderly group there is an excess mortality of about 10 % 
the first year. Further studies are necessary to elucidate the etiology of these differ-
ences and whether they may be modifiable. This study implies that in treating el-
derly stage I-III colorectal cancer patients the focus should be on the peri-operative 
process and the first postoperative year. 
Importance of the first postoperative year in the prognosis of elderly colorectal cancer patients.
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Abstract
Aims: Thirty-day mortality after surgery for colorectal cancer may vastly under-
estimate 1-year mortality. This study aims to quantify the excess mortality in the 
first postoperative year of stage I-III colorectal cancer patients and to identify risk 
factors for excess mortality.
Methods: All 2131 patients who were operated with curative intent for stage I-
III colorectal cancer in the Western region of the Netherlands, between January 
1 2006 and December 31 2008, were analyzed.  Thirty-day mortality and relative 
survival were calculated. Also Relative Excess Risks of death (RER) were estimated 
using a multivariable model. 
Results: Thirty-day mortality was 4.9%. One-year mortality was 12.4%. Risk factors 
for Excess Mortality (EM) in the first postoperative year for colon cancer patients 
were emergency surgery (EM 29.7%, RER (Relative Excess Risk) 2.5 (95%CI 2.5-5.0), a 
Charlson score >1 (EM 12.6%, RER 2.3 (1.5-3.7)), stage II or III disease (EM 14,9%, RER 
3.9 (1.9-8.1)) and postoperative adverse events (EM 22,6%, RER 2.1 (1.4-3.2)).  
Conclusions: The 30-day mortality rate highly underestimates the risk of dying 
in the first year after surgery, with excess 1-year mortality rates varying from 15 
to 30%.  This excess mortality was especially prominent in patients with co-mor-
bidities, higher stages of disease, emergency surgery, and postoperative surgical 
complications. 
Chapter 8 Risk factors for excess mortality in the first year after curative surgery for colorectal cancer
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Introduction
Adverse postoperative events are most often recorded as 30-day mortality and 
postoperative complications.  Large studies show that colorectal cancer surgery 
can be considered as high risk with reported postoperative mortality and compli-
cation rates around 5% and 20-40% respectively. 1-4 
For the prognosis of colorectal cancer patients that undergo curative surgery, ad-
verse postoperative events constitute a determining factor. Several studies showed 
that complications are of prognostic importance, because they can cause delayed 
mortality. 5,-6 Furthermore, specific complications such as anastomotic leaks are 
associated with local recurrences and reduced survival.7-9 Elderly patients with se-
vere co-morbidities, lower social economic status, a stage III tumor or preoperative 
tumor complications, have been shown to be at higher risk for postoperative ad-
verse events.10-12
Earlier studies have shown that 30-day mortality after surgery for colorectal cancer 
vastly underestimates 1-year mortality,13-14 even in young colorectal cancer pa-
tients that were operated with curative intent. Furthermore, Dekker et al showed 
that 1-year excess mortality (1-year mortality adjusted for expected mortality in the 
general population) was the main determining factor for age related survival dif-
ferences: after surviving the first year, elderly had the same cancer related survival 
as younger patients.14 This suggests that there may be a prolonged impact of the 
assault of surgery. Up to date little information exists on the etiology of the excess 
mortality in the first postoperative year. Because of the lack of reported determi-
nants of excess mortality in the contemporary literature, we set out to determine 
the role of co-morbidity, emergency surgery and postoperative complications, ex-
pecting that these factors are main determinants for 1-year excess mortality. Espe-
cially in elderly patients where the incidence of co-morbidity is higher and emer-
gency surgery and postoperative complications occur more frequently.  
Risk factors for excess mortality in the first year after curative surgery for colorectal cancer
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The identification of risk factors would help to stratify patients according to their 
risk. Moreover, risk factors may be modifiable and targeted optimization of care 
may result in an improved prognosis. 
Therefore, the first aim of this study was to quantify the excess mortality in the first 
postoperative year of stage I-III colorectal cancer patients operated with curative 
intent according to several patient and tumor characteristics. The second aim of 




In the Netherlands, all newly diagnosed malignancies are registered in the na-
tionwide population based Netherlands Cancer Registry (NCR). The Leiden Cancer 
Registry, part of the NCR, collects data on all cancer patients diagnosed in one of 
the nine affiliated hospitals in the Midwestern part of the Netherlands. This region 
comprises one university hospital, six teaching hospitals and two non-teaching 
hospitals and serves a population of 1.7 million inhabitants. 
Independently trained data managers collect data from the original patient files 
after receiving an automatic report from the Dutch pathology reporting system 
“PALGA.” Information on patient characteristics, tumor characteristics, treatment, 
hospital of diagnosis and/or treatment and follow-up are recorded. Tumor site and 
morphology are coded according to the International Classification of Diseases for 
Oncology (ICD-0).15 Cancers are staged according to the TNM classification of Ma-
lignant Tumors, 6th edition.16 The quality of the data is high, and completeness is 
estimated to be at least 95%.17-18
In 2006, a regional audit for colorectal cancer surgery (KIC) was started in the nine 
Chapter 8 Risk factors for excess mortality in the first year after curative surgery for colorectal cancer
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affiliated hospitals of the Leiden Cancer Registry. The data collection was extended 
to data that reflected quality of care and case mix factors. These prospectively col-
lected data were used for benchmarking and feedback on each hospitals process, 
ultimately to improve the quality of care in the entire region. Data were collected 
on patient demographics (age, sex, co-morbidities and socio-economic status 
(SES)), tumor characteristics (localization, TNM staging) and treatment characteris-
tics ((neo-) adjuvant treatment, type of surgery, emergency, hospital of treatment, 
surgical complications and length of stay). Apart from ASA scores, completeness of 
data was more than 98%. 
Patients
All patients who had a resection of stage I, II or III tumor of the colon (C18), the 
recto-sigmoid (C19) or the rectum (C20) from 1 January 2006 to 31 December 2008 
in one of the affiliated hospitals, were identified (patients with a stage IV tumor, 
with a tumor of the appendix and patients who did not undergo a resection of the 
tumor, were excluded). Age was categorized in younger than 65 years, 65 to 74 
years and 75 years and older. Co-morbidity was recorded according to a slightly 
modified version of the Charlson index, used by the Dutch Cancer Registry. ASA 
scores were categorized as ASA I and II or ASA III and IV. Missing data from the ASA 
score were included as a separate category. SES was categorized as low, interme-
diate and high, based on area-based data concerning income, employment and 
education, provided by the Netherlands Institute for Social Research.[19] Surgical 
complications comprised superficial wound infections, abdominal wall problems 
(i.e., dehiscence), deep infections, and intra-abdominal complications including 
bleeding, ileus, abscess or anastomotic leaks. As a substitute for overall compli-
cations (both surgical and non-surgical such as pulmonary or cardiac events), a 
prolonged length of stay was used, which was defined as a hospital admission of 
15 days or longer after surgery. Vital status of all patients was obtained actively 
on a regular basis through linkage of the cancer registry data with the integrated 
database of the municipal registry and the central bureau for genealogy. Follow-up 
was completed until January 1 2010. 
Risk factors for excess mortality in the first year after curative surgery for colorectal cancer
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Statistical analysis
All analyses were done for colon and rectum cancer patients separately. Stratified 
by several characteristics, 30-day mortality, 1-year overall mortality (all causes) and 
1-year excess mortality rates were calculated. Excess mortality was calculated by 
(Observed number of deaths in the 1st year – Expected number of deaths in the 
matched general population) / Number of patients. Expected number of deaths 
was calculated using national life tables matched on age, sex and year of incidence. 
Survival curves of the relative survival in the first year were constructed. Relative 
survival is the preferred way to describe the prognosis of elderly cancer patients as 
it takes into account the risk of dying of other causes than the disease of interest 
in the absence of cause of death in the database. Relative survival was calculated 
as the ratio of the observed survival among the cancer patients and the expected 
survival. Relative Excess Risks of death (RER) with p-value were estimated using a 
multivariable generalized linear model with a Poisson distribution, based on col-
lapsed relative survival data, using exact survival times. 
Results
From January 1, 2006 until December 31, 2008, 2131 patients had a colorectal re-
section in one of the nine affiliated hospitals of the CCCW, for stage I-III colorectal 
cancer; 1407 for colon cancer and 724 for rectal cancer. Table 1 shows character-
istics of the study population for colon and rectal cancer patients. Colon patients 
were older, more often female, had more comorbidity and more often required 
emergency surgery. 
30-day mortality, 1-year mortality and excess mortality
The overall observed 30-day mortality was 4.9%, the 1-year mortality 12.4%. Me-
dian follow-up time was 24.6 (range 0.03-47.9) months. All patients had follow up 
for at least one year unless they died previously. Table 2 shows crude overall mor-
tality and excess mortality rates of stage I-III colon and rectal cancer patients in the 
first year after surgery, according to several characteristics. The observed 1-year 
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Table 1
Characteristics of the population according to localization  
Variables Colon cancer Rectal cancer
Age (years) <65 371 26.4 264 36.5
65-74 390 27.7 236 32.6
≥75 646 45.9 244 30.9
Sex Male 672 47.8 406 56.1
Female 735 52.2 318 43.9
Stage I 234 16.6 214 29.6
II 661 47.0 231 31.9
III 512 36.4 279 38.5
Emergency Emergent 188 13.4 17 2.4
Elective 1219 86.6 707 97.6
ASA I / II 633 45.0 45.0 56.8
III / IV / V 297 21.1 21.1 17.0
Unknown 477 33.9 33.9 26.2
Charlson 0 757 53.8 444 61.3
1 358 25.4 160 22.1
2 or more 292 20.8 120 16.6
Complications No 1155 82.1 559 77.2
Yes 252 17.9 165 22.8
Hospital stay < 15 days 956 67.9 471 65.0
≥ 15 days 419 29.8 238 32.9
Unknown 32 2.3 15 2.1
SES High 449 31.9 243 33.6
Intermediate 480 34.1 241 33.3
Low 478 34.0 240 33.1
Total 1407 100% 724 100%
Risk factors for excess mortality in the first year after curative surgery for colorectal cancer
DEF-zw-Proefschrift-JW#PROEF-13-april-2012.indd   133 13-4-2012   18:20:35
134
Chapter 8 Risk factors for excess mortality in the first year after curative surgery for colorectal cancer
Table 2













Overall 6.3 14.8 10.9 2.4 7.9 4.8
Sex 
Male 7.7 16.2 12.1 3.5 9.6 6.2
Female 4.9 13.5 9.8 0.9 5.7 3.2
Age 
<65 1.6 5.9 5.3 0.4 2.3 1.6
65-74 4.1 12.3 10.2 0.4 6.8 4.5
≥75 10.2 21.4 14.6 6.7 15.6 8.9
SES 
High 4.7 12.9 9.0 2.5 7.0 3.5
Intermediate 8.5 15.2 11.5 2.9 9.1 6.7
Low 5.4 16.1 12.1 1.7 7.5 4.2
ASA 
I/II 1.9 7.9 4.4 1.0 5.1 2.3
III/IV 11.1 24.9 19.9 6.5 14.6 10.2
Unknown 9.0 17.6 13.8 2.6 9.5 6.6
Stage 
I 6.8 9.8 6.1 1.9 4.7 1.3
II 5.9 13.8 9.5 3.0 8.2 5.4
III 6.5 18.4 14.9 2.2 10.0 7.1
Emergency 
Emergent 18.1 32.9 29.7 N.A. 
Elective 4.4 11.9 8.0
Comorbidity 
No 4.3 10.5 7.7 0.3 4.4 1.7
Yes 7.7 17.8 13.2 4.5 11.5 8.0
Charlson 
0 4.1 10.8 7.5 0.7 4.7 1.8
1 6.7 17.0 12.6 3.8 10.0 6.9
2 or more 11.3 22.3 17.5 6.7 16.7 13.0
Complications
No 5.2 12.4 8.3 1.4 6.1 2.9
Yes 11.1 25.8 22.6 5.5 13.9 11.2
Hospital stay
< 15 days 5.4 9.8 6.2 2.3 5.5 3.0
≥ 15 days  8.4 26.5 22.0 2.5 11.3 7.2
Unknown 3.1 9.4 5.0 0 26.7 24.3
Colon                                                                    Rectal  
Bold and italic:  p-value<0.05 for the different value within a variable. .
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mortality rates of patients older than 75, were 21% and 16% for colon and rectal 
patients respectively. High excess mortality rates were observed in colon cancer 
patients with ASA III/IV (19.9%), a stage III tumor (14.9%), a Charlson score of 2 or 
higher (17.5%) and in patients with postoperative surgical complications (22.6%) 
or a prolonged length of stay (22%). Of all colon cancer patients with an emergency 
resection, 33% died in the first year, an excess mortality of 30%.  In rectal cancer 
patients high excess mortality rates were observed in elderly (8.9%), patients with a 
Charlson 2 or higher (13%) and patients with postoperative complications (11.2%). 
Figure 1 shows relative survival curves of all patients in the cohort (a) and an ex-
ample of relative survival in a specific subgroup: colon cancer patients treated in 
an emergency setting (b). 
Figure 1
Relative Survival in the first year: all patients (a) and colon patients treated in emergency setting (b). 
The red line marks the 30th day after surgery. 
The blue line represents the relative survival in the first year. The space between the red dotted line and the blue line repre-
sents the excess mortality after 30 days and within the first year after surgery.
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Risk factors for excess mortality in the first year
Figure 2 shows all identified risk factors for 1-year mortality for colon and rectal 
cancer patients separately. The effect is represented as adjusted relative excess 
risk (RER) for 1-year mortality. In table 3 (supplementary) the results of univariate 
and multivariable analysis for risk factors for excess mortality in the first year are 
shown.
For colon cancer patients, significant risk factors for excess mortality in the first 
year after surgery, were a stage III tumor (RER 2.6 (1.3-5.3), p <0.001), a Charlson 
score > 1 (RER 2.5 (1.6-4.0) p = 0.001), an emergency resection (RER 3.3 (2.5-5.0), 
p < 0.001) and postoperative surgical complications (RER 2.1 (1.4-3.3) p < 0.001). 
Particular co-morbidities, that increase the risk of excess mortality, were a previous 
tumor (RER 1.8 (1.2-2.8) p = 0.009), pulmonary disease (RER 2.1 (1.3-3.2) p =0.001), 
gastro-intestinal disease (RER 2.0 (1.1-3.6) p=0.02) and neurological disease (RER 
1.7 (1.0-2.8) p= 0.04). 
For rectal cancer patients risk factors for excess mortality in the first year, were 
age ≥ 75years (RER 7.0 (1.8-27.4) p=0.009), Charlson score > 1 (RER 5.2 (1.7-15.9) p 
=0.01), and postoperative surgical complications (RER 5.9 (1.3-26.8). Particular co-
morbidities that increase the risk were, hypertension (RER 2.4 (1.1-5.5) p=0.04), vas-
cular disease (RER 3.4 (1.3-9.3) p=0.02), kidney disease (RER 7.9 (2.4-26.5) p=0.001) 
and neurological disease (RER 3.3 (1.0-10.4) p=0.04). 
 
Figure 2
Factors associated with 1-year Relative Survival in multivariable analysis for colon and rectal cancer 
patients separately. At the Y-axis, the effect size is represented as adjusted relative excess risk (RER) for 1 year mortality, 
compared to the reference group, which always has a RER of 1. 
Chapter 8 Risk factors for excess mortality in the first year after curative surgery for colorectal cancer
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Supplementary table to figure 2
Multivariable One-year Relative Survival, expressed as relative excess risk (RER) for colon and rectal 
cancer patients separately. Multivariable analyses include all variables with p-value of 0.1 or smaller. 




















































































































































































































































































































































































































































































































































































































































    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    


















Risk factors for excess mortality in the first year after curative surgery for colorectal cancer
DEF-zw-Proefschrift-JW#PROEF-13-april-2012.indd   137 13-4-2012   18:20:36
138
Discussion
The excess mortality in the first year after surgery for stage I-III colorectal cancer is 
high. Overall, 12.4 % of all patients died within the first year, compared to a 4.9 % 
30- day mortality rate. Thus, the 30-day mortality rate highly underestimates the 
risk of dying in the first year after surgery. After adjustment for expected mortal-
ity in the general population, patients with co-morbidities, patients with stage III 
tumors, patients requiring emergency resection, and patients with postoperative 
surgical complications were at higher risk for excess mortality, with excess 1-year 
mortality rates varying from 15 to 30%.  
The present study is the first detailed population based study, quantifying excess 
mortality after colorectal cancer surgery with curative intent, and examining risk 
factors for excess mortality within the first year. Clinical, accurate data of the Neth-
erlands Cancer Registry were used, and variables not only comprised age and stage, 
but also data on co-morbidities, emergency and postoperative complications were 
available. Moreover relative survival and excess mortality rates were used as out-
come measures. This also takes into account mortality which is not attributable to 
the examined disease or the treatment of the disease. 
The results in this study should be interpreted with regard to several limitations 
inherent to its observational design. In the univariate and multivariable analysis 
potential confounders were examined and added to the model (shown in supple-
mentary table). In calculations of expected mortality, patients with severe comor-
bidity may not match well with the general population. This could have led to a 
slight underestimation of the expected mortality in this group, resulting in a lower 
excess mortality. 
Furthermore, only data on postoperative surgical complications were available.  To 
estimate the impact of both surgical and non-surgical complications (for example 
pneumonia, delirium, cardiac event or urinary tract infection), a prolonged length 
Chapter 8 Risk factors for excess mortality in the first year after curative surgery for colorectal cancer
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of stay was used as a substitute of postoperative complications in general. In this 
study, a prolonged length of stay was defined as a stay of 15 days or longer. An 
uneventful postoperative period is unlikely to result in a longer hospital stay, and 
therefore, it can function as a proxy for overall complications. This assumption is in 
line with a study of Cohen et al, who demonstrated a mean length of stay after col-
orectal surgery of 16 days in the presence of complications versus 6 days when no 
complications occurred.20 In the present study a prolonged length of stay occurred 
in 30.4% of the patients. This is also consistent with findings in literature. 20-21
Acknowledging these limitations, the present study provides valuable information, 
showing that 30-day mortality underreports postoperative mortality after colorec-
tal surgery.  This is consistent with previous studies. 13-14  Visser et al reported a 
doubling of 30-day mortality to 9.1% at 90 days after surgery. A previous study 
from our group showed that 1-year excess mortality was the main determinant for 
age related survival differences. 14 In the present data, the steepest decline in rela-
tive survival was observed during the first 7 to 11 months after surgery. The excess 
mortality was especially high in patients with comorbidities, stage III disease, emer-
gency surgery and postoperative surgical complications or a prolonged length of 
stay. These risk factors have been described before as risk factors for postoperative 
mortality and survival.11-12-22-23 However, these reports did not adjust for expect-
ed mortality in the general population, thereby not taking into account the risk of 
dying of other causes than colorectal cancer. 
The aim of identifying risk factors for 1-year excess mortality was to find targets for 
improvement of patient care. However, these risk factors may not be easily mal-
leable.  
Comorbidity
The prevalence of comorbid disease is increasing with the aging population and 
improvements in modern medicine.24-25 Patients with comorbidity may have less 
biological reserve and comorbidities alter organ functions.26 More research is 
needed on these mechanisms and the influence of comorbidities on postopera-
Risk factors for excess mortality in the first year after curative surgery for colorectal cancer
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tive outcomes. Obviously, optimizing peri-operative care to reduce surgical risk by 
thorough preoperative assessment and by additional supportive measures may 
improve the prognosis of patients. A multidisciplinary approach with integrated 
chronic disease management in cancer patients also in the post-hospital period 
seems warranted. 
Stage III disease
Patients with stage III disease had an increased risk of excess 1-year mortality. This 
could be due to cancer recurrences. Although it is unlikely a large part of early 
mortality is due to cancer recurrences in patients operated with curative intent. An 
earlier study on relapses in these patients showed that only a very limited number 
of patients had a recurrence within the first year. Furthermore, only ten percent of 
patients with a recurrence die within one year.27
Emergency surgery
Emergency surgery has consistently been demonstrated to be a major risk factor 
for adverse outcome in colorectal surgery. Efforts should be made to reduce the 
number of patients in need of an emergent intervention. In this respect national 
screening programs could be helpful. If colorectal cancer could be identified at an 
earlier (asymptomatic) stage, it could be expected the need for emergent surgery 
can be reduced.
Postoperative surgical complications or a prolonged length of stay
Also patients with postoperative surgical complications or a prolonged length of 
stay had an increased risk for excess mortality in the first year. These results com-
pare to a recent study of Greenblatt et al.5 They showed that readmission after 
colectomy, due to a postoperative complication, was predictive for 1-year mortal-
ity. Two recent studies of Ghaferi et al showed that differences in death after ma-
jor complications were the primary determinant of variation of mortality between 
hospitals.28-29 This indicates that effective management of postoperative compli-
cations may reduce postoperative mortality and improve patient outcomes.  This 
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provides a potential target for improvement of the quality of cancer care. Not only 
prevention of complications, but also early recognition and aggressive treatment 
of complications can improve patient outcomes.  Identifying structures, processes 
and best practices to reduce the occurrence of complications and improve the 
management of complications should have priority.  Although randomized con-
trolled trials are pivotal for determination of efficacious interventions, large cohort 
studies and comparative effectiveness research are essential to fill critical gaps in 
defining optimal strategies for complication management. 30
Conclusions
In conclusion the excess mortality in the first postoperative year after colorectal 
cancer surgery is high and reflects postoperative risk more accurate than 30-day 
mortality. The presence of co-morbidities, a stage III tumor, emergency resection, 
and postoperative surgical complications were predictive for excess mortality, with 
excess 1-year mortality rates as high as 15 to 30%.  These risk factors may not be 
easily modifiable. Nevertheless, their identification is important to develop tailored 
management of high risk patients. Moreover, identifying effective strategies for 
both prevention and treatment of complications could have the potential to im-
prove patient outcomes.  
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Abstract
Background: Especially in elderly patients mortality after colorectal cancer surgery 
is not limited to the immediate postoperative period. The excess 1-year mortality 
explains age related differences in colorectal cancer survival. To gain better insight 
in its etiology, causes of death were studied in a population based cohort of stage 
I-III colorectal cancer patients.
Methods: All 1924 patients who had a resection for stage I-III colorectal cancer 
in 2006, 2007 and 2008 in the Western region of the Netherlands were identified. 
Data were merged with causes of death data from the Central Bureau of Statistics 
Netherlands. Cause of death according to patient and tumour characteristics were 
assessed. To calculate excess mortality as compared to the general population, na-
tional data were used.
Results: Overall 13.2% of patients died within the first postoperative year. One-
year mortality increased with age. It was as high as 43% in elderly patients that 
underwent emergency surgery. In 75% of patients, death was attributed to the 
colorectal cancer. In 25% of all patients, registered deaths were attributed to post-
operative complications. Elderly patients with comorbidity more frequently died 
due to complications (p<0.01). Death of other causes was similar to background 
mortality according to age group.
Conclusion: In the presently studied cohort of stage I to III colorectal cancer pa-
tients that died within one year of surgery, cause of death was predominantly at-
tributed to colorectal cancer. Because it is not to be expected that in this cohort 
the number of deaths from recurrences is very high, the excess 1-year mortality 
signifies the prolonged impact of the insult of surgery. Especially in elderly patients 
it has a large impact on colorectal cancer survival. Therefore, in elderly patients the 
aim should be to limit the physiological insult of surgery, with a prolonged involve-
ment in the post-hospital period.  
Chapter 9 The prolonged impact of the insult of surgery in elderly patients.
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Introduction
Recently there has been an increasing emphasis on peri-operative risk in colorectal 
surgery. 
In this respect the surgical management of the elderly patient forms one of the 
most prominent issues. The elderly population is very heterogeneous and although 
excellent results of colorectal cancer surgery in these patients are reported 1-2, co-
morbidity and frailty challenge surgical management in these patients. 
An important outcome measure for surgery is postoperative mortality. This is usu-
ally described as mortality within thirty days after surgery. However, recent studies 
have shown that 30-day mortality after surgery is not an appropriate measure of 
surgical risk, as a significant proportion of patients die beyond this period 3-5. Es-
pecially in elderly patients a significant proportion fails to thrive in the months that 
follow colorectal surgery. The excess mortality beyond thirty days has been shown 
to sustain up to one year after surgery. It is the single most important explanation 
for age related differences in colorectal cancer survival 6. But even in younger col-
orectal cancer patients that underwent curative surgery a significant 1-year excess 
mortality exists. In high risk patients this can even increase to 15-30% 7. This shows 
that the deleterious physiological impact of surgery and postoperative complica-
tions is not limited to the immediate postoperative period. Considering the large 
impact on overall and disease-specific survival, information on the etiology of the 
1-year excess mortality is important. Earlier studies identified risk factors such as 
high age, emergency surgery, postoperative complications and re-admittance 7-9. 
However, up to date information on the cause of death for these patients is lim-
ited.
To improve overall care for elderly colorectal cancer patients it is important to 
know whether patients die as a consequence of their cancer, the treatment they 
receive or by competing causes of death. This could allow for improvements in the 
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care for and counseling of elderly colorectal cancer patients. It could also provide 
important information for outcome registrations and audits. 
The aim of this study is to gain a better insight in the etiology of the 1-year excess 
mortality by studying causes of death in a population based cohort of stage I-III 
colorectal cancer patients, with a special emphasis on elderly patients.  
Methods
Data 
In the Netherlands, all newly diagnosed malignancies are registered in the nation-
wide population based Netherlands Cancer Registry (NCR). The Leiden Cancer Reg-
istry, part of the NCR, collects data on all cancer patients diagnosed in one of the 
nine affiliated hospitals in the western part of the Netherlands. This region com-
prises one university hospital, six teaching hospitals and two non-teaching hospi-
tals and serves a population of 1.7 million inhabitants. 
Independently trained data managers collect data from the original patient files 
after receiving an automatic report from the Dutch pathology reporting system 
“PALGA”. Information on patient characteristics, tumor characteristics, treatment, 
hospital of diagnosis and/or treatment and follow-up are recorded. Tumor site and 
morphology are coded according to the International Classification of Diseases for 
Oncology (ICD-0)10. Cancers are staged according to the TNM classification of Ma-
lignant Tumors 11. The quality of the data is high, and completeness is estimated to 
be at least 95% 12-13. 
In 2006, a regional audit for colorectal cancer care (KIC) was started in the nine af-
filiated hospitals of the Leiden Cancer Registry. The data collection was extended 
to data that reflected quality of care and case mix factors. These prospectively col-
lected data were used for benchmarking and feedback on each hospitals process, 
ultimately to improve the quality of care in the entire region. Data were collected 
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on patient demographics (age, sex, co-morbidities and socio-economic status 
(SES)), tumor characteristics (localization, TNM staging) and treatment characteris-
tics ((neo-) adjuvant treatment, type of surgery, emergency, hospital of treatment, 
surgical complications and length of stay). Apart from ASA scores, completeness of 
data was more than 98%. 
Patients
All patients who had a resection of stage I, II or III tumor of the colon (C18), the 
recto-sigmoid (C19) or the rectum (C20) from January 1st 2006 to December 31st 
2008 in one of the affiliated hospitals, were identified (patients with a stage IV tu-
mor, with a tumor of the appendix and patients who did not undergo a resection 
of the tumor, were excluded). Vital status of all patients was obtained actively on a 
regular basis through linkage of the cancer registry data with the integrated data-
base of the municipal registry and the central bureau for genealogy. Follow-up was 
completed until January 1 2010. 
Data of patients who died in the first year after surgery, were merged with causes 
of death data from the Central Bureau of Statistics Netherlands that records data 
on the primary and three underlying causes of death according to ICD-9. Cause of 
death was grouped into:  
1) Died of colorectal cancer: colorectal cancer as primary cause of death or metasta-
ses as primary cause of death with colorectal cancer as underlying cause of death. 
Death due to complications (in the group died of colorectal cancer) were coded as 
yes if one of the underlying codes indicated complications as cause of death.
2) Died with colorectal cancer: patient died of other causes than colorectal cancer, 
but with colorectal cancer as underlying cause. 
3) Died of other causes: patients died of other causes than colorectal cancer (col-
orectal cancer not mentioned in primary or underlying causes). 
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Age was divided into <65, 65-74 and 75 years or older. Co-morbidity was recorded 
according to a slightly modified version of the Charlson index, used by the Neth-
erlands Cancer Registry. ASA scores were categorized as ASA I and II or ASA III and 
IV. Missing data from the ASA score were included as a separate category. Surgical 
complications comprised superficial wound infections, abdominal wall problems 
(i.e., dehiscence), deep infections, and intra-abdominal complications including 
bleeding, ileus, abscess or anastomotic leaks. As a substitute for overall complica-
tions (both surgical and non-surgical such as pulmonary or cardiac events), a pro-
longed length of stay was used, which was defined as a hospital admission of 15 
days or longer after surgery. 
Cause of death according to patient and tumour characteristics were assessed; dif-
ferences were tested with chi-squared or Fischer’s exact, where appropriate. Analy-
ses were stratified for colon and rectal cancer. To calculate excess mortality as com-
pared to the general population, national data were used. They were matched on 
sex, year and age. Data concerning recurrences was not available in this dataset. 
Results
From January 1st 2006 through December 31st 2008, 1924 patients had a resection 
in one of the nine affiliated hospitals of the Leiden Cancer Registry, for stage I-III 
colorectal cancer; 1279 for colon cancer and 645 for rectal cancer. Table 1 shows 
the characteristics of the study population. Overall 13% of patients died within the 
first postoperative year. Besides gender and year of surgery all depicted character-
istics were associated with 1-year mortality. Among patients aged 75 years or older, 
patients that underwent emergency surgery, patients with a high comorbidity bur-
den (Charlson >1; ASA III/IV) and patients that had a prolonged length of stay (LOS) 
1-year mortality rates were as high as 20-33 %. For elderly patients that underwent 
emergency surgery the 1-year mortality rate was even 43%. 
Most patients that did not survive the first year died beyond 30-days (61% of all 
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Table 1
Mortality of 1924 patients who had a resection in one of the nine affiliated hospitals of the Leiden 
Cancer Registry, for stage I-III colorectal cancer from January 1st 2006 through December 31st 2008 
(1279 colon cancer patients and 645 rectal cancer patients), according to patient, tumor and treatment 
characteristics.  
Characteristics N Alive % Died in the 1st year % p-value
Sex Male 981 85.5 14.5 0.1
Female 943 88.0 12.0
Age <65 530 94.7 5.3 <0.001
65-74 581 89.5 10.5
75+ 813 79.6 20.4
Year 2006 677 86.6 13.4 0.5
2007 610 85.7 14.3
2008 637 87.9 12.1
Stage I 408 92.4 7.6 <0.001
II 816 86.6 13.4
III 700 83.6 16.4
Tumor Colon 1279 84.4 15.6 <0.001
Rectal 645 91.5 8.5
Emergency Surgery Yes 183 67.8 32.2 <0.001
No 1741 88.7 11.3
Charlson 0 1088 90.6 9.4 <0.001
1 467 84.8 15.2
2 or more 369 77.8 22.2
Comorbidity No 856 91.0 9.0 <0.001
Yes 1068 83.3 16.7
ASA I/II 951 92.7 7.3 <0.001
III / IV 381 76.6 23.4
Unknown 592 83.6 16.4
Surgical Complications No 1540 89.0 11.0 <0.001
Yes 384 77.6 22.4
Age <65 530 94.7 5.3 <0.001
65-74 581 89.5 10.5
75+ 813 79.6 20.4
The prolonged impact of the insult of surgery in elderly patients.
DEF-zw-Proefschrift-JW#PROEF-13-april-2012.indd   151 13-4-2012   18:20:37
152
patients). We found no age related differences here (p=0.4). The proportion of pa-
tients that died beyond 30-days increased with tumor stage (p<0.01), lower comor-
bidity burden (p=0.02), elective surgery (for colon cancer p=0.02) and prolonged 
length of stay (p<0.01). 
Characteristics N Alive %
Died in the
 1st year %
p-value
Year 2006 677 86.6 13.4 0.5
2007 610 85.7 14.3
2008 637 87.9 12.1
Stage I 408 92.4 7.6 <0.001
Overall II 816 86.6 13.4
III 700 83.6 16.4
Tumor Colon 1279 84.4 15.6 <0.001
Rectal 645 91.5 8.5
Emergency Surgery Yes 183 67.8 32.2 <0.001
No 1741 88.7 11.3
Charlson 0 1088 90.6 9.4 <0.001
1 467 84.8 15.2
2 or more 369 77.8 22.2
Comorbidity No 856 91.0 9.0 <0.001
Yes 1068 83.3 16.7
ASA I/II 951 92.7 7.3 <0.001
III / IV 381 76.6 23.4
Unknown 592 83.6 16.4
Surgical Complications No 1540 89.0 11.0 <0.001
Yes 384 77.6 22.4
Length of Stay regular 1276 91.2 8.8 <0.001
prolonged 605 77.5 22.5
Unknown 43 83.7 16.3
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Table 2
One-year mortality and cause of death, for patients with colon cancer (A) and rectal cancer (B).  
COLON (A)  Cause of death
1-year mortality Colon cancer* With colon cancer** Other causes# Unknown cause
n=200 (15.6%) n=149 (74.5%) n=9 (4.5%) n=35 (17.5%) n=7 (3.5%)
<65 years 22 16 1 3 2
11.0% 72.7% 4.6% 13.6% 9.1%
65-74 years 47 34 1 9 3
23.5% 72.4% 2.1% 19.1% 6.4%
75+ years 131 99 7 23 2
65.5% 75.6% 5.3% 17.6% 1.5%
RECTAL (B)
1-year mortality Rectal cancer* With rectal cancer** Other causes# Unknown cause
n=55 (8.5%) n=35 (63.6%) n=7 (12.7%)  n=10 (18.2%) n=3 (5.5%)
<65 years 6 4 1 1 0
11.0% 66.6% 16.7% 16.7%
65-74 years 14 6 2 4 2
25.5% 42.9% 14.3% 28.5% 14.3%
75+ 35 25 4 5 1
63.5% 71.4% 11.4% 14.3% 2.9%
p-value <0.001 <0.001 0.3 0.2 0.4
*Colon or rectal cancer as primary cause of death, or other cancer with colorectal cancer with underlying cause of 
death, **Other causes as primary cause of death with colon or rectal cancer as underlying cause of death, #Other 
causes as primary cause of death without colon or rectal cancer as underlying cause of death
Table 2 shows the causes of death that were registered for the patients that died 
within 1-year of surgery for colon and rectal cancer patients. About 65% of patients 
that died within 1-year of surgery were 75 years or older. Deaths in the first year 
after colorectal surgery were predominantly attributed to the colorectal cancer. 
Distribution of causes of death was similar for different age groups. The incidence 
of 1-year mortality and death due to colorectal cancer increased with age. 
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When excess 1-year mortality (observed / expected deaths) was compared to the 
general population, death of other causes was similar to background mortality 
(standardized mortality ratio of general population) according to age group. No 
differences were found here between colon and rectal cancer patients.
Death certificates in the Netherlands also register whether death was due to com-
plications. Table 3 shows 1-year mortality that was attributed to complications. 
With increasing age death in the first postoperative year is more frequently attrib-
uted to complications. In elderly patients 25% of early mortality is due to compli-
cations. No clear association was found between comorbidity and death due to 
complications for all patients. However, elderly colon cancer patients with comor-
bidities more frequently died due to complications (p<0.01). Especially elderly pa-
tients with neurologic disease, diabetes and cardiac disease more frequently died 
due to complications. 
No association was found for LOS and death due to complications. 
There was a strong association between the occurrence of surgical complications 
and death due to complications, which increased with age (table 4). It seems that 
the significance of having a surgical complication increases with age. In elderly 
Table 3
Mortality in the first postoperative year attributed to complications 
Complications  <65 65-74 75+
No 23 (82.1%) 53 (86.9%) 125 (75.3%)
Yes 5 (17.9%) 8 (13.1%) 41 (24.7%)
Total* 28 (100%) 61 (100%) 165 (100%)
Difference between the age categories p<0.001. 
*Total number of patients who died in the first postoperative year. 
Incidence of death due to complications: 0.9% <65 years (5/530), 1.4% 
65-74 years and 5.0% in 75 and older. 
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patients whose deaths were attributed to complications, the incidence of surgi-
cal complications was 40-71%. Within this group the type of surgical complication 
was predominantly abdominal (ileus, abcess, anastomotic leak). For elderly colon 
cancer patients also abdominal wall problems (i.e. dehiscence) were significantly 
associated with mortality due to complications. 
Discussion
In this study we found that deaths in the first year after colorectal cancer surgery 
were predominantly attributed to the colorectal cancer. The incidence of this early 
mortality increased with age. It was as high as 43% in elderly patients that under-
went emergency surgery. Distribution of causes of death was similar for different 
Table 4










<65 No 9.1 0.3 No 25.0 0.7
Yes 27.3 Yes 0
65-74 No 6.7 0.05 No 0 0.3
Yes 29.4 Yes 20.0
75-79 No 7.4 0.02 No 0 0.04
Yes 40.0 Yes 62.5
80-84 No 20.0 0.047 No 12.5 0.07
Yes 55.6 Yes 75.0
85-89 No 11.1 0.004 No 20.0 0.7
Yes 71.4 Yes 25.0
90+ No 0 0.1 No No patients 
Yes 50.0 Yes One patient
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age categories. Up to 25% of all registered deaths were attributed to postopera-
tive complications. This underlines the impact the surgery has on the excess 1-year 
mortality, especially in elderly patients with a decreased functional reserve and a 
reduced ability to cope with the physiological challenges of the surgery and its 
consequences. 
The reliability of cause of death coding in The Netherlands has been shown to be 
high for major causes of death such as cancer and myocardial infarction, but for 
chronic diseases it can be low 14. The accuracy of cause of death statements has 
been debated in many investigations 15-17. The attribution of the cause of death 
depends on data from the physician completing the death certificate. He may not 
know the patient or may not be aware of the earlier diagnosis of cancer. It also 
depends on subjective judgments of the possible pathway of morbid events lead-
ing directly to death by both the physician and the coding medical registry clerk. 
The attribution of deaths to specific causes can be confusing. Should deaths within 
one month after surgery be attributed to surgery or to the cancer for which the 
surgery was performed? It seems that conventionally treatment-related deaths 
are not being attributed to cancer. Brown et al. found that non-cancer mortality 
was considerably higher in cancer patients than in the general population 16. In 
population based studies nowadays this problem is usually countered by the use of 
relative survival as an outcome measure. In an earlier publication of our group we 
used this technique to show that there is a significant excess mortality the first year 
after colorectal surgery 6. In the present study early mortality was predominantly 
categorized as caused by the colorectal cancer. This suggests that among physi-
cians and moreover medical registry clerks in the Midwestern part of The Nether-
lands there is consensus on how to code treatment related deaths of patients with 
cancer. There is certainly an argument for coding deaths from cancer treatment 
as cancer mortality. The World Health Organization defined the cause of death as 
“the disease or injury which initiated the train of morbid events leading directly to 
death” 18. Furthermore, by including treatment related deaths cancer mortality can 
serve as a reliable measure for the progress against cancer19. 
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Apart from confusions in attributing deaths to treatment or cancer, difficulties have 
been shown in classifying deaths from other causes but with colorectal cancer 17. 
This makes it difficult to interpret the group of patients that have died due to other 
causes but with CRC in the present study. This group is fairly small (1% of all pa-
tients). In a cohort of stage I to III colorectal cancer patients operated with curative 
intent, it is to be expected that early recurrences will be limited. Although a limited 
number of patients could have been under-staged. They could have already had 
occult metastases at the time of surgery. Since most patients in the present cohort 
had a preoperative abdominal CT-scan and a chest X-ray (elective patients that had 
no CT-scan underwent an abdominal ultrasound before surgery) and 28% also had 
a chest CT-scan, this is not likely to be a significant group of patients. Earlier popula-
tion based studies on colorectal cancer prognosis show that in patients undergo-
ing curative resections, recurrences within the first year are rare 20. Even in these 
patients, only a small number of recurrences will cause mortality within 1-year.  
This argument is also important for interpreting the group of colorectal cancer 
deaths in the present study. Since it is not likely that more than a very small num-
ber of deaths attributed to the colorectal cancer are in fact attributable to cancer 
progression, they will have to be attributed to the cancer treatment. This would 
imply that the vast majority of colorectal cancer deaths within the first year will 
have to be attributed to the impact of the surgery and its consequences, although 
the administration of chemotherapy may have been of influence here. 
For the majority of these patients the physician coding the cause of death saw no 
apparent complication that lead directly to their death. Probably the physiological 
insult of the surgery initiated a chain of events that eventually caused a failure to 
thrive in these patients, without an apparent causal event other than the debilitat-
ing effect of the surgery itself.
Death certificates showed that up to 25% of colorectal cancer deaths are attributed 
to postoperative complications. This illustrates that in a significant number of cases 
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coded as death due to colorectal cancer it was apparent that death occurred as a 
direct consequence of postoperative complications. This is an interesting group. 
In this study we found no clear association between comorbidity and death due 
to complications for all patients. However, elderly patients with comorbidity did 
more frequently die of complications. This could be a result of the fact that comor-
bidity has a relatively more severe impact in patients with limited physiological 
resources.  
Surprisingly we found no association between prolonged LOS and death due to 
complications. It has been shown that prolonged LOS is related to the occurrence 
of (medical) complications 21. Possibly a prolonged LOS also depicts the efforts 
made to rescue patients from the consequences of complications, thereby neutral-
izing its association with death due to complications. 
The strong association of surgical (especially abdominal) postoperative complica-
tions and death due to complications may seem logical. However, it is often as-
sumed that the larger part of postoperative deaths in the elderly is caused by medi-
cal complications. As Iversen et al. showed, postoperative medical complications 
are the main cause of early death after emergency surgery for colonic cancer. Pos-
sibly surgical complications are relatively more apparent for the coding physician 
at the time of death. The importance of surgical complications seems to increase 
with age. A surgical complication in itself may be a manifestation of the decreased 
potential to recover from surgery in the elderly. Moreover, surgical complications 
may have a relatively more severe impact in elderly patients with limited physi-
ological resources.  
Limitations and strength
The limitations of this study are consequential to limitations in the accuracy of cod-
ing the cause of death as discussed above. Its strength is the fact that this study 
uses reliable population based data. Furthermore, this study is the first to study 
cause of death in patients that did not survive the first year after curative colorectal 
cancer resection. It could help to elucidate the etiology of the 1-year excess mor-
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tality in the elderly, that has been shown to be the major influence on age related 
differences in cancer survival 6. 
Clinical implications
This study implies that we have to concentrate on improving the outcome of col-
orectal cancer surgery as it is the primary influence on early cancer mortality espe-
cially in elderly patients.
 The very finely balanced physiological resources in the frail elderly colorectal can-
cer patient demand extra care to optimise their cardiopulmonary, nutritional and 
performance status. Active participation of a multidisciplinary team is hereby re-
quired, aimed to maximise the physiological reserve and minimise the impact of 
the surgery. Possibly minimally invasive surgery could be of use here. 
Although there are concerns that elderly patients tolerate poorly the cardiovascu-
lar changes associated with pneumoperitoneum, laparoscopic surgery has been 
shown to be safe and beneficial in the elderly 22-25. Moreover, the benefits of lap-
aroscopic colorectal resection were found to be more pronounced in the elderly 
26. Less tissue trauma, early mobilisation and faster recovery that could limit the 
impact of the surgery may be especially helpful in elderly patients with limited 
reserves. 
It has been shown that better physical performance status and serious postop-
erative complications consistently predicted recovery. Substantial numbers of pa-
tients, especially elderly, have a protracted recovery. Even six months after abdomi-
nal surgery performance based measures such as timed walk, functional reach and 
grip strength does not returned to preoperative levels in 40-60% of patients 27. 
A prehabilitation programme to improve or at least maintain functional capacity 
preoperatively may play a role in decreasing complication rates after colorectal 
surgery 28. 
The high 1-year excess mortality we found after colorectal cancer surgery not only 
highlights the importance of the peri-operative period, where complications and 
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re-admittance seem important determining factors 8-9. It also turns our attention 
to the post-hospital period as a potential new area for quality improvement. Fur-
ther studies are necessary to elucidate the aetiology of the 1-year excess mortal-
ity and whether modifiable risk factors exist. However, it seems clear that further 
efforts should be made to minimise the physiological insult of surgery but also 
its consequences. A continued attention to comorbid conditions after surgery and 
appropriate medical follow up may be helpful. This may decrease the number of 
hospital readmissions as approximately 75% of readmissions within the first 90 
days were not related to the surgery itself 29. Analogue to the enhanced recovery 
principle 30-31, there is an argument for developing a sustained enhanced recovery 
program for elderly colorectal cancer patients.
Conclusions
Cause of death statements on death certificates should be interpreted with care. 
In the presently studied cohort of stage I to III colorectal cancer patients that died 
within one year of surgery, cause of death was predominantly attributed to col-
orectal cancer. Because it is not to be expected that in this cohort the number of 
deaths from recurrences is very high, the excess 1-year mortality signifies the pro-
longed impact of the insult of surgery. This is supported by the finding that up 
to 25% of deaths was attributed to postoperative complications. Considering the 
high mortality in the first postoperative year, the focus in the surgical treatment of 
elderly colorectal cancer patients should be on limiting the physiological insult of 
surgery, with a prolonged involvement in the post-hospital period.  
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Chapter 10 Summary, general discussion and future directives
Summary
The incidence of colorectal cancer is high and expected to grow in the Western 
world 1. Colorectal cancer surgery can be considered high risk surgery. It accounts 
for a disproportionate share of the morbidity, mortality and excess length of stay 
(LOS) in general surgery 2. Therefore, it is a very important focus for quality en-
hancement programs.
For an optimal quality of care it is elementary to study what constitutes the risk of 
adverse outcome in colorectal cancer surgery and to identify chances for improve-
ment. Objective information on risk profiles is indispensible both in the care for an 
individual patient and for comparative analyses on a hospital or population level. 
It can provide better information on prognosis and opens possibilities for more 
tailored treatment. It can also allow for adjusted treatment protocols for different 
risk groups. 
In this thesis different risk factors and outcome measures for colorectal cancer pa-
tients are studied. 
Accurate staging in colorectal cancer is important for a balanced clinical decision 
on further treatment and an accurate estimation of prognosis. In chapter 2 the 
prognostic capacity of the metastatic lymph node ratio (LNR) is assessed in stage 
III rectal cancer in addition to the 7th edition of the TNM classification 3. The use 
of LNR could improve identification of high risk patients and may also have the 
advantage to be less dependent on the number of retrieved lymph nodes than N 
stage. Especially in rectal cancer adequate retrieval of lymph nodes can be trouble-
some. This study shows that the LNR is an independent prognostic factor for overall 
survival and local recurrence in stage III rectal cancer. We demonstrate LNR is a 
reliable measure for overall survival from a lymph node yield of two or more. Our 
study shows that for an adequate prediction of local recurrence, at least six lymph 
nodes need to be retrieved. Stratification of patients is possible by dividing them in 
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quartiles. However, in this study, the LNR cut off point with the best discriminating 
power was 0.60, this means patients with lower LNR values can be considered low 
risk and patients with a LNR value above 0.60 should be considered high risk pa-
tients. We found this cut off value could improve prediction of prognosis per stage 
in addition to the TNM stage. It could add to the discussion on further (adjuvant) 
treatment in the multidisciplinary team meeting.
Patient and treatment characteristics are main determining factors for risk and out-
come in colorectal cancer surgery. Often patient and treatment factors interact. 
Anastomotic leakage is a major problem in colorectal surgery, which unfortunately 
occurs all too frequently. It often results in serious morbidity, increased healthcare 
costs and even death. Anastomotic leaks are also associated with local recurrences 
and reduced survival4-6. It has been reported that clinical risk assessment for anas-
tomotic leakage by the operating surgeon has a low predictive value and underes-
timates leakage risk 7. Chapter 3 describes the development and testing of a risk 
score for anastomotic leakage. A validated easy to use risk score could facilitate the 
intra-operative decision regarding whether or not to construct a (non-functional) 
stoma. However, anastomotic leakage is thought to have many causes. Creation 
of a predictive model that takes all these factors into account requires a very large 
and detailed database. Therefore, we pursued an alternative approach for this 
study. Instead of using a statistically-derived predictive model, we created a risk 
score through a heuristic combination of risk factors identified from the literature. 
This Colon Leakage Score (CLS) was then tested on a consecutive series of patients 
undergoing a left-sided colorectal resection with primary anastomosis. Our study 
shows that the CLS can determine the risk of anastomotic leakage for the individu-
al patient. What risk of anastomotic leakage is acceptable is of course debatable. In 
our opinion, a risk of anastomotic leakage of lower than 3% does not justify a non-
functional stoma, because a stoma can also cause problems (morbidity, discomfort 
and higher cost). If we choose to accept a 3% risk of anastomotic leakage as a cut 
off, only less than 20% of patients would be considered high risk and we would not 
have to worry about 80% of patients.
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In the end, it is up to the surgeon and patient to determine their own cut off CLS 
value considering their preferences concerning the risk of anastomotic leakage 
versus (temporary) stomata. The receiver-operating characteristics curve and the 
logistic regression curves displayed in chapter 3 could offer a useful tool to guide 
this clinical decision. After confirmation by larger multi-centre series the CLS po-
tentially solves a difficult clinical problem.
The number of patients with multiple malignancies is increasing. Because cancer 
treatment improves and cancer screening programs develop cancer survivors may 
increasingly develop a second primary tumour8-10. The proportion of second- or 
higher order invasive cancers reported to the US International Cancer Institutes 
Surveillance, Epidemiology and End Results Program (SEER) has increased to over 
10% in 2008 11. However, the influence of an earlier non-colorectal cancer on sur-
vival of colorectal cancer patients is not clear. Chapter 4 investigates its prognostic 
importance. This study showed that patients with a previous non-colorectal cancer 
have a higher mortality compared to patients with colorectal cancer as a first pri-
mary tumour. However, further analyses that were not published in the article of 
chapter 4, showed that the difference in survival was not explained by a difference 
in disease specific mortality. This suggests that a second primary colorectal cancer 
has the same clinic pathological behaviour as a primary colorectal cancer. There-
fore, an earlier malignancy in the history of colorectal cancer patients could just be 
regarded as comorbidity. In this respect, it is presently not clear whether a previous 
malignancy should be a regarded as marker for a higher inherent risk of cancer 
(cancer biology) and harmful lifestyle factors, or whether it is the damage caused 
by the previous malignancy or its treatment that determines its consequences. 
The presence of comorbidity effects treatment decisions12-15 and the prognosis of 
patients receiving colorectal cancer treatment 16-20. Consequently, comorbidity is 
believed to be an important confounder in the analysis of postoperative adverse 
events and omitting risk adjustment for comorbidity is argued to induce bias in 
studies that do not take it into account. However, despite the growing number of 
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studies addressing comorbidity, the added value of comorbidity in models predict-
ing the outcome of colorectal cancer is not clarified. It is also unknown whether dif-
ferent comorbidity measures are comparable in predicting mortality, and if these 
measures can equally predict other postoperative adverse events, such as postop-
erative complications. Chapter 5 compares frequently used comorbidity measures 
and their additional value in models predicting the outcome of colorectal cancer.  It 
shows that, all used comorbidity measures (ASA score, the Sum of Diseased Organ 
Systems, the Charlson Comorbidity Index and specific comorbidities) had similar 
predictive values. Thus, any of these measures can be used for predicting 30-day 
mortality and prolonged length of stay. For the occurrence of postoperative surgi-
cal complications, only a high ASA score and gastro-intestinal comorbidity were 
found to be risk factors. 
Although comorbidity is an independent risk factor for 30-day mortality and pro-
longed length of stay after colorectal cancer surgery, the additional value of comor-
bidity in models predicting postoperative adverse events seems only marginal.  
To optimise efficiency with regard to audits and quality improvement programs, 
only the most important comorbid factors should be identified to minimize the 
burden and costs of data collection, without compromising risk-adjustment.
Chapters 6 and 7 address old age as a risk factor for impaired survival and elabo-
rate on what constitutes age related survival differences. 
The EUROCARE Working Group (EUROpean CAncer REgistry-based study on surviv-
al and CARE of cancer patients) observed a significant survival improvement from 
1988 to 1999 for all cancers combined and for almost every cancer site, includ-
ing colon cancer 21. However, survival increased at a slower rate in the elderly, so 
that the gap in survival between younger and older patients widened. Elderly pa-
tients less frequently receive adjuvant chemotherapy and more often discontinue 
treatment 22. The administration of adjuvant treatment for elderly stage III colon 
cancer patients was found to be influenced by socioeconomic status, gender, and 
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comorbidity 12. Besides, comorbidity also influences surgical eligibility and other 
treatment options. However, in recent years the focus on elderly colorectal can-
cer patients has increased. Several studies concluded that age per se is not a con-
traindication for more aggressive or adjuvant treatment 23. Therefore, nowadays 
more elderly patients are considered for extensive therapy in routine practice. As 
a consequence an improved outcome for elderly patients could be expected. We 
hypothesized that the gap in survival between young and elderly patients shown 
in the EUROCARE data might be decreasing. So, the aim of the study in chapter 6 
was to describe treatments and compare survival rates over time between elderly 
(≥75 years), aged (65-75 years) and younger (<65 years) colon cancer patients. 
In this population-based study covering the mid-western region of the Netherlands 
over a period of 15 years, substantial changes in treatment of colon cancer were 
found; use of adjuvant chemotherapy for patients with stage III disease increased 
over time, resection rates remained stable over time for patients with curable dis-
ease in all age groups, while resection rates among metastatic patients decreased, 
and administration of chemotherapy for stage IV colon cancer patients increased 
for all age groups.
Survival increased significantly over time for younger patients after adjusting for 
confounders (such as sex, age, grade, and stage and treatment). The survival of 
aged patients also improved after adjusting for sex, age, grade, and stage, but not 
after adjusting for treatment as well. The survival of elderly patients did not im-
prove after either of the adjustments. This leaves a gap in survival between young 
and elderly similar to the EUROCARE data. 
The near future will have to show if a more extensive and hopefully better tailored 
treatment can help elderly to close this gap.
The number of elderly colorectal cancer patients is high and expected to increase 
in the future. If survival of elderly colorectal cancer patients is worse compared to 
younger patients it is important to know what constitutes this difference.
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Differences in survival by age groups in colorectal cancer may be explained by 
variations in tumour factors, patient characteristics and therapy. Notwithstanding 
these differences, several studies found a similar disease specific survival for elderly 
and young colorectal cancer patients. This would indicate that the excess mortality 
in elderly colorectal cancer patients is due to competing causes of death. To gain a 
better insight in survival differences between age groups, the study in chapter 7 
aims to compare population-based survival data of colorectal cancer patients for 
different age groups. It not only regards overall and relative survival but also con-
ditional relative survival under the condition of surviving one year. Furthermore, to 
comprehend the challenge of treating elderly colorectal cancer patients this study 
focuses on age related differences in 30-day and 1-year mortality. We found that 
when survival data for colorectal cancer are corrected for expected death of other 
causes and first year mortality, age differences disappear. Therefore, decreased sur-
vival in the elderly is mainly due to differences in early mortality. Only for stage III 
disease elderly patients fare worse, probably as a result of less extensive adjuvant 
treatment. The overall difference between the younger and elderly age groups is 
that within the elderly group there is an excess mortality of about 10 % the first 
year. This study implies that in treating elderly stage I-III colorectal cancer patients 
the focus should be on the peri-operative process as well as the first postoperative 
year. 
Postoperative mortality is one of the most important outcome measures for sur-
gery. This is usually described as mortality within thirty days after surgery. However, 
earlier studies have shown that 30-day mortality after surgery is not an appropriate 
measure of surgical risk, as a significant proportion of patients die in the months 
that follow 24-26. This suggests that there may be a prolonged impact of the insult 
of surgery. Chapter 8 and Chapter 9 look into the aetiology of the excess mortality 
in the first postoperative year. 
Chapter 8 identifies risk factors. We found that the excess mortality in the first year 
after surgery for stage I-III colorectal cancer is high. Overall, 12.4 % of all patients 
Summary, general discussion and future directives
DEF-zw-Proefschrift-JW#PROEF-13-april-2012.indd   169 13-4-2012   18:20:38
170
died within the first year, compared to a 4.9 % 30- day mortality rate. After adjust-
ment for expected mortality in the general population, patients with comorbidi-
ties, patients with stage III tumours, patients requiring emergency resection, and 
patients with postoperative surgical complications were at higher risk for excess 
mortality, with excess 1-year mortality rates varying from 15 to 30%.  
The identification of these risk factors provides potential targets for improvement 
of patient outcomes. Moreover, identifying effective strategies for both prevention 
and management of complications must have priority. 
Chapter 9 investigates cause of death for patients that do not survive the first 
postoperative year. Cause of death statements on death certificates should be in-
terpreted with care. In the studied cohort of stage I-III colorectal cancer patients 
that died within one year of surgery, cause of death was predominantly attributed 
to colorectal cancer. Because it is not to be expected that the number of deaths 
from recurrences or faulted diagnoses -i.e. under staged stage IV patients- is very 
high in this cohort, the excess 1-year mortality signifies a prolonged impact of the 
insult of surgery. This is supported by the finding that up to 25% of deaths was also 
attributed to postoperative complications. Therefore, in the surgical treatment of 
colorectal cancer patients the focus should be on limiting the physiological insult 
of surgery, with prolonged involvement in the post-hospital period.
Chapter 10 Summary, general discussion and future directives
DEF-zw-Proefschrift-JW#PROEF-13-april-2012.indd   170 13-4-2012   18:20:38
171
General discussion and future directives
Risk assessment to enhance quality of care
The outcome and prognosis for colorectal cancer patients after surgery is deter-
mined by a plethora of interacting factors. These factors can be divided into tu-
mour/ stage related, treatment related and patient related subcategories. Ideally, 
for an optimal informed treatment, knowledge of all these factors and their inter-
action should be available. Alas, it is impossible to appreciate the complete scale 
of multi-factorial interaction of effects and uncertainties will remain on this issue. 
It is not the aim of this thesis to produce a final overview of all important risk fac-
tors or outcome measures for colorectal cancer patients. We chose to investigate 
the possibilities of risk stratification and hopefully identify some modifiable risk 
factors. A better insight in peri-operative risk is important. For an individual pa-
tient this should guide clinical judgment and the administration of tailored care. 
Furthermore, in modern practise there is a high demand for individualised risk as-
sessment to be shared with the patient at the time of consenting. On a hospital or 
population level knowledge of risk factors can lead to adjusted (better tailored) 
treatment protocols and better information on case mix influences. The identifica-
tion and optimisation of modifiable risk factors has the potential to improve the 
overall care for patients. 
Risk assessment in general surgery has greatly advanced over the last two decades. 
In 1991 the Department of Veterans Affairs (VA) has systematically collected and 
analysed risk-adjusted surgical data in VA hospitals, the National Surgical Quality 
Improvement Program (NSQIP). Based on observed hospital variations in outcome 
structural changes have been implemented that have led to a significant reduc-
tion of complications, 30-day mortality and length of hospital stay together with 
an increased patient satisfaction27. The program has now been adopted by the 
American College of Surgeons and the implementation of the ACS-NSQIP dem-
onstrated improvements in surgical outcome similar to the VA experience. In the 
Netherlands different quality enhancement programs have been started. A region-
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al multidisciplinary audit for colorectal cancer care (KIC) in the Midwestern part of 
the Netherlands supplied some of the data used in this thesis. In 2009 a nationwide 
audit (DSCA) has started with the ultimate goal to improve the care for colorectal 
cancer patients in the Netherlands. The audit started as a surgical audit, but will be 
multidisciplinary in the near future. It intends both to increase the transparency 
of colorectal care and to collect valuable data for quality enhancement as it can 
help to identify opportunities for improvement and stimulates according action. 
Now in its third year the DSCA offers a large database used for research. Targeted 
quality enhancement projects are being offered to negative outliers. For short term 
outcomes positive trends are already starting to outline, for instance in the increas-
ing number of harvested lymph nodes. Long term effects have to be awaited but 
based on experiences in other countries, reduction of adverse events after colorec-
tal cancer surgery could be anticipated in the future.         
Anastomotic leakage
Anastomotic leakage is a major problem in colorectal cancer surgery, causing 
morbidity, worse cancer outcome and death. Although it is still widely regarded 
as technical failure, a vast literature on the comparison of different techniques has 
not shown clear differences in leak rate 28-30. In this thesis we show that patient fac-
tors play an important role in the occurrence of anastomotic leaks. In combination 
with tumour location (height), intra-operative blood loss and the duration of the 
surgery, they could predict the risk of an anastomotic leak.
The importance of blood loss and the duration of the surgery within the colon leak-
age score (CLS), described in chapter 3, is interesting. These items could be con-
sidered surrogate markers for the skill and training of the surgeon. However, there 
could also be a direct relation with the operations stress response and the wound 
healing process.  
One of the appealing assets of the CLS is its logic. It is based upon the notion that it 
is the inherent healing power of a patient (depicted by several patient factors) and 
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the severity of the physiological insult of the surgery (operation factors) that de-
termine the outcome. The problem remains that presently we do not exactly know 
what determines  the impact of the physiological challenges the surgery poses and 
what constitutes a patients physical capacity to recover. Focussed research espe-
cially on high risk groups is warranted.
Recently, there has been a trend to create more non-functional stomas to coun-
teract the problem of anastomotic leakage. In the Dutch Surgical Colorectal Audit 
the number of non-functional stomas was as high as 70% in rectal resections (un-
published data). The problem is that unnecessary stoma’s also induce morbidity 
and discomfort and increase healthcare costs 31. In addition, continuity is never 
restored in many patients. In the future predictive scores like the CLS should be 
used to guide appropriate use of non-functional stomas.
  
Comorbidity
Comorbidity is of critical importance in the care for an individual patient. The pres-
ence of comorbidity effects treatment decisions12-15 and the prognosis of patients 
undergoing colorectal cancer treatment 16-20.
To ensure favourable outcomes, on a hospital level great efforts should be made 
to optimise peri-operative evaluation and subsequent treatment of comorbidities. 
However, in this thesis we found that, although comorbidity is an important risk 
factor for 30-day mortality and a prolonged length of stay after colorectal cancer 
surgery, the importance of comorbidity in models predicting postoperative ad-
verse events, is only marginal. This means that for risk-adjustment in colorectal 
cancer surgery comparisons, comorbidity is not as important as often considered. 
With regard to audits and quality improvement programs this could mean only the 
most important clinical comorbid factors have to be taken into account so that the 
burden and costs of data collection can be minimised, without compromising risk-
adjustment. However, if audits are to be including long term outcome measures in 
the future, then comorbidity can be expected to be an important parameter, as it 
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represents a greater risk of non cancer related mortality. For the DSCA a long-term 
oncologic evaluation is scheduled.
Emergency surgery
Emergency surgery has consistently been demonstrated to be a major risk factor 
for adverse outcome in colorectal surgery. Prior resuscitation and stabilisation are 
elementary to reduce this risk. However, in some cases the risk of delaying sur-
gery for medical stabilisation is higher than any potential gain (for instance with 
imminent blow-out). Therefore, efforts should be made to reduce the number of 
patients in need of an emergent intervention. In this respect the intended national 
screening program, which is to be implemented in 2012, could be helpful. If col-
orectal cancer could be identified at an earlier (asymptomatic) stage, the need for 
emergent surgery will probably be lower.
Elderly patients more frequently undergo emergency surgery. This could be an ef-
fect of less aggressive diagnostics and treatment in the elderly. A more liberal pol-
icy to consider elderly for well prepared elective surgery, could lower the number 
of emergency operations, leading to a better overall outcome for elderly patients. 
Also a faster trajectory from diagnosis to surgery for patients with imminent ob-
struction could diminish the need for emergency surgery. 
Complications
Peri-operative risk factors are directly linked to postoperative complications. Dif-
ferent studies showed that variations in preoperative status are related to opera-
tive outcomes 32, hospital length of stay 33 and hospital costs 34. Furthermore, the 
occurrence of postoperative complications itself is among the most important 
predictors of further adverse outcome after colorectal surgery. Therefore, develop-
ing strategies to reduce postoperative complications is critical. In three ACS-NSQIP 
studies Ghaferi et al. showed that while rates of individual complications did not 
vary significantly among hospitals with differing mortality rates, mortality in pa-
tients with major complications was almost twice as high in hospitals with very 
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high overall mortality as in those with very low overall mortality35-37. This failure to 
rescue phenomena suggests that the quality of peri-operative care once complica-
tions occur is just as important as the efforts to prevent them. To improve the out-
come of colorectal cancer surgery in the future both prevention and management 
of complications is critical.
Old age
In recent years the focus on elderly colorectal cancer patients has increased. Octo-
genarians and nonagenarians are a rapidly growing segment of the population. It is 
important to realise that the elderly population forms a very heterogeneous group. 
The onset and severity of the progressive functional inadequacy of physiological 
systems, that comes with senescence is variable from individual to individual. Age 
alone is therefore not the primary influence on the outcome after surgery for col-
orectal cancer. Rather the combination of comorbid status and an impaired physi-
cal capacity to recover from adverse events that may occur before, during and after 
surgery determines the outcome in elderly patients 38. This is also referred to as 
frailty. Although frailty is defined variably it is likely to be correlated with disability, 
comorbidity and self rated health, and should identify a group that is vulnerable to 
adverse outcomes.39
Notwithstanding the fact that increasing age is an independent risk factor for post-
operative adverse events, even after adjustment for comorbid conditions, several 
studies concluded that age per se is not a contraindication for more aggressive 
or adjuvant treatment 23. Therefore, nowadays more elderly patients are consid-
ered for extensive therapy in routine practice. However, elderly colorectal cancer 
patients tend to have a more advanced stage of disease 23. They have more co-
morbidity and are treated less aggressive than their younger counterparts19. Co-
morbidity for its part influences surgical eligibility and other treatment options18. 
Furthermore, it represents a greater risk of non cancer related mortality. Elderly pa-
tients less frequently receive adjuvant chemotherapy and more often discontinue 
treatment before completion22. 
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In this thesis we found that although the survival of aged patients (65-75 years) 
improved, the survival of elderly patients (older than 75 years) did not improve in 
the period of 1990-2005. From this thesis we can deduce two possible explana-
tions. Firstly, there is still an under-treatment of elderly, especially in stage III colon 
patients. This may not be entirely modifiable due to frailty and comorbidity pre-
cluding the use of adjuvant chemotherapy. Secondly, in elderly patients there is 
a higher excess mortality. This is possibly due to a more profound and prolonged 
impact of the insult of surgery in the elderly. Elderly tend to have a decreased func-
tional reserve and a reduced ability to cope with the physiological challenges of the 
surgery and its consequences. In this thesis we showed that after adjusting for the 
expected mortality in the population and for mortality in the first year, age related 
survival differences disappeared. This underlines that the deleterious physiological 
impact of surgery and postoperative complications is not limited to the immediate 
postoperative period. A significant proportion of these patients potentially fail to 
thrive in the months that follow colorectal surgery 26. 
In order to improve survival in the elderly, in the future more focus should be on 
non cancer specific (neo)adjuvant treatment, not only on the (neo)adjuvant cancer 
treatment. The very finely balanced physiological resources in the frail elderly col-
orectal cancer patient demand extra care to optimise their cardiopulmonary, nutri-
tional and performance status. Also the timing of the surgery should be discussed. 
Active participation of a multidisciplinary team is hereby required, aimed to maxi-
mise the physiological reserve and minimise the impact of the surgery. Possibly 
minimally invasive surgery could be of use here. Although there are concerns that 
elderly patients tolerate poorly the cardiovascular changes associated with pneu-
moperitoneum, laparoscopic surgery has been shown to be safe and beneficial in 
the elderly 40-43. Moreover, the benefits of laparoscopic colorectal resection were 
found to be more pronounced in the elderly 44. Less tissue trauma, early postopera-
tive mobilisation and faster recovery that could limit the impact of the surgery may 
be especially helpful in elderly patients with limited reserves. 
The near future will have to show if a more extensive and hopefully better tailored 
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multidisciplinary treatment, with extra focus on the peri-operative and post-hospi-
tal period, can help elderly to close the gap. 
However, we have to keep in mind that, for very old people in particular, the qual-
ity of life after surgery is of overriding importance. Before undertaking surgery we 
must first understand what can be accomplished with our operation, what the 
physiologic cost will be for the patient, and what each patient wants and can tolerate.
Prolonged impact of surgery
An important finding in this thesis is the fact that 30-day mortality, a widely used 
outcome measure, vastly underestimates 1-year mortality. Thereby it underesti-
mates the true impact of surgery on survival of colorectal cancer patients. It has 
been shown that physical performance status and serious postoperative complica-
tions consistently predicted recovery. Substantial numbers of patients, especially 
elderly, have a protracted recovery. Even six months after abdominal surgery per-
formance based measures such as timed walk, functional reach and grip strength 
have not returned to preoperative levels in 40-60% of patients 45. A prehabilitation 
programme to improve or at least maintain functional capacity preoperatively may 
play a role in decreasing complication rates after colorectal surgery 46. It has also 
been suggested that preoperative cognitive status and depression may be related 
to recovery. This is interesting since depression is treatable and there is some evi-
dence that postoperative delirium can be prevented 47. There is a growing litera-
ture on mind-body interventions that use mindfulness-based stress reduction to 
decrease anxiety and sleep disturbances to attenuate stress response 48. 
The high 1-year excess mortality we found after colorectal cancer surgery not only 
highlights the importance of the peri-operative period, where complications and 
re-admittance seem important determining factors 49-50, it also turns our attention 
to the post-hospital period as a potential new area for quality improvement and au-
diting. Further studies are necessary to elucidate the aetiology of the 1-year excess 
mortality and whether modifiable risk factors exist. However, it seems clear that 
further efforts should be made to minimise the physiological insult of surgery but 
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also its consequences. A continued attention to comorbid conditions after surgery 
and appropriate medical follow up may be helpful. This may decrease the number 
of hospital readmissions, because approximately 75% of readmissions within the 
first 90 days are not related to the surgery itself 51. Analogue to the enhanced re-
covery principle 52-53, there is an argument for developing a sustained enhanced 
recovery program.
 
The responsibility of the surgeon
In addressing risk and outcome in colorectal cancer surgery tension exists between 
considering large cohorts and the care for an individual patient. Population based 
risks of adverse outcomes are often difficult to interpret and translate to a clinical 
situation. It is up to the surgeon to make an educated judgement of a patient’s risk. 
He must provide for appropriate well organised peri-operative care, up standard 
surgical skill and dedicated counselling of the patient. All these factors are neces-
sary for a well balanced treatment, considering personal preferences and reducing 
risk to allow for the best possible outcome. This work can not be done without 
the support and contribution of a dedicated multidisciplinary team. Therefore, the 
surgeon has to be a team player. Improvement of surgical care is the result of team 
effort, rather than individual technical brilliance.
Finally, it is the responsibility of the surgeon to focus on continued education and 
development, dedication to the patient and the willingness to confront his actual 
outcomes and hold them up against relevant bench-marks. 
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Nederlandse samenvatting
De incidentie van darmkanker is hoog in de westerse wereld en zal naar verwa-
chting door de vergrijzing nog toenemen 1. Darmkanker chirurgie is hoogrisico 
chirurgie. Het zorgt voor een buiten proportionele morbiditeit, mortaliteit en ver-
lengde opnameduur binnen de algemene chirurgie 2. Daarom vormt darmkanker 
chirurgie een belangrijk aandachtsgebied voor kwaliteitsverbetering.
Voor een optimale kwaliteit van zorg is het van groot belang te weten welke risi-
cofactoren een rol spelen bij het ontstaan van ongewenste uitkomsten en welke 
mogelijkheden er zijn om deze te beïnvloeden. Objectieve informatie ten aanzien 
van risicoprofielen is onmisbaar, zowel in de zorg voor de individuele patiënt als 
voor vergelijkend onderzoek op ziekenhuis en populatie niveau. Meer inzicht in 
risicoprofielen kan zorgen voor een betere inschatting van prognose en opent 
mogelijkheden voor zorg op maat. Deze kennis kan ook aanleiding geven om be-
handel protocollen aan te passen aan specifieke risicogroepen.
In dit proefschrift worden verschillende risico factoren en uitkomstmaten voor 
darmkanker patiënten bestudeerd. 
Nauwkeurige stadiering van darmkanker is essentieel voor een evenwichtige 
klinische beslissing over verdere behandeling en voor een betrouwbare schatting 
van de prognose. De studie in hoofdstuk 2 beoordeelt de voorspellende waarde 
van de metastatische lymfeklier ratio (LNR; aantal uitgezaaide gedeeld door het 
aantal gevonden lymfeklieren) in stadium III endeldarm kanker, in aanvulling op de 
nieuwste TNM classificatie 3. Het gebruik van LNR zou de identificatie van hoogri-
sico patiënten kunnen verbeteren, met als bijkomend voordeel dat LNR minder 
afhankelijk is van het gevonden aantal lymfklieren dan het N stadium. Vooral in en-
deldarm kanker kan het terugvinden van een adequate hoeveelheid lymfeklieren 
lastig zijn. Onze studie toont aan dat LNR een onafhankelijke voorspellende factor 
is voor overleving en lokaal recidief in stadium III endeldarm kanker. LNR gaf een 
betrouwbare inschatting van de overleving vanaf een lymfeklier opbrengst van 
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twee of meer. Voor een adequate voorspelling van lokaal recidief, moeten min-
stens zes lymfeklieren worden teruggevonden. Indeling van patiënten naar risico 
is mogelijk door hen in kwartielen te verdelen. In deze studie echter, was de LNR 
waarde met het beste onderscheidend vermogen 0.60. Dit betekent dat patiënten 
met een lagere LNR beschouwd kunnen worden als laagrisico en de patiënten met 
een LNR waarde boven 0.60 als hoogrisico. Deze afkapwaarde kon de voorspelling 
van prognose per stadium verbeteren, in aanvulling op het TNM stadium. De LNR 
kan daarom bijdragen aan de discussie in de multidisciplinaire bespreking van 
patiënten. 
Patiënt en behandeling karakteristieken zijn bepalende factoren voor risico en uit-
komst in darmkankerchirurgie. Deze factoren zijn vaak met elkaar verbonden. 
Naadlekkage is een belangrijk probleem in de darmchirurgie, dat jammer genoeg 
maar al te vaak voorkomt. Het leidt vaak tot ernstige morbiditeit, verhoogde ge-
zondheidszorgkosten en zelfs sterfte van de patiënt. Naadlekkages zijn tevens ge-
associeerd met lokaal recidief en verminderde overleving 4-6. Er is beschreven dat 
klinische inschatting van het risico op naadlekkage door de betrokken chirurg een 
lage voorspellende waarde heeft en het risico op naadlekkage wordt onderschat 7. 
Hoofdstuk 3 beschrijft de ontwikkeling en evaluatie van een risicoscore voor naa-
dlekkage bij darm operaties. Een gevalideerde eenvoudig te gebruiken risicoscore 
kan de intra-operatieve beslissing om al dan niet een (deviërend) stoma aan te leg-
gen vergemakkelijken. Naadlekkage heeft waarschijnlijk vele oorzaken. Voor het 
maken van een voorspellend model dat met al deze factoren rekening houdt is een 
zeer groot en gedetailleerd gegevensbestand nodig (meer dan 1860 patiënten). 
Daarom gebruiken wij een alternatieve benadering voor deze studie. Wij maak-
ten een risicoscore door een intuïtieve combinatie van risicofactoren die in de 
literatuur beschreven worden. Deze Colon Lekkage Score (CLS) werd vervolgens 
toegepast op een opeenvolgende reeks patiënten die een linkszijdige colorectale 
resectie met primaire anastomosis ondergingen. Onze studie toont aan dat de CLS 
het risico van naadlekkage kan vaststellen voor de individuele patiënt. Wij kunnen 
discussiëren over welk risico op naadlekkage acceptabel is, maar naar onze men-
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ing is het bij een risico kleiner dan 3% niet verstandig om een deviërend stoma 
aan te leggen, omdat een stoma ook problemen (morbiditeit, ongemak en hogere 
kosten) kan veroorzaken. Als we een risico op naadlekkage van 3% accepteren als 
afkapwaarde, dan zijn in onze serie slechts 20% van de patiënten hoogrisico en 
zouden we ons dus over 80% van de patiënten geen zorgen hoeven te maken. 
Uiteindelijk is het aan de chirurg en zijn patiënt om hun eigen afkapwaarde te bep-
alen, gebaseerd op persoonlijke preferenties ten aanzien van de afweging van het 
risico op naadlekkage tegen een (tijdelijke) stoma. De ROC curve en de logistische 
regressie curve uit hoofdstuk 3 kunnen een handvat bieden om de besluitvorming 
te ondersteunen. Als de waarde van de CLS bevestigd wordt in grotere multi-cen-
tre studies kan deze score helpen een moeilijk klinisch probleem op te lossen.
Het aantal patiënten met meerdere maligniteiten neemt toe. Omdat de behandel-
ing van kanker verbetert en screenings programma’s zich ontwikkelen, kunnen 
overlevenden in toenemende mate een tweede tumor ontwikkelen 8-10. De pro-
portie patiënten met meerdere invasieve kankers in de US International Cancer In-
stitutes Surveillance, Epidemiology and End Results Program (SEER) is toegenomen 
tot boven de 10% in 2008 11. De invloed van een eerdere andere maligniteiten op 
de overleving van darmkanker patiënten is echter niet duidelijk. Hoofdstuk 4 gaat 
hierop in. Deze studie laat zien dat patiënten met een eerdere niet-darmkanker een 
hogere sterfte hebben dan patiënten met darmkanker als eerste maligniteit. Ech-
ter, verdere analyses die niet in het artikel van hoofstuk 4 gepubliceerd zijn, tonen 
aan dat het verschil in overleving niet verklaard wordt door een verschil in ziekte 
specifieke overleving. Dit lijkt te suggereren dat darmkanker als tweede maligniteit 
hetzelfde klinisch pathologische gedrag heeft als een darmkanker als eerste ma-
ligniteit. Een eerdere maligniteit in de anamnese van darmkanker patiënten zou 
daarom beschouwd kunnen worden als comorbiditeit. Het is tot op heden niet 
duidelijk of een eerdere maligniteit dan beschouwd moet worden als een marker 
voor een verhoogd kanker risico (kanker biologie) en een risicovolle levensstijl, of 
dat schade door de eerdere kanker of de behandeling hiervan haar consequenties 
bepaald. 
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De aanwezigheid van comorbiditeit beïnvloed behandelbeslissingen12-15 en de 
prognose van patiënten die behandeld worden voor darmkanker16-20. Daarom 
wordt comorbiditeit gezien als belangrijke verstorende factor in de analyse van 
postoperatieve uitkomsten en het weglaten van comorbiditeit in risicocorrectie 
zou studies minder betrouwbaar maken. Ondanks het toenemend aantal stud-
ies naar comorbiditeit is de toegevoegde waarde van comorbiditeit, in modellen 
voor het voorspellen van de uitkomsten van darmkanker, niet opgehelderd. Het is 
ook onbekend of verschillende comorbiditeitsscores vergelijkbaar zijn in het voor-
spellen van sterfte en of deze scores net zo goed andere postoperatieve uitkom-
sten kunnen voorspellen, zoals postoperatieve complicaties.
Hoofdstuk 5 vergelijkt veelgebruikte comorbiditeitsscores en hun toegevoegde 
waarde in modellen die de uitkomsten van darmkanker chirurgie voorspellen. Het 
toont aan dat alle gebruikte comorbiditeitsscores (ASA score, de Sum of Diseased 
Organ Systems, de Charlson Comorbidity Index en specifieke comorbiditieten) de-
zelfde voorspellende waarde hebben. Dus elk van deze scores zou gebruikt kunnen 
worden om 30-dagen sterfte en een verlengde opnameduur te voorspellen. Voor 
het optreden van postoperatieve chirurgische complicaties waren alleen hoge ASA 
score en gastrolintestinale comorbiditeit risicofactoren. 
Hoewel comorbiditeit een onafhankelijke risicofactor was voor 30-dagen sterfte 
en een verlengde opnameduur na darmkanker chirurgie, bleek de aanvullende 
waarde van comorbiditeit in voorspellende modellen slechts marginaal. Om de ef-
ficiëntie van audits en verbetertrajecten te optimaliseren zouden alleen de aller-
belangrijkste comorbiditeits factoren geïdentificeerd moeten worden. Dit vermin-
dert de administratie last en de kosten van het vergaren van relevante gegevens, 
zonder de mogelijkheden van risicocorrectie te beperken.
De hoofdstukken 6 en 7 behandelen hoge leeftijd als risicofactor voor vermind-
erde overleving en gaan in op de oorzaken van leeftijdsgebonden verschillen in 
overleving. 
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De EUROCARE Working Group (EUROpean CAncer REgistry-based study on survival 
and CARE of cancer patients) vond,tijdens de periode van1988 tot 1999, significante 
verbeteringen in de overleving voor alle vormen van kanker inclusief darmkanker 
21. Echter de overleving verbeterde langzamer voor de ouderen (≥ 75 jaar), zodat 
de al bestaande overlevingsachterstand voor ouderen toenam ten opzichte van de 
jongere patiënten. Oudere patiënten krijgen minder vaak adjuvante chemothera-
pie en maakten hun kuren vaker niet af22. Het is aangetoond dat het toedienen van 
adjuvante behandeling aan oudere stadium III darmkanker patiënten beïnvloed 
wordt door socio-economische status, geslacht en comorbiditeit 12. Tegelijk beïnv-
loed comorbiditeit ook de chirurgische mogelijkheden en andere behandelopties. 
De aandacht voor oudere darmkanker patiënten is de laatste jaren toegenomen. 
Verschillende studies hebben vastgesteld dat leeftijd op zich geen contra-indicatie 
is voor meer agressieve of adjuvante behandeling 23. Daarom komen tegenwoordig 
in de dagelijkse praktijk meer ouderen in aanmerking voor uitgebreide behandel-
ing. Als een gevolg hiervan zou een verbeterde uitkomst voor ouderen dan ook te 
verwachten zijn. Wij verwachtten dat de achterstand in overleving van ouderen ten 
opzichte van jongeren, zoals getoond in de EUROCARE data, kleiner zou worden. 
Het doel van de studie in hoofdstuk 6 was om de behandelingen en verschillen in 
overleving te beschrijven tussen oudere oudere (≥75 jaar), jongere oudere (65-75 
jaar) en jongere (<65 jaar) darmkanker patiënten, over een periode van 15 jaar. 
In deze populatiestudie van de regio van het Integraal Kanker Centrum West, von-
den we substantiële veranderingen in de behandeling van darmkanker; het ge-
bruik van adjuvante chemotherapie voor stadium III patiënten nam over de tijd 
toe, resectie percentages bleven gelijk voor patiënten met curabele ziekte in alle 
leeftijdsgroepen, terwijl resectie percentages bij gemetastaseerde patiënten afna-
men. De toediening van chemotherapie voor stadium IV darmkanker patiënten 
nam toe voor alle leeftijdsgroepen. Er was een significante toename in overlev-
ing voor jongere patiënten na correctie voor verstorende factoren (zoals geslacht, 
leeftijd, differentiatie graad, stadium en behandeling). De overleving van jongere 
ouderen verbeterde eveneens na correctie voor geslacht, leeftijd, differentiatie 
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graad en stadium, maar niet na correctie voor behandeling. De overleving van ou-
dere ouderen verbeterde niet, ook niet na correctie voor verstorende factoren. Dit 
resulteerde in het achterblijven van de overleving van oudere ouderen vergelijk-
baar met de EUROCARE data. 
De nabije toekomst zal moeten uitwijzen of uitgebreidere en hopelijk beter 
aangepaste zorg op maat, de ouderen zal helpen deze overleving achterstand in 
te lopen. 
Naar verwachting neemt het hoge aantal oudere darmkanker patiënten de ko-
mende jaren nog toe. Als de overleving van oudere darmkanker patiënten achter-
blijft, is het belangrijk om te weten hoe dat komt.
Verschillen in overleving van darmkanker tussen verschillende leeftijdsgroepen 
zou verklaard kunnen worden door verschillen in tumorfactoren, patiëntfactoren 
en behandelingsfactoren. Ondanks deze verschillen vonden verschillende studies 
een vergelijkbare ziektespecifieke overleving voor oudere en jongere darmkanker 
patiënten. Dit zou betekenen dat de oversterfte van ouderen veroorzaakt wordt 
door andere doodsoorzaken dan de darmkanker. 
Om een beter inzicht te krijgen in overlevingsverschillen tussen leeftijdsgroepen, 
was het doel van de studie in hoofdstuk 7 om populatiebreed overlevingsgetal-
len van darmkanker patiënten te vergelijken tussen verschillende leeftijdsgroepen. 
De studie keek niet alleen naar algemene en relatieve overleving, maar ook naar 
conditionele relatieve overleving onder de conditie dat het eerste jaar overleefd 
wordt. Om beter te begrijpen waarin de uitdaging ligt voor de behandeling van 
oudere darmkanker patiënten, keek onze studie verder naar leeftijdsgebonden 
verschillen in 30-dagen en 1-jaar sterfte. Wij vonden dat als overlevingsgetallen 
van darmkanker patiënten gecorrigeerd werden voor de verwachte sterfte aan 
andere doodsoorzaken (de achtergrond sterfte in de populatie) en sterfte in het 
eerste jaar, leeftijdsgebonden verschillen in overleving verdwenen. Het bleek dus 
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dat de verminderde overleving van de ouderen vooral berust op vroege sterfte. 
Alleen bij stadium III ziekte deden ouderen het slechter, mogelijk als resultaat van 
minder uitgebreide adjuvante behandeling. Het algemene verschil in de prognose 
van jongere en oudere darmkanker patiënten kwam dus neer op een oversterfte 
van 10 % in de oudere groep in het eerste jaar. Onze studie impliceert dat bij het 
behandelen van oudere darmkanker patiënten de aandacht gericht moet zijn op 
het peri-operatieve proces en het eerste jaar na de operatie. 
Postoperatieve sterfte is een van de belangrijkste uitkomstmaten binnen de chiru-
rgie. Meestal wordt deze beschreven als sterfte binnen 30 dagen. Zoals verschil-
lende studies echter hebben aangetoond, is 30-dagen sterfte geen goede maat 
voor chirurgisch risico, want een significant deel van de patiënten sterft alsnog 
in de maanden die volgen24-26. Dit lijkt te suggereren dat er een verlengd effect 
uitgaat van de impact van de chirurgische behandeling. Hoofdstuk 8 en 9 gaan 
verder in op de etiologie van de oversterfte in het eerste jaar na de operatie. 
Hoofdstuk 8 identificeert risicofactoren. We vonden dat de oversterfte in het 
eerste jaar na chirurgie voor stadium I-III darmkanker hoog was. Over het geheel 
ging 12.4 procent van alle patiënten dood binnen het eerste jaar na de operatie, 
ten opzichte van 4.9% 30-dagen sterfte. Na correctie voor de verwachte sterfte in 
de populatie, hadden patiënten met comorbiditeit, stadium III ziekte, spoedoper-
aties en patiënten met postoperatieve chirurgische complicaties een hogere 1-jaar 
sterfte, die varieerde van 15 tot 30%. De identificatie van deze risicofactoren kan 
handvatten bieden voor het verbeteren van de uitkomsten van darmkanker chirur-
gie. Het ontwikkelen van strategieën om complicaties te voorkomen en effectief te 
behandelen moet daarbij prioriteit hebben. 
Hoofdstuk 9 onderzoekt de doodsoorzaken van darmkanker patiënten die het 
eerste jaar na de operatie niet overleven. Overlijdensaktes moeten met enige ter-
ughoudendheid beschouwd worden. In onze studie van stadium I-III darmkanker 
patiënten werd de sterfte in het eerste jaar na de operatie voornamelijk toege-
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schreven aan de darmkanker. Omdat het niet voor de hand ligt dat veel van deze 
patiënten stierven aan een recidief of een foute stadiering (patiënten die eigenlijk 
al stadium IV hadden), benadrukt de 1-jaar oversterfte dat er een verlengd effect 
uitgaat van de impact van de operatie. Dit wordt ondersteund door het feit dat 
tot 25% van de sterfte werd toegeschreven aan postoperatieve complicaties. Hi-
erom moet in de chirurgische behandeling extra aandacht gegeven worden aan 
het beperken van de fysiologische impact van de operatie en moet er meer betrok-
kenheid zijn bij de periode na ontslag.
Discussie en aandachtspunten voor de toekomst
Het gebruik van risico inschatting om de kwaliteit van zorg te verbeteren
De uitkomst en prognose van geopereerde darmkanker patiënten wordt bepaald 
door uiteenlopende en onderling verbonden factoren. Deze risico factoren zijn 
onder te verdelen in tumor/ stadium, behandeling en patiënt factoren. Idealiter 
zouden voor een optimale behandeling al deze factoren en hun interacties bekend 
moeten zijn. Helaas is het onmogelijk om een compleet overzicht te verkrijgen van 
alle risicofactoren en hun oorzaken en gevolgen. Er zal altijd een zekere mate van 
onzekerheid blijven. Het is niet de bedoeling van dit proefschrift om een defini-
tief overzicht te geven van alle risico’s en uitkomsten van darmkanker chirurgie. 
We hebben ervoor gekozen om de mogelijkheden van risicostratificatie te onder-
zoeken en hopelijk enkele risico factoren te identificeren, die te beïnvloeden zijn. 
Een beter inzicht in peri-operatieve risico’s is belangrijk. Voor de individuele patiënt 
kan dit een leidraad zijn voor de klinische besluitvorming en zorg op maat. Op 
ziekenhuis en populatie niveau kan kennis van risicofactoren leiden tot op maat 
aangepaste behandelingsprotocollen en betere informatie over case mix inv-
loeden. De identificatie en optimalisatie van beïnvloedbare risico factoren kan een 
belangrijke verbetering betekenen in de zorg voor darmkanker patiënten.
Het vaststellen van risico’s voor patiënten heeft de laatste twintig jaar een grote 
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vlucht genomen. Vanaf 1991 heeft de Department of Veterans Affairs (VA) system-
atisch risicogecorrigeerde chirurgische gegevens verzameld en geanalyseerd, in 
het National Surgical Quality Improvement Program (NSQIP). Op basis van verschil-
len in uitkomsten tussen ziekenhuizen werden structurele veranderingen doorge-
voerd, die hebben geleid tot een significante afname van het aantal postoperatieve 
complicaties, 30 dagen sterfte en opnameduur, tegelijk met een grotere tevre-
denheid bij patiënten27. Het programma is ondertussen overgenomen door de 
American College of Surgeons en de implementatie (ACS-NSQIP) heeft geleid tot 
dezelfde verbeteringen in chirurgische uitkomst als bij de VA ziekenhuizen. In Ned-
erland zijn verschillende kwaliteit verbetertrajecten gestart. Een deel van de data 
uit dit proefschrift is afkomstig van een multidisciplinaire regionale audit van de 
zorg voor darmkanker patiënten in de IKW-regio (KIC). In 2009 is een nationale au-
dit (DSCA) gestart met het uiteindelijke doel de zorg voor darmkanker patiënten in 
Nederland te verbeteren. Deze audit is begonnen als een chirurgische audit, maar 
zal in de nabije toekomst multidisciplinair worden. De bedoeling is dat de trans-
parantie van de zorg hierdoor verbetert en dat het tegelijkertijd waardevolle infor-
matie verkregen wordt die kan helpen de kwaliteit van de zorg te verbeteren. Door 
het vaststellen van verbeterpunten en het stimuleren van passende initiatieven. In 
zijn derde jaar levert de DSCA ondertussen een grote database die gebruikt wordt 
voor onderzoek. Klinieken die het slechter lijken te doen dan verwacht, worden 
nader bekeken en krijgen verbeter initiatieven aangeboden. Voor korte termijn uit-
komsten worden al positieve trends waargenomen, zoals het toenemende aantal 
lymfeklieren dat geoogst wordt. Lange termijn effecten moeten nog afgewacht 
worden, maar gelet op de ervaringen in andere landen, is een afname van ongew-
enste uitkomsten na darmkanker chirurgie te verwachten.
Naadlekkage
Naadlekkage is een groot probleem in de darmkanker chirurgie, dat kan leiden tot 
morbiditeit, slechtere kanker uitkomst en sterfte. Hoewel naadlekkage nog steeds 
vaak wordt beschouwd als technisch falen, laat de literatuur geen verschillen in uit-
komsten zien tussen verschillende technieken28-30. In dit proefschrift laten we zien 
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dat patiënt factoren een belangrijke rol spelen in het optreden van naadlekkage. 
Gecombineerd met de afstand tot de anus, het intra-operatieve bloedverlies en de 
duur van de operatie, konden zij het risico op naadlekkage voorspellen. 
Het belang van bloedverlies en duur van de operatie in de Colon Lekkage Score 
(CLS), zoals beschreven in hoofdstuk 3 is interessant. Deze onderdelen zouden be-
schouwd kunnen worden als afgeleiden van de behendigheid en training van de 
chirurg. Er zou echter ook een directe relatie kunnen zijn met de lichamelijke stress 
respons op de operatie en het wondgenezingsproces.
Een van de aansprekende onderdelen van de CLS is zijn logica. De score is geba-
seerd op het besef dat de genezingspotentie van de patiënt (weergegeven als 
verschillende patiënt factoren) en de ernst van de fysiologische impact van de 
operatie (operatie factoren), de uitkomst bepalen. Het probleem is dat we tot op 
heden niet goed weten wat de impact bepaald van de fysieke uitdagingen die het 
chirurgische trauma veroorzaakt en waaruit de fysieke genezingspotentie van een 
patiënt bestaat. Verder onderzoek hiernaar is nodig, in het bijzonder bij hoog risico 
groepen. 
De laatste tijd is er een trend ontstaan om meer ontlastende stoma’s aan te leg-
gen, om zo het probleem van naadlekkage tegen te gaan. In de DSCA is het aantal 
ontlastende stoma’s 70% bij rectum chirurgie (ongepubliceerde data). Het probl-
eem is dat onnodige stoma’s morbiditeit en ongemak opleveren en de kosten hier-
door stijgen31. Bij veel patiënten worden de stoma’s ook nooit meer opgeheven. In 
de toekomst zouden voorspellende scores zoals de CLS kunnen helpen om meer 
gepast gebruik van ontlastende stoma’s te maken. 
Comorbiditeit
Comorbiditeit is van essentieel belang in de zorg voor de individuele patiënt. De 
aanwezigheid van comorbiditeit beïnvloedt de besluitvorming ten aanzien van de 
behandeling12-15 en ook de prognose van darmkanker patiënten16-20.
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Om te zorgen voor gunstige uitkomsten moet op ziekenhuis niveau de peri-op-
eratieve evaluatie en behandeling van comorbiditeit geoptimaliseerd worden. 
Echter, in dit proefschrift vonden wij dat, hoewel comorbiditeit een significante 
risicofactor is voor 30-dagen sterfte en verlengde opnameduur na darmkanker 
chirurgie, het belang van comorbiditeit in modellen die postoperatieve ongewen-
ste uitkomsten voorspellen slechts marginaal is. Dit betekent dat bij risicocorrec-
ties voor vergelijking in darmkanker chirurgie comorbiditeit niet zo belangrijk is 
als vaak gedacht wordt. Met het oog op audits en kwaliteit verbetertrajecten kan 
dit betekenen dat alleen de allerbelangrijkste comorbiditeit meegenomen hoeft te 
worden. Dit zou kunnen leiden tot het minimaliseren van de registratielast zonder 
dat dit gevolgen heeft voor risicocorrectie.  Als audits echter ook voor de lange ter-
mijn uitkomsten willen registreren dan zal comorbiditeit wel weer een belangrijke 
factor zijn, omdat ze een groter risico op niet kanker gerelateerde sterfte tot gevolg 
heeft. Voor de DSCA is lange termijn oncologische evaluatie overigens gepland.
Spoedoperaties
Spoedoperaties vormen een belangrijke risicofactor voor ongewenste uitkomsten 
bij darmkanker chirurgie. Het voor een spoedoperatie eerst resusciteren en stabi-
liseren van een patiënt is van elementair belang om het risico te verlagen. In som-
mige gevallen is het risico van uitstel van de operatie echter groter dan het poten-
tiële voordeel (bijvoorbeeld bij dreigende blow-out). Daarom moet het streven zijn 
om het aantal patiënten te verminderen dat een spoedoperatie nodig heeft. Hierbij 
zou het voorgenomen nationale screenings programma, dat in 2012 ingevoerd zal 
worden, kunnen helpen. Als darmkanker eerder (asymptomatisch) gevonden kan 
worden, zou dit de noodzaak voor spoedoperaties kunnen verminderen. 
Ouderen ondergaan vaker spoedoperaties. Mogelijk is dit het gevolg van minder 
agressieve diagnostiek en behandeling bij oudere patiënten. Dan zou een meer lib-
eraal (laagdrempelig) beleid om bij ouderen, gepland en goed voorbereid, darm-
kanker te opereren, het aantal spoedoperaties mogelijk kunnen verminderen. Ook 
een versneld traject van diagnose naar operatie bij patiënten met een dreigende 
obstructie zou kunnen bijdragen aan het verminderen van het aantal spoedoper-
aties.
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Complicaties
Peri-operatieve risicofactoren zijn direct verbonden met postoperatieve compli-
caties. Meerdere studies hebben laten zien dat pre-operatieve verschillen tussen 
patiënten gerelateerd zijn aan postoperatieve uitkomsten32, opnameduur33 en 
ziekenhuiskosten34. Daarnaast is het optreden van postoperatieve complicaties zelf 
een van de belangrijkste oorzaken van verdere ongewenste uitkomsten na darm-
chirurgie. Daarom is het ontwikkelen van strategieën om postoperatieve compli-
caties te verminderen erg belangrijk. In drie ACS-NSQIP studies hebben Ghaferi et 
al. laten zien dat, hoewel het percentage complicaties niet significant verschillend 
was tussen ziekenhuizen met een hoge en een lage postoperatieve sterfte, de ster-
fte na complicaties in ziekenhuizen met een hoge sterfte bijna twee keer zo hoog 
was als in ziekenhuizen met een lage sterfte35-37. Dit fenomeen wordt ook wel het 
failure to rescue genoemd. Het suggereert dat de kwaliteit van de peri-operatieve 
zorg wanneer complicaties optreden minstens zo belangrijk is als de pogingen 
om complicaties te voorkomen. Om de uitkomsten van darmkanker chirurgie in 
de toekomst te verbeteren moeten zowel het voorkomen als vroeg opsporen en 
agressief behandelen van complicaties prioriteit hebben.
Ouderdom
De laatste jaren is de aandacht voor oudere darmkanker patiënten toegenomen. 
Tachtig- en negentigjarigen vormen een snel groeiend segment van de bevolk-
ing. Het belangrijk te bedenken dat de oudere populatie een heterogene groep 
is. Zowel het optreden als de ernst van het toenemend tekortschieten van fysi-
ologische systemen, zoals die bij veroudering optreden, wisselt van individu tot 
individu. Leeftijd op zich is daarom niet de belangrijkste factor die de uitkomst 
na darmkanker chirurgie bepaald. Het is meer de combinatie van comorbiditeit 
en een verminderde fysieke capaciteit om te herstellen van de tegenslagen die 
kunnen optreden voor, tijdens en na een operatie, die de uitkomst voor oudere 
patiënten bepaald38. Dit wordt ook wel aangeduid met het Engelse begrip frailty 
(kwetsbaarheid). Hoewel dit begrip wisselend wordt gedefinieerd, is het meestal 
gecorreleerd aan lichamelijke gebreken, comorbiditeit en verminderd welbev-
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inden. Het zou patiënten moeten aanduiden die kwetsbaar zijn en een verhoogd 
risico hebben op ongewenste uitkomsten 39.  
Hoewel toenemende leeftijd een onafhankelijke risicofactor is voor ongewenste 
uitkomsten, zelfs na correctie voor comorbiditeit, hebben verschillende stud-
ies geconcludeerd dat leeftijd op zich geen reden is om af te zien van agressieve 
of adjuvante behandeling23. Daarom komen tegenwoordig meer ouderen in de 
dagelijkse praktijk in aanmerking voor een uitgebreide behandeling. Toch hebben 
oudere darmkanker patiënten vaker een meer gevorderd stadium van de ziekte23. 
Ze hebben meer comorbiditeit en worden nog steeds minder agressief behandeld 
dan jongere patiënten19. Comorbiditeit op zijn beurt beïnvloed of iemand in aan-
merking komt voor een operatie of een andere behandeling18. Daarnaast geeft 
comorbiditeit een groter risico op niet kanker gerelateerde sterfte. Oudere patiënt-
en krijgen minder vaak adjuvante chemotherapie en maken vaker hun kuren niet 
af22. 
In dit proefschrift vonden wij dat hoewel de overleving van patiënten van 65 tot 75 
jaar verbeterde, de overleving van patiënten boven de 75 jaar gelijk bleef tussen 
1990 en 2005. 
In dit proefschrift kunnen we twee verklaringen hiervoor vinden. Ten eerste is er nog 
steeds een onderbehandeling van ouderen (>75), vooral bij stadium III patiënten. 
Dit is mogelijk niet helemaal te voorkomen als gevolg van zwakte of comorbiditeit 
die het gebruik van adjuvante chemotherapie in de weg staat.
Ten tweede is er bij ouderen een hogere oversterfte. Dit is mogelijk het gevolg van 
een zwaardere en meer langdurige aanslag die de operatie vormt voor de oudere 
patiënt. Ouderen hebben vaak verminderde functionele reserves en afgenomen 
mogelijkheden, om te gaan met de fysiologische uitdagingen van de operatie en 
zijn gevolgen. In dit proefschrift hebben we laten zien dat na correctie voor de 
verwachte mortaliteit in een populatie en voor de sterfte in het eerste jaar, leeftijds-
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gebonden verschillen in overleving na darmkanker chirugie verdwenen. Dit onder-
streept het feit dat het verwoestende fysiologische effect van een darmkanker op-
eratie en postoperatieve complicaties niet beperkt blijft tot directe postoperatieve 
periode. Een significant deel van de patiënten komt er na een darmkanker operatie 
uiteindelijk niet meer boven op26. 
Om de overleving van ouderen te verbeteren zouden we ons in de toekomst meer 
moeten richten op niet kanker specifieke voorbehandeling en niet alleen op de 
kanker specifieke neo-adjuvante behandeling. Het zeer subtiele evenwicht van 
fysiologische marges bij fragiele oudere darmkanker patiënten vereist extra zorg 
om hun cardiopulmonale toestand, hun voedingstoestand en hun fysieke prestat-
ies te optimaliseren. Ook een optimale timing van de operatie zou bediscussieerd 
moeten worden. Actieve betrokkenheid van een multidisciplinair team is hierbij 
noodzakelijk, gericht op het optimaliseren van fysiologische reserves en het mini-
maliseren van de impact van de operatie. Mogelijk zou minimaal invasieve chir-
urgie hierbij van nut kunnen zijn. Hoewel er zorgen bestaan dat ouderen slecht 
opgewassen zijn tegen de cardiovasculaire en pulmonale gevolgen van een 
pneumperitoneum, is aangetoond dat laparoscopie veilig is en van voordeel kan 
zijn bij ouderen40-43. De voordelen van laparoscopie lijken zelfs meer uitgesproken 
bij ouderen44. Minder weefsel beschadiging, sneller postoperatief mobiliseren en 
een sneller herstel van de patiënt zou de impact van de operatie kunnen beperken. 
Dit kan vooral nuttig zijn bij oudere patiënten met beperkte reserves.
De nabije toekomst zal moeten tonen of uitgebreidere en hopelijk meer op de 
patiënt aangepaste multidisciplinaire behandeling, met extra aandacht voor de 
peri-operatieve zorg ook na de opname, kan helpen om de achterstand van oudere 
darmkanker patiënten goed te maken. 
We mogen echter niet vergeten dat, in het bijzonder voor hele oude mensen, de 
kwaliteit van leven na een operatie het allerbelangrijkste is. We moeten daarom 
steeds goed bedenken wat er met een operatie te bereiken is, wat de gevolgen 
hiervan voor de patiënt kunnen zijn, en wat elke patiënt wil en aankan.
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Verlengde impact van de operatie
Een belangrijke bevinding in dit proefschrift is het feit dat 30-dagen sterfte, een 
veel gebruikte uitkomstmaat, een ernstige onderschatting geeft van 1-jaar ster-
fte. Hierdoor onderschat de 30 dagen sterfte de werkelijke impact van de oper-
atie op de overleving van darmkanker patiënten. Het is aangetoond dat fysieke 
fitheid en serieuze postoperatieve complicaties het herstel na een operatie kunnen 
voorspellen. Veel patiënten, vooral ouderen, hebben een vertraagd herstel. Zelfs 6 
maanden na een buikoperatie zijn prestatiematen, zoals loopsnelheid, functionele 
reikwijdte en knijpkracht nog niet terug op het niveau van voor de operatie bij 40-
60% van de patiënten45. Een trainingsprogramma om preoperatief de functionele 
capaciteit te verbeteren of tenminste op niveau te houden, zou een rol kunnen 
spelen bij het verminderen van complicaties na darmoperaties46. Het is ook gesug-
gereerd dat preoperatieve cognitieve toestand en depressie gerelateerd zijn aan 
herstel. Dit is interessant omdat depressie behandelbaar is en er is enig bewijs dat 
een postoperatief delier verkomen kan worden47. Er verschijnt steeds meer liter-
atuur over lichaam en geest interventies die met behulp van op mindfulness geba-
seerde stress reducerende therapie angst en slaap stoornissen behandelen om zo 
de lichamelijke stress reactie te verminderen48.
De hoge 1-jaar oversterfte die wij vonden na darmkanker chirurgie, benadrukt niet 
alleen het belang van de peri-operatieve periode, waar complicaties en heropname 
belangrijke factoren lijken49-50, maar richt ook onze aandacht op de periode na de 
opname in het ziekenhuis, als een nieuw terrein voor kwaliteit verbetertrajecten 
en audits. Meer studies zijn nodig om meer te weten te komen over de oorzaken 
van oversterfte het eerste jaar na een darmkanker operatie en of deze factoren te 
beïnvloeden zijn. Echter, het lijkt duidelijk dat verdere inspanningen nodig zijn om 
de fysiologische impact van de operatie en zijn gevolgen te minimaliseren. Een 
voortdurende aandacht voor comorbiditeit ook na de operatie en hierbij passende 
follow up zou hierbij kunnen helpen. Hierdoor zou mogelijk ook het aantal hero-
pnames verminderd kunnen worden, omdat 75% van de heropnames in de eerste 
90 dagen niet gerelateerd zijn aan de operatie zelf51. Analoog aan het enhanced 
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recovery principe, zou je kunnen pleiten voor een sustained enhanced recovery 
programma52-53.
De verantwoordelijkheid van de chirurg
Bij het bespreken van risico’s en uitkomsten bij darmkankerchirurgie bestaat er 
een spanningveld tussen het beschouwen van grote groepen en de zorg voor de 
individuele patiënt. In populaties vastgestelde risicofactoren zijn vaak moeilijk te 
vertalen naar een klinische situatie. Het is aan de chirurg om zich een onderbouwd 
oordeel te vormen van het risico van zijn patiënt, dit te bespreken en te vertalen 
in een toegewijd advies. Hij moet zorgen voor aangepaste, goed georganiseerde 
peri-operatieve zorg en zijn chirurgische vaardigheden op niveau houden. Al deze 
factoren zijn nodig voor een uitgebalanceerde behandeling, die rekening houdt 
met persoonlijke voorkeuren en tegelijk het risico op ongewenste uitkomsten 
beperkt om zo de optimale uitkomst mogelijk te maken. 
Dit werk kan niet gedaan worden zonder de steun en bijdrage van een toegewijd 
multidisciplinair team. Daarom moet de chirurg een teamspeler zijn. Verbeterin-
gen in de chirurgische zorg zijn vooral het gevolg van teamwork en niet zozeer van 
individueel technisch uitblinken.
Tot slot is het de verantwoordelijkheid van de chirurg om zich voortdurend te 
scholen en te ontwikkelen, toegewijd te zijn aan de patiënt en bereid te zijn om 
zijn daadwerkelijke uitkomsten onder ogen te zien en ze te spiegelen aan relevante 
bench-marks. 
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Risk and Outcome









in Colorectal Cancer Surgery
Jan Willem Dekker
Surgery always concerns the balance of risk and ben-
efit. Both risk and benefit can vary immensely among 
patients. Outcome and prognosis are determined by 
several patient, tumour and treatment characteris-
tics. In order to achieve the best possible outcomes 
for colorectal cancer patients, detailed and objective 
information on risk profiles is indispensible. For the 
individual patient it should guide clinical judgment 
and the administration of tailored care. On a hospital 
or population level knowledge of risk factors can lead 
to adjusted (better tailored) treatment protocols and 
better information on case mix influences adding to an 
improved care for colorectal cancer patients. 
JW-Dekker cover aangepast 17 april.indd   1 17-4-2012   8:10:31
Uitnodiging
Voor het bijwonen van de 
openbare verdediging van
het proefschrift
“Risk and outcome 
in colorectal cancer surgery”
woensdag 16 mei om 15:00 uur
in het Groot Auditorium
van het Academiegebouw
Rapenburg 73 te Leiden
U bent van harte uitgenodigd 
voor de receptie ter plaatse 
na afloop 









2596 TH Den Haag
kim.en.jw.promoveren@gmail.com
DEF-uitnodiging-boekenlegger 15april-JW.indd   1 15-4-2012   18:15:44
